<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="100" offset="0" totalResults="6530"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="4098" label="Small molecule therapeutic"></FilterOption><FilterOption id="585" count="3247" label="Oral formulation"></FilterOption><FilterOption id="761" count="2607" label="Biological therapeutic"></FilterOption><FilterOption id="648" count="2543" label="Intravenous formulation"></FilterOption><FilterOption id="595" count="2349" label="Tablet formulation"></FilterOption><FilterOption id="740" count="2139" label="Infusion"></FilterOption><FilterOption id="746" count="1781" label="Solution"></FilterOption><FilterOption id="751" count="1500" label="Film coating"></FilterOption><FilterOption id="586" count="1476" label="Capsule formulation"></FilterOption><FilterOption id="573" count="1360" label="Immunoglobulin-G"></FilterOption><FilterOption id="898" count="1201" label="Formulation powder"></FilterOption><FilterOption id="647" count="1182" label="Subcutaneous formulation"></FilterOption><FilterOption id="85" count="1181" label="Protein recombinant"></FilterOption><FilterOption id="750" count="995" label="Freeze drying"></FilterOption><FilterOption id="169" count="851" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="1263" count="690" label="Immuno-oncology"></FilterOption><FilterOption id="168" count="629" label="Monoclonal antibody human"></FilterOption><FilterOption id="1652" count="515" label="Prodrug"></FilterOption><FilterOption id="1647" count="482" label="Natural product"></FilterOption><FilterOption id="594" count="472" label="Oral suspension formulation"></FilterOption><FilterOption id="80" count="423" label="Peptide"></FilterOption><FilterOption id="902" count="382" label="Orally disintegrating tablet"></FilterOption><FilterOption id="805" count="380" label="Daily dosing"></FilterOption><FilterOption id="589" count="366" label="Sustained release formulation"></FilterOption><FilterOption id="175" count="358" label="Drug combination"></FilterOption><FilterOption id="593" count="353" label="Oral liquid formulation"></FilterOption><FilterOption id="651" count="306" label="Intramuscular formulation"></FilterOption><FilterOption id="745" count="264" label="Suspension"></FilterOption><FilterOption id="766" count="258" label="Parenteral formulation unspecified"></FilterOption><FilterOption id="166" count="232" label="Chimeric monoclonal antibody"></FilterOption><FilterOption id="180" count="206" label="Antibody fragment"></FilterOption><FilterOption id="894" count="204" label="Liquid formulation"></FilterOption><FilterOption id="348" count="195" label="PEGylated formulation"></FilterOption><FilterOption id="743" count="178" label="Granule"></FilterOption><FilterOption id="74" count="165" label="Glycoprotein"></FilterOption><FilterOption id="84" count="164" label="Protein fusion"></FilterOption><FilterOption id="66" count="156" label="Antibiotic"></FilterOption><FilterOption id="616" count="147" label="Inhalant formulation"></FilterOption><FilterOption id="128" count="133" label="Cell culture technique"></FilterOption><FilterOption id="112" count="132" label="DNA technology"></FilterOption><FilterOption id="90" count="129" label="Steroid"></FilterOption><FilterOption id="596" count="126" label="Injectable formulation"></FilterOption><FilterOption id="660" count="125" label="Oral sustained release formulation"></FilterOption><FilterOption id="649" count="122" label="Intraperitoneal formulation"></FilterOption><FilterOption id="667" count="122" label="Peptidomimetic"></FilterOption><FilterOption id="207" count="117" label="Protein conjugated"></FilterOption><FilterOption id="127" count="107" label="Cell culture"></FilterOption><FilterOption id="852" count="106" label="Intravesical formulation"></FilterOption><FilterOption id="599" count="105" label="Nanoparticle formulation injectable"></FilterOption><FilterOption id="630" count="104" label="Stereochemistry"></FilterOption><FilterOption id="680" count="102" label="Buccal formulation systemic"></FilterOption><FilterOption id="701" count="101" label="Nucleoside synthesis"></FilterOption><FilterOption id="641" count="99" label="Controlled release formulation"></FilterOption><FilterOption id="171" count="91" label="Monoclonal antibody conjugated"></FilterOption><FilterOption id="603" count="87" label="Systemic formulation unspecified"></FilterOption><FilterOption id="611" count="86" label="Dermatological formulation"></FilterOption><FilterOption id="723" count="85" label="Drug coating"></FilterOption><FilterOption id="617" count="83" label="Aerosol formulation inhalant"></FilterOption><FilterOption id="618" count="82" label="Powder formulation inhalant"></FilterOption><FilterOption id="558" count="76" label="Transdermal formulation"></FilterOption><FilterOption id="742" count="72" label="Pellet"></FilterOption><FilterOption id="590" count="68" label="Enteric coated formulation"></FilterOption><FilterOption id="51" count="66" label="Monoclonal antibody"></FilterOption><FilterOption id="208" count="66" label="Protein conjugation"></FilterOption><FilterOption id="159" count="64" label="Oligosaccharide"></FilterOption><FilterOption id="620" count="62" label="Ophthalmic formulation"></FilterOption><FilterOption id="167" count="60" label="Monoclonal antibody murine"></FilterOption><FilterOption id="756" count="57" label="Pharmaceutical carrier"></FilterOption><FilterOption id="1646" count="56" label="Injectable controlled release formulation"></FilterOption><FilterOption id="598" count="56" label="Liposome formulation injectable"></FilterOption><FilterOption id="662" count="56" label="Quick release formulation"></FilterOption><FilterOption id="62" count="54" label="Virus recombinant"></FilterOption><FilterOption id="559" count="50" label="Oral controlled release formulation"></FilterOption><FilterOption id="661" count="50" label="Oral quick release formulation"></FilterOption><FilterOption id="615" count="49" label="Aerosol formulation dermatological"></FilterOption><FilterOption id="1164" count="49" label="Antibody drug conjugate"></FilterOption><FilterOption id="102" count="48" label="Nucleotide and derivatives"></FilterOption><FilterOption id="652" count="46" label="Intra-articular formulation"></FilterOption><FilterOption id="807" count="45" label="Monthly dosing"></FilterOption><FilterOption id="776" count="42" label="Oral gel formulation"></FilterOption><FilterOption id="753" count="41" label="Microparticle formulation"></FilterOption><FilterOption id="347" count="38" label="Intratumoral formulation"></FilterOption><FilterOption id="236" count="38" label="Macrolide"></FilterOption><FilterOption id="962" count="34" label="Biosimilar product"></FilterOption><FilterOption id="170" count="34" label="Multivalent monoclonal antibody"></FilterOption><FilterOption id="724" count="32" label="Radiolabeling"></FilterOption><FilterOption id="103" count="31" label="Oligonucleotide"></FilterOption><FilterOption id="806" count="31" label="Weekly dosing"></FilterOption><FilterOption id="569" count="30" label="Oligonucleotide antisense"></FilterOption><FilterOption id="901" count="30" label="Recombinant enzyme"></FilterOption><FilterOption id="267" count="28" label="Multivalent antibody"></FilterOption><FilterOption id="1" count="23" label="Antibody"></FilterOption><FilterOption id="537" count="23" label="Chimeric antibody"></FilterOption><FilterOption id="1669" count="23" label="Emulsion formulation"></FilterOption><FilterOption id="731" count="23" label="Imaging"></FilterOption><FilterOption id="111" count="22" label="Cloning technology"></FilterOption><FilterOption id="659" count="21" label="Ophthalmic liquid formulation"></FilterOption><FilterOption id="67" count="20" label="Antigen"></FilterOption><FilterOption id="612" count="20" label="Emulsion dermatological"></FilterOption><FilterOption id="142" count="20" label="Liposome formulation"></FilterOption></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="3665" count="322" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="3657" count="301" label="Metastatic breast cancer"></FilterOption><FilterOption id="2399" count="204" label="Adenocarcinoma"></FilterOption><FilterOption id="3713" count="191" label="Advanced solid tumor"></FilterOption><FilterOption id="837" count="174" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="1069" count="169" label="Metastasis"></FilterOption><FilterOption id="3658" count="158" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="291" count="148" label="Rheumatoid arthritis"></FilterOption><FilterOption id="159" count="143" label="HIV-1 infection"></FilterOption><FilterOption id="307" count="129" label="Squamous cell carcinoma"></FilterOption><FilterOption id="49" count="125" label="Breast tumor"></FilterOption><FilterOption id="153" count="125" label="Hepatitis C virus infection"></FilterOption><FilterOption id="1828" count="122" label="Multiple myeloma"></FilterOption><FilterOption id="3246" count="97" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="3257" count="96" label="Stage IV melanoma"></FilterOption><FilterOption id="213" count="88" label="Multiple sclerosis"></FilterOption><FilterOption id="1185" count="85" label="Chronic obstructive pulmonary disease"></FilterOption><FilterOption id="158" count="84" label="HIV infection"></FilterOption><FilterOption id="3669" count="84" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="4250" count="81" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="1771" count="81" label="Transitional cell carcinoma"></FilterOption><FilterOption id="3866" count="80" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3666" count="78" label="Metastatic stomach cancer"></FilterOption><FilterOption id="14" count="77" label="Alzheimers disease"></FilterOption><FilterOption id="1262" count="76" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="319" count="75" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="84" count="74" label="Crohns disease"></FilterOption><FilterOption id="80" count="72" label="Coronary artery disease"></FilterOption><FilterOption id="20" count="71" label="Pain"></FilterOption><FilterOption id="3083" count="71" label="Peritoneal tumor"></FilterOption><FilterOption id="1731" count="69" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1749" count="68" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="2243" count="68" label="Fallopian tube cancer"></FilterOption><FilterOption id="3673" count="68" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="55" count="66" label="Cardiac failure"></FilterOption><FilterOption id="1734" count="65" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="31" count="64" label="Asthma"></FilterOption><FilterOption id="1745" count="64" label="Follicle center lymphoma"></FilterOption><FilterOption id="337" count="63" label="Ulcerative colitis"></FilterOption><FilterOption id="121" count="62" label="Factor VIII deficiency"></FilterOption><FilterOption id="1767" count="62" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="3667" count="62" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="281" count="60" label="Psoriasis"></FilterOption><FilterOption id="57" count="59" label="Cardiovascular disease"></FilterOption><FilterOption id="799" count="59" label="Ovary tumor"></FilterOption><FilterOption id="1261" count="58" label="Small-cell lung cancer"></FilterOption><FilterOption id="1705" count="55" label="Endometrioid carcinoma"></FilterOption><FilterOption id="224" count="55" label="Myocardial infarction"></FilterOption><FilterOption id="255" count="53" label="Parkinsons disease"></FilterOption><FilterOption id="17" count="52" label="Anemia"></FilterOption><FilterOption id="1542" count="52" label="Atrial fibrillation"></FilterOption><FilterOption id="2454" count="46" label="Glioblastoma"></FilterOption><FilterOption id="3664" count="46" label="Metastatic prostate cancer"></FilterOption><FilterOption id="3256" count="45" label="Stage III melanoma"></FilterOption><FilterOption id="3466" count="42" label="Metastatic bladder cancer"></FilterOption><FilterOption id="1272" count="42" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="238" count="41" label="Obesity"></FilterOption><FilterOption id="299" count="40" label="Schizophrenia"></FilterOption><FilterOption id="1735" count="39" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="1781" count="38" label="Psoriatic arthritis"></FilterOption><FilterOption id="318" count="38" label="Systemic lupus erythematosus"></FilterOption><FilterOption id="119" count="37" label="Epilepsy"></FilterOption><FilterOption id="1128" count="35" label="Neuroendocrine tumor"></FilterOption><FilterOption id="245" count="35" label="Osteoarthritis"></FilterOption><FilterOption id="3378" count="35" label="Soft tissue sarcoma"></FilterOption><FilterOption id="427" count="35" label="Uterine cervix tumor"></FilterOption><FilterOption id="2380" count="34" label="Bladder cancer"></FilterOption><FilterOption id="552" count="34" label="Bleeding"></FilterOption><FilterOption id="1080" count="34" label="Female infertility"></FilterOption><FilterOption id="3510" count="34" label="Pulmonary artery hypertension"></FilterOption><FilterOption id="1744" count="32" label="Mantle cell lymphoma"></FilterOption><FilterOption id="3676" count="31" label="Ischemic stroke"></FilterOption><FilterOption id="203" count="31" label="Lymphoma"></FilterOption><FilterOption id="316" count="30" label="B-cell lymphoma"></FilterOption><FilterOption id="623" count="30" label="Head and neck tumor"></FilterOption><FilterOption id="325" count="30" label="Thromboembolism"></FilterOption><FilterOption id="3258" count="29" label="Acute coronary syndrome"></FilterOption><FilterOption id="1728" count="29" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="88" count="29" label="Cystic fibrosis"></FilterOption><FilterOption id="3251" count="29" label="End stage renal disease"></FilterOption><FilterOption id="3439" count="29" label="Partial seizure"></FilterOption><FilterOption id="178" count="28" label="Hypertension"></FilterOption><FilterOption id="65" count="28" label="Stroke"></FilterOption><FilterOption id="398" count="27" label="Ankylosing spondylitis"></FilterOption><FilterOption id="191" count="27" label="Influenza virus infection"></FilterOption><FilterOption id="3003" count="27" label="Juvenile rheumatoid arthritis"></FilterOption><FilterOption id="3147" count="27" label="Open angle glaucoma"></FilterOption><FilterOption id="2376" count="27" label="Overactive bladder"></FilterOption><FilterOption id="249" count="27" label="Pancreas tumor"></FilterOption><FilterOption id="1102" count="26" label="Atopic dermatitis"></FilterOption><FilterOption id="1228" count="26" label="Factor IX deficiency"></FilterOption><FilterOption id="4898" count="26" label="Major depressive disorder"></FilterOption><FilterOption id="152" count="25" label="Hepatitis B virus infection"></FilterOption><FilterOption id="836" count="25" label="Insulin dependent diabetes"></FilterOption><FilterOption id="725" count="25" label="Solid tumor"></FilterOption><FilterOption id="1765" count="24" label="Cholangiocarcinoma"></FilterOption><FilterOption id="574" count="24" label="Deep vein thrombosis"></FilterOption><FilterOption id="276" count="24" label="Prostate tumor"></FilterOption><FilterOption id="1078" count="23" label="Lung embolism"></FilterOption><FilterOption id="1108" count="22" label="Glioma"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8489" count="299" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8481" count="269" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8712" count="242" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8719" count="236" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8998" count="236" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="8713" count="230" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8505" count="204" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8663" count="204" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8639" count="194" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="15312" count="173" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="15287" count="166" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="8522" count="162" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="8738" count="159" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8514" count="154" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8513" count="154" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="9153" count="148" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="7547" count="144" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8996" count="137" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8640" count="135" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="8721" count="133" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="9247" count="127" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="7538" count="127" label="Lymphoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7569" count="126" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7879" count="125" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9122" count="124" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8430" count="124" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="9213" count="124" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="7680" count="124" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="15212" count="124" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="8187" count="122" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"></FilterOption><FilterOption id="8163" count="120" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9215" count="119" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="8078" count="118" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="8523" count="118" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8720" count="115" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8722" count="112" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="7563" count="111" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7611" count="109" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="15207" count="108" label="Solid tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15293" count="107" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="6863" count="106" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="3900" count="102" label="Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response"></FilterOption><FilterOption id="8151" count="101" label="Colorectal tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9218" count="101" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="3736" count="99" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="1503" count="96" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="2622" count="91" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="7908" count="90" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="1626" count="90" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="1624" count="90" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="22595" count="89" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="26033" count="88" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="8555" count="87" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8519" count="87" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"></FilterOption><FilterOption id="8516" count="86" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="15218" count="86" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="10830" count="85" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="4144" count="85" label="Rheumatoid arthritis - Assessment of adverse events"></FilterOption><FilterOption id="8077" count="84" label="Leukemia - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8651" count="83" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="6940" count="83" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="1359" count="83" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="15285" count="83" label="Solid tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8744" count="82" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8641" count="82" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="7679" count="81" label="Lymphoma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9155" count="80" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="7045" count="80" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="37159" count="79" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="7027" count="79" label="Melanoma - Assessment of adverse events"></FilterOption><FilterOption id="1345" count="78" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="8997" count="77" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="7564" count="77" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="6924" count="77" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7360" count="77" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="6919" count="76" label="Melanoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7367" count="76" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="10828" count="74" label="Ovary tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8725" count="73" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8189" count="73" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="8508" count="73" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="4139" count="73" label="Rheumatoid arthritis - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7891" count="72" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7049" count="72" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="13352" count="71" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8759" count="70" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="7909" count="69" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="7354" count="69" label="Multiple myeloma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="3883" count="69" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response"></FilterOption><FilterOption id="7489" count="68" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"></FilterOption><FilterOption id="13344" count="67" label="Pancreas tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="4000" count="67" label="Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)"></FilterOption><FilterOption id="3809" count="66" label="Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="25874" count="66" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"></FilterOption><FilterOption id="11717" count="65" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="1358" count="65" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="13357" count="65" label="Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="10545" count="65" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15215" count="65" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="10540" count="64" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"></FilterOption></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="12"><FilterOption id="L" count="4243" label="Launched"></FilterOption><FilterOption id="C3" count="623" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="526" label="Phase 2 Clinical"></FilterOption><FilterOption id="DX" count="501" label="Discontinued"></FilterOption><FilterOption id="PR" count="121" label="Pre-registration"></FilterOption><FilterOption id="C1" count="104" label="Phase 1 Clinical"></FilterOption><FilterOption id="NDR" count="103" label="No Development Reported"></FilterOption><FilterOption id="R" count="63" label="Registered"></FilterOption><FilterOption id="W" count="43" label="Withdrawn"></FilterOption><FilterOption id="DR" count="34" label="Discovery"></FilterOption><FilterOption id="S" count="11" label="Suspended"></FilterOption><FilterOption id="CU" count="5" label="Clinical"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="23137" count="385" label="Novartis AG"></FilterOption><FilterOption id="19446" count="358" label="Roche Holding AG"></FilterOption><FilterOption id="18767" count="301" label="Pfizer Inc"></FilterOption><FilterOption id="28355" count="273" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="15065" count="199" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="14190" count="198" label="AstraZeneca plc"></FilterOption><FilterOption id="17810" count="191" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="26178" count="172" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="14455" count="133" label="Bayer AG"></FilterOption><FilterOption id="1144568" count="127" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="14881" count="123" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="1067538" count="123" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1072507" count="111" label="AbbVie Inc"></FilterOption><FilterOption id="1091809" count="107" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="1059823" count="103" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="15331" count="101" label="Celgene Corp"></FilterOption><FilterOption id="25599" count="100" label="Novartis Pharma AG"></FilterOption><FilterOption id="1009547" count="100" label="Sanofi SA"></FilterOption><FilterOption id="14109" count="94" label="Amgen Inc"></FilterOption><FilterOption id="16450" count="93" label="Gilead Sciences Inc"></FilterOption><FilterOption id="18614" count="87" label="Novo Nordisk A/S"></FilterOption><FilterOption id="30062" count="80" label="AstraZeneca AB"></FilterOption><FilterOption id="29218" count="77" label="AbbVie Deutschland GmbH &amp; Co KG"></FilterOption><FilterOption id="15133" count="76" label="Bristol-Myers Squibb International Corp"></FilterOption><FilterOption id="1121088" count="72" label="Novartis Farmaceutica SA"></FilterOption><FilterOption id="1038736" count="63" label="PETHEMA Foundation"></FilterOption><FilterOption id="19453" count="61" label="Genentech Inc"></FilterOption><FilterOption id="22546" count="53" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="1003983" count="51" label="Bayer HealthCare AG"></FilterOption><FilterOption id="1013295" count="44" label="Astellas Pharma Inc"></FilterOption><FilterOption id="13601" count="43" label="Abbott Laboratories"></FilterOption><FilterOption id="1057369" count="43" label="La Paz University Hospital (Madrid)"></FilterOption><FilterOption id="1119200" count="42" label="Sanofi-Aventis Research and Development"></FilterOption><FilterOption id="1110770" count="41" label="Novartis Farma SpA"></FilterOption><FilterOption id="17839" count="39" label="Eli Lilly SA"></FilterOption><FilterOption id="23119" count="39" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1050515" count="39" label="ViiV Healthcare Ltd"></FilterOption><FilterOption id="15414" count="37" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1005244" count="36" label="Biogen Inc"></FilterOption><FilterOption id="22586" count="36" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="1042061" count="36" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="1087775" count="35" label="Novartis Oncology"></FilterOption><FilterOption id="24652" count="35" label="Shire plc"></FilterOption><FilterOption id="1145220" count="32" label="GlaxoSmithKline Research &amp; Development Ltd"></FilterOption><FilterOption id="18101" count="32" label="Merck KGaA"></FilterOption><FilterOption id="27053" count="31" label="Glaxo Group Research Ltd"></FilterOption><FilterOption id="1040862" count="31" label="Hospital General Universitario Gregorio Marañon"></FilterOption><FilterOption id="20348" count="31" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="23780" count="30" label="Actelion Ltd"></FilterOption><FilterOption id="1045910" count="30" label="Hospital Clinico San Carlos"></FilterOption><FilterOption id="1122528" count="30" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="20452" count="30" label="UCB SA"></FilterOption><FilterOption id="19620" count="29" label="Eisai Inc"></FilterOption><FilterOption id="17259" count="29" label="Ipsen"></FilterOption><FilterOption id="1103352" count="28" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="1044292" count="28" label="Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="17216" count="28" label="Incyte Corp"></FilterOption><FilterOption id="15121" count="27" label="Bristol-Myers Squibb Belgium SA"></FilterOption><FilterOption id="1079538" count="27" label="Instituto de Investigación Hospital Universitario La Paz"></FilterOption><FilterOption id="22563" count="26" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="1110884" count="25" label="Biogen Idec Research Ltd"></FilterOption><FilterOption id="1020322" count="25" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="24166" count="25" label="GlaxoSmithKline Biologicals"></FilterOption><FilterOption id="19461" count="25" label="Hoffmann-La Roche Inc"></FilterOption><FilterOption id="20556" count="25" label="Universidad Complutense de Madrid"></FilterOption><FilterOption id="14112" count="25" label="Wyeth"></FilterOption><FilterOption id="1003570" count="24" label="Janssen R&amp;D (Ireland)"></FilterOption><FilterOption id="18008" count="24" label="MedImmune LLC"></FilterOption><FilterOption id="16299" count="24" label="Sanofi Genzyme"></FilterOption><FilterOption id="22554" count="23" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="21991" count="23" label="Takeda Oncology"></FilterOption><FilterOption id="14913" count="22" label="Eisai Ltd"></FilterOption><FilterOption id="1035512" count="22" label="EMD Serono Inc"></FilterOption><FilterOption id="17332" count="22" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="1095980" count="22" label="NOVARTIS FARMACEUTICA, S.A. DE C.V."></FilterOption><FilterOption id="22598" count="22" label="Unilfarma Lda"></FilterOption><FilterOption id="DOL1000131" count="21" label="Universidad Autonoma de Madrid"></FilterOption><FilterOption id="22555" count="20" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="27108" count="20" label="Glaxo SA"></FilterOption><FilterOption id="1039423" count="20" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="1007052" count="20" label="Universidad Europea De Madrid"></FilterOption><FilterOption id="1092773" count="19" label="Hospital Puerta de Hierro Majadahonda"></FilterOption><FilterOption id="28611" count="18" label="Actelion Pharmaceuticals Ltd"></FilterOption><FilterOption id="22545" count="18" label="Boehringer Ingelheim AB"></FilterOption><FilterOption id="27847" count="18" label="Boston Scientific Corp"></FilterOption><FilterOption id="13979" count="17" label="Alexion Pharmaceuticals Inc"></FilterOption><FilterOption id="22549" count="17" label="Boehringer Ingelheim Austria GmbH"></FilterOption><FilterOption id="1099195" count="17" label="Clínica IVI Madrid"></FilterOption><FilterOption id="1042371" count="17" label="Spanish Oncology Genito-Urinary Group"></FilterOption><FilterOption id="20300" count="17" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1143375" count="16" label="AbbVie Pte Ltd"></FilterOption><FilterOption id="21283" count="16" label="Astellas Pharma Europe BV"></FilterOption><FilterOption id="1122527" count="16" label="Boehringer Ingelheim Finland Ky"></FilterOption><FilterOption id="22556" count="16" label="Boehringer Ingelheim France SARL"></FilterOption><FilterOption id="22590" count="16" label="Boehringer Ingelheim SA"></FilterOption><FilterOption id="1046331" count="16" label="Fundacion SEIMC-GESIDA"></FilterOption><FilterOption id="1084801" count="16" label="Medica Scientia Innovation Research"></FilterOption><FilterOption id="1045284" count="16" label="Spanish Cooperative Group for Gastrointestinal Tumour Therapy"></FilterOption><FilterOption id="1045513" count="16" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="14199" count="16" label="Wyeth Pharmaceuticals"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="7"><FilterOption id="4" count="3378" label="Completed"></FilterOption><FilterOption id="2" count="1385" label="Recruiting"></FilterOption><FilterOption id="3" count="965" label="No longer recruiting"></FilterOption><FilterOption id="6" count="596" label="Terminated"></FilterOption><FilterOption id="1" count="99" label="Not yet recruiting"></FilterOption><FilterOption id="12" count="82" label="Status not specified"></FilterOption><FilterOption id="5" count="25" label="Suspended"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="4243" label="Yes"></FilterOption><FilterOption id="NO" count="2287" label="No"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="3713" count="111" label="Advanced solid tumor"></FilterOption><FilterOption id="3665" count="102" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="3657" count="77" label="Metastatic breast cancer"></FilterOption><FilterOption id="2399" count="73" label="Adenocarcinoma"></FilterOption><FilterOption id="1069" count="60" label="Metastasis"></FilterOption><FilterOption id="3658" count="57" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="307" count="50" label="Squamous cell carcinoma"></FilterOption><FilterOption id="3669" count="49" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="3866" count="41" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3673" count="39" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="3666" count="35" label="Metastatic stomach cancer"></FilterOption><FilterOption id="1771" count="34" label="Transitional cell carcinoma"></FilterOption><FilterOption id="3257" count="33" label="Stage IV melanoma"></FilterOption><FilterOption id="3667" count="30" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="319" count="27" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="3466" count="26" label="Metastatic bladder cancer"></FilterOption><FilterOption id="1262" count="26" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="4250" count="25" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="1767" count="24" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="1261" count="24" label="Small-cell lung cancer"></FilterOption><FilterOption id="49" count="23" label="Breast tumor"></FilterOption><FilterOption id="57" count="23" label="Cardiovascular disease"></FilterOption><FilterOption id="2454" count="23" label="Glioblastoma"></FilterOption><FilterOption id="1705" count="22" label="Endometrioid carcinoma"></FilterOption><FilterOption id="3246" count="22" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="427" count="22" label="Uterine cervix tumor"></FilterOption><FilterOption id="1749" count="21" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="1745" count="21" label="Follicle center lymphoma"></FilterOption><FilterOption id="1828" count="21" label="Multiple myeloma"></FilterOption><FilterOption id="3664" count="19" label="Metastatic prostate cancer"></FilterOption><FilterOption id="224" count="19" label="Myocardial infarction"></FilterOption><FilterOption id="837" count="19" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="799" count="19" label="Ovary tumor"></FilterOption><FilterOption id="3083" count="18" label="Peritoneal tumor"></FilterOption><FilterOption id="291" count="18" label="Rheumatoid arthritis"></FilterOption><FilterOption id="2243" count="17" label="Fallopian tube cancer"></FilterOption><FilterOption id="1731" count="16" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="2380" count="16" label="Bladder cancer"></FilterOption><FilterOption id="1734" count="16" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="159" count="15" label="HIV-1 infection"></FilterOption><FilterOption id="793" count="14" label="Mouth tumor"></FilterOption><FilterOption id="1765" count="13" label="Cholangiocarcinoma"></FilterOption><FilterOption id="84" count="13" label="Crohns disease"></FilterOption><FilterOption id="3676" count="13" label="Ischemic stroke"></FilterOption><FilterOption id="3378" count="13" label="Soft tissue sarcoma"></FilterOption><FilterOption id="337" count="13" label="Ulcerative colitis"></FilterOption><FilterOption id="316" count="12" label="B-cell lymphoma"></FilterOption><FilterOption id="203" count="12" label="Lymphoma"></FilterOption><FilterOption id="1240" count="12" label="Mesothelioma"></FilterOption><FilterOption id="3467" count="12" label="Metastatic renal cancer"></FilterOption><FilterOption id="1128" count="12" label="Neuroendocrine tumor"></FilterOption><FilterOption id="55" count="11" label="Cardiac failure"></FilterOption><FilterOption id="2975" count="11" label="Ewing sarcoma"></FilterOption><FilterOption id="623" count="11" label="Head and neck tumor"></FilterOption><FilterOption id="2054" count="11" label="Hematological neoplasm"></FilterOption><FilterOption id="1744" count="11" label="Mantle cell lymphoma"></FilterOption><FilterOption id="1272" count="11" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="2726" count="11" label="Neuroblastoma"></FilterOption><FilterOption id="725" count="11" label="Solid tumor"></FilterOption><FilterOption id="3256" count="11" label="Stage III melanoma"></FilterOption><FilterOption id="65" count="11" label="Stroke"></FilterOption><FilterOption id="3258" count="10" label="Acute coronary syndrome"></FilterOption><FilterOption id="14" count="10" label="Alzheimers disease"></FilterOption><FilterOption id="1815" count="10" label="Bacterial pneumonia"></FilterOption><FilterOption id="651" count="10" label="Cancer"></FilterOption><FilterOption id="989" count="10" label="Colorectal tumor"></FilterOption><FilterOption id="1080" count="10" label="Female infertility"></FilterOption><FilterOption id="1108" count="10" label="Glioma"></FilterOption><FilterOption id="3198" count="10" label="Larynx tumor"></FilterOption><FilterOption id="1507" count="10" label="Pancreatic ductal adenocarcinoma"></FilterOption><FilterOption id="3351" count="10" label="Papillary thyroid tumor"></FilterOption><FilterOption id="794" count="10" label="Pharynx tumor"></FilterOption><FilterOption id="3678" count="10" label="Urethral cancer"></FilterOption><FilterOption id="760" count="9" label="Brain tumor"></FilterOption><FilterOption id="3251" count="9" label="End stage renal disease"></FilterOption><FilterOption id="153" count="9" label="Hepatitis C virus infection"></FilterOption><FilterOption id="213" count="9" label="Multiple sclerosis"></FilterOption><FilterOption id="1768" count="9" label="Nasopharyngeal carcinoma"></FilterOption><FilterOption id="127" count="9" label="Stomach tumor"></FilterOption><FilterOption id="318" count="9" label="Systemic lupus erythematosus"></FilterOption><FilterOption id="552" count="8" label="Bleeding"></FilterOption><FilterOption id="759" count="8" label="Central nervous system tumor"></FilterOption><FilterOption id="80" count="8" label="Coronary artery disease"></FilterOption><FilterOption id="161" count="8" label="Hodgkins disease"></FilterOption><FilterOption id="20" count="8" label="Pain"></FilterOption><FilterOption id="249" count="8" label="Pancreas tumor"></FilterOption><FilterOption id="2448" count="8" label="Rhabdomyosarcoma"></FilterOption><FilterOption id="398" count="7" label="Ankylosing spondylitis"></FilterOption><FilterOption id="1516" count="7" label="Biliary cancer"></FilterOption><FilterOption id="1735" count="7" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="100" count="7" label="Diabetic nephropathy"></FilterOption><FilterOption id="3003" count="7" label="Juvenile rheumatoid arthritis"></FilterOption><FilterOption id="1078" count="7" label="Lung embolism"></FilterOption><FilterOption id="1746" count="7" label="Marginal zone B-cell lymphoma"></FilterOption><FilterOption id="3668" count="7" label="Metastatic lung cancer"></FilterOption><FilterOption id="2637" count="7" label="Non-alcoholic steatohepatitis"></FilterOption><FilterOption id="717" count="7" label="Seizure disorder"></FilterOption><FilterOption id="1728" count="6" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="2193" count="6" label="Anal tumor"></FilterOption><FilterOption id="1755" count="6" label="Anaplastic large cell lymphoma"></FilterOption></Filter><Filter label="Registry Id" name="trialRegistries" total="31"><FilterOption id="1000" count="6328" label="CT.gov"></FilterOption><FilterOption id="1001" count="4598" label="EudraCT"></FilterOption><FilterOption id="1030" count="1027" label="RSRM CTR"></FilterOption><FilterOption id="1006" count="710" label="JapicCTI"></FilterOption><FilterOption id="1023" count="490" label="UKCRN"></FilterOption><FilterOption id="1019" count="376" label="DRKS"></FilterOption><FilterOption id="1004" count="311" label="WHO ICTRP"></FilterOption><FilterOption id="1012" count="281" label="CTRI"></FilterOption><FilterOption id="1035" count="262" label="Singapore HSA CTR"></FilterOption><FilterOption id="1021" count="244" label="NMRR"></FilterOption><FilterOption id="1033" count="167" label="Mexico CTR"></FilterOption><FilterOption id="1039" count="150" label="CDE"></FilterOption><FilterOption id="1009" count="148" label="HKClinicalTrials.com"></FilterOption><FilterOption id="1038" count="105" label="PHRR"></FilterOption><FilterOption id="1002" count="68" label="ISRCTN"></FilterOption><FilterOption id="1011" count="52" label="ANZCTR"></FilterOption><FilterOption id="1020" count="28" label="ReBec"></FilterOption><FilterOption id="1010" count="20" label="CRiS"></FilterOption><FilterOption id="1003" count="19" label="UMIN"></FilterOption><FilterOption id="1008" count="12" label="Hong Kong CCTCTR"></FilterOption><FilterOption id="1015" count="11" label="NTR"></FilterOption><FilterOption id="1018" count="8" label="SLCTR"></FilterOption><FilterOption id="1040" count="6" label="REec"></FilterOption><FilterOption id="1016" count="4" label="PACTR"></FilterOption><FilterOption id="1037" count="3" label="TCTR"></FilterOption><FilterOption id="1032" count="1" label="Chile CTR"></FilterOption><FilterOption id="1031" count="1" label="Estonia CTR"></FilterOption><FilterOption id="1014" count="1" label="IRCT"></FilterOption><FilterOption id="1013" count="1" label="RPCEC"></FilterOption><FilterOption id="1026" count="1" label="SANCTR"></FilterOption><FilterOption id="1024" count="1" label="TzCTR"></FilterOption></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="8"><FilterOption id="1" count="151" label="Lack of Efficacy"></FilterOption><FilterOption id="2" count="125" label="Not Reported"></FilterOption><FilterOption id="5" count="108" label="Patient Enrollment Issues"></FilterOption><FilterOption id="4" count="103" label="Other"></FilterOption><FilterOption id="8" count="64" label="Sponsor/Business Decision"></FilterOption><FilterOption id="7" count="43" label="Safety Issues"></FilterOption><FilterOption id="3" count="32" label="Operational Issues"></FilterOption><FilterOption id="6" count="5" label="Planned, not Initiated"></FilterOption></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="3803" count="114" label="paclitaxel"></FilterOption><FilterOption id="44383" count="108" label="carboplatin"></FilterOption><FilterOption id="2953" count="92" label="docetaxel"></FilterOption><FilterOption id="3199" count="87" label="gemcitabine"></FilterOption><FilterOption id="12205" count="53" label="capecitabine"></FilterOption><FilterOption id="6736" count="51" label="rituximab"></FilterOption><FilterOption id="3536" count="46" label="pemetrexed disodium"></FilterOption><FilterOption id="8047" count="45" label="bevacizumab"></FilterOption><FilterOption id="3792" count="43" label="oxaliplatin"></FilterOption><FilterOption id="6386" count="36" label="trastuzumab"></FilterOption><FilterOption id="6050" count="33" label="metformin hydrochloride"></FilterOption><FilterOption id="2871" count="26" label="irinotecan"></FilterOption><FilterOption id="6408" count="25" label="vinorelbine"></FilterOption><FilterOption id="10252" count="24" label="insulin glargine"></FilterOption><FilterOption id="7310" count="24" label="ritonavir"></FilterOption><FilterOption id="14163" count="23" label="adalimumab"></FilterOption><FilterOption id="13928" count="23" label="enoxaparin sodium"></FilterOption><FilterOption id="29016" count="23" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="49219" count="23" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="44375" count="22" label="warfarin"></FilterOption><FilterOption id="11961" count="21" label="erlotinib"></FilterOption><FilterOption id="3072" count="21" label="etoposide phosphate"></FilterOption><FilterOption id="7413" count="19" label="darbepoetin alfa"></FilterOption><FilterOption id="15954" count="18" label="bortezomib"></FilterOption><FilterOption id="3313" count="18" label="fulvestrant"></FilterOption><FilterOption id="37370" count="17" label="azacitidine"></FilterOption><FilterOption id="2784" count="17" label="letrozole"></FilterOption><FilterOption id="47000" count="16" label="bendamustine"></FilterOption><FilterOption id="8165" count="16" label="tiotropium bromide"></FilterOption><FilterOption id="44401" count="16" label="vancomycin"></FilterOption><FilterOption id="10388" count="15" label="cetuximab"></FilterOption><FilterOption id="2836" count="15" label="clopidogrel"></FilterOption><FilterOption id="7934" count="15" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="3081" count="15" label="exemestane"></FilterOption><FilterOption id="23625" count="15" label="peginterferon alfa-2a"></FilterOption><FilterOption id="70667" count="15" label="pembrolizumab"></FilterOption><FilterOption id="15254" count="14" label="atazanavir"></FilterOption><FilterOption id="12973" count="14" label="sunitinib"></FilterOption><FilterOption id="4577" count="14" label="topotecan"></FilterOption><FilterOption id="3669" count="13" label="mycophenolate mofetil"></FilterOption><FilterOption id="29831" count="13" label="sorafenib"></FilterOption><FilterOption id="4529" count="13" label="temozolomide"></FilterOption><FilterOption id="3321" count="12" label="anastrozole"></FilterOption><FilterOption id="32981" count="12" label="darunavir"></FilterOption><FilterOption id="10172" count="12" label="efavirenz"></FilterOption><FilterOption id="13340" count="12" label="everolimus"></FilterOption><FilterOption id="11460" count="12" label="imatinib"></FilterOption><FilterOption id="14493" count="12" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="10309" count="11" label="abiraterone"></FilterOption><FilterOption id="2807" count="11" label="atorvastatin"></FilterOption><FilterOption id="13022" count="11" label="epirubicin"></FilterOption><FilterOption id="6156" count="11" label="fludarabine"></FilterOption><FilterOption id="8832" count="11" label="glimepiride"></FilterOption><FilterOption id="48181" count="11" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="27572" count="11" label="lenalidomide"></FilterOption><FilterOption id="4567" count="10" label="etanercept"></FilterOption><FilterOption id="14336" count="10" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="10411" count="10" label="insulin aspart"></FilterOption><FilterOption id="33591" count="10" label="lapatinib"></FilterOption><FilterOption id="3616" count="10" label="meropenem"></FilterOption><FilterOption id="54804" count="10" label="nivolumab"></FilterOption><FilterOption id="4510" count="9" label="tacrolimus"></FilterOption><FilterOption id="28773" count="8" label="eribulin mesylate"></FilterOption><FilterOption id="6850" count="8" label="infliximab"></FilterOption><FilterOption id="3360" count="8" label="interferon beta-1a, Biogen"></FilterOption><FilterOption id="14681" count="8" label="lopinavir + ritonavir"></FilterOption><FilterOption id="11519" count="8" label="mitoxantrone"></FilterOption><FilterOption id="27696" count="8" label="pomalidomide"></FilterOption><FilterOption id="72699" count="7" label="atezolizumab"></FilterOption><FilterOption id="5999" count="7" label="ciclosporin, Novartis"></FilterOption><FilterOption id="13239" count="7" label="decitabine"></FilterOption><FilterOption id="3159" count="7" label="fluticasone propionate"></FilterOption><FilterOption id="5148" count="7" label="liraglutide"></FilterOption><FilterOption id="22395" count="7" label="ranibizumab"></FilterOption><FilterOption id="5369" count="7" label="ribavirin"></FilterOption><FilterOption id="42858" count="7" label="ustekinumab"></FilterOption><FilterOption id="44384" count="6" label="ceftriaxone"></FilterOption><FilterOption id="3353" count="6" label="insulin lispro"></FilterOption><FilterOption id="36630" count="6" label="ipilimumab"></FilterOption><FilterOption id="3474" count="6" label="lamivudine"></FilterOption><FilterOption id="53227" count="6" label="obinutuzumab"></FilterOption><FilterOption id="13460" count="6" label="oseltamivir"></FilterOption><FilterOption id="43738" count="6" label="pazopanib"></FilterOption><FilterOption id="9702" count="6" label="recombinant interferon beta-1a, Merck Serono"></FilterOption><FilterOption id="4234" count="6" label="risedronate sodium"></FilterOption><FilterOption id="44312" count="6" label="salmeterol"></FilterOption><FilterOption id="10488" count="6" label="tolterodine"></FilterOption><FilterOption id="15130" count="6" label="vinflunine"></FilterOption><FilterOption id="59062" count="5" label="dolutegravir"></FilterOption><FilterOption id="4728" count="5" label="emtricitabine"></FilterOption><FilterOption id="53981" count="5" label="enzalutamide"></FilterOption><FilterOption id="5267" count="5" label="leuprorelin acetate"></FilterOption><FilterOption id="12978" count="5" label="moxifloxacin"></FilterOption><FilterOption id="42299" count="5" label="ofatumumab"></FilterOption><FilterOption id="3750" count="5" label="ondansetron"></FilterOption><FilterOption id="21374" count="5" label="pegfilgrastim"></FilterOption><FilterOption id="28532" count="5" label="pertuzumab"></FilterOption><FilterOption id="44313" count="5" label="simvastatin"></FilterOption><FilterOption id="4513" count="5" label="tamsulosin hydrochloride"></FilterOption><FilterOption id="36332" count="5" label="ticagrelor"></FilterOption></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="6258" count="238" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="5125" count="236" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"></FilterOption><FilterOption id="5132" count="225" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="5193" count="219" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="20282" count="217" label="Lung tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="6247" count="211" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"></FilterOption><FilterOption id="6294" count="207" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="10704" count="195" label="Solid tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6272" count="186" label="Breast tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="4702" count="176" label="Lymphoma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5270" count="174" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6554" count="169" label="Leukemia - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6393" count="167" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="6331" count="165" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="5365" count="165" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="6328" count="163" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"></FilterOption><FilterOption id="5345" count="158" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="6859" count="156" label="HIV infection - Pregnant or Breast Feeding Subjects"></FilterOption><FilterOption id="5291" count="154" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"></FilterOption><FilterOption id="6377" count="152" label="Breast tumor - Subjects with history of/planned radiotherapy"></FilterOption><FilterOption id="5282" count="151" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"></FilterOption><FilterOption id="10761" count="151" label="Solid tumor - Subjects with Evidence of Metastasis - Subjects with brain/CNS metastasis"></FilterOption><FilterOption id="5139" count="141" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="6252" count="133" label="Breast tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6253" count="122" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"></FilterOption><FilterOption id="6845" count="121" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="20281" count="119" label="Lung tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6756" count="118" label="Lung tumor - Subjects with History of/Scheduled for Other Cancer Therapies"></FilterOption><FilterOption id="6260" count="115" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="5349" count="115" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"></FilterOption><FilterOption id="4692" count="115" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="5128" count="113" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"></FilterOption><FilterOption id="20290" count="110" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="6302" count="110" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"></FilterOption><FilterOption id="5269" count="110" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="20114" count="109" label="Pain - Subjects with Co-morbid Conditions - Subjects co-morbid with CNS disorders/diseases"></FilterOption><FilterOption id="5149" count="107" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="5163" count="105" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="12316" count="105" label="Solid tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="5841" count="103" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="5826" count="101" label="Colorectal tumor - Subjects with Metastatic Colorectal Cancer - Subjects with brain metastases or leptomeningeal carcinomatosis"></FilterOption><FilterOption id="10739" count="101" label="Solid tumor - Subjects with History of Other Non Anti-cancer Drugs/Agents"></FilterOption><FilterOption id="20289" count="100" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"></FilterOption><FilterOption id="5277" count="100" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for biological therapy"></FilterOption><FilterOption id="4769" count="100" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="5285" count="98" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="6534" count="97" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="20112" count="95" label="Pain - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6783" count="93" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for immunotherapy"></FilterOption><FilterOption id="6065" count="93" label="Multiple myeloma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6261" count="92" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="17519" count="91" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="5344" count="89" label="Lung tumor - Protocol Specified Other Exclusion Criteria"></FilterOption><FilterOption id="9810" count="89" label="Ovary tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6259" count="88" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="5347" count="87" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Subjects with abnormal laboratory values"></FilterOption><FilterOption id="10378" count="87" label="Pancreas tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5856" count="86" label="Colorectal tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="5864" count="85" label="Colorectal tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="4810" count="85" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"></FilterOption><FilterOption id="5962" count="83" label="Colorectal tumor - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="6820" count="83" label="HIV infection - Subjects with Opportunistic/Other Infections"></FilterOption><FilterOption id="4909" count="83" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="10736" count="83" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"></FilterOption><FilterOption id="6767" count="82" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"></FilterOption><FilterOption id="6361" count="81" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"></FilterOption><FilterOption id="5879" count="80" label="Colorectal tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6941" count="80" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"></FilterOption><FilterOption id="6892" count="80" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="6757" count="80" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects with history of/current participation in other clinical trials"></FilterOption><FilterOption id="5949" count="79" label="Colorectal tumor - Subjects with history of/scheduled to receive radiation therapy"></FilterOption><FilterOption id="6660" count="79" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"></FilterOption><FilterOption id="20174" count="79" label="Pain - Subjects with History/ Scheduled to Undergo Other Therapy/Procedures - Subjects with history/scheduled to receive other drug therapies"></FilterOption><FilterOption id="6474" count="78" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="3058" count="78" label="Chronic obstructive pulmonary disease - Subjects co-morbid with Respiratory Diseases/Disorders"></FilterOption><FilterOption id="5744" count="78" label="Head and neck tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="20123" count="78" label="Pain - Subjects with Co-morbid Conditions - Subjects with infectious disorders/disease"></FilterOption><FilterOption id="4967" count="78" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="4847" count="76" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"></FilterOption><FilterOption id="10732" count="76" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="10738" count="76" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="9003" count="75" label="Bladder cancer - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="5848" count="75" label="Colorectal tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="17531" count="75" label="End stage renal disease - Subjects co-morbid with infections"></FilterOption><FilterOption id="4764" count="74" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of stem cell therapy"></FilterOption><FilterOption id="20292" count="73" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="17557" count="72" label="Breast tumor - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="4762" count="72" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subject with history of radiotherapy"></FilterOption><FilterOption id="9809" count="72" label="Ovary tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="5176" count="70" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"></FilterOption><FilterOption id="5470" count="70" label="Melanoma - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="10717" count="70" label="Solid tumor - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"></FilterOption><FilterOption id="5934" count="69" label="Colorectal tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="17541" count="69" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"></FilterOption><FilterOption id="837" count="69" label="Non-insulin dependent diabetes - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="5954" count="68" label="Colorectal tumor - Subjects with History of/Scheduled for Intervention/Surgery"></FilterOption><FilterOption id="5236" count="68" label="Lung tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="4783" count="68" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="851" count="68" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 1 diabetes mellitus"></FilterOption><FilterOption id="925" count="68" label="Non-insulin dependent diabetes - Subjects with History of/Active Malignancy/Cancer"></FilterOption></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="48" label="201905"></FilterOption><FilterOption count="45" label="201705"></FilterOption><FilterOption count="43" label="201803"></FilterOption><FilterOption count="43" label="201904"></FilterOption><FilterOption count="42" label="201802"></FilterOption><FilterOption count="40" label="201603"></FilterOption><FilterOption count="38" label="201509"></FilterOption><FilterOption count="37" label="201807"></FilterOption><FilterOption count="37" label="201901"></FilterOption><FilterOption count="36" label="201906"></FilterOption><FilterOption count="35" label="201504"></FilterOption><FilterOption count="35" label="201510"></FilterOption><FilterOption count="35" label="201708"></FilterOption><FilterOption count="35" label="201709"></FilterOption><FilterOption count="34" label="201512"></FilterOption><FilterOption count="34" label="201801"></FilterOption><FilterOption count="34" label="201809"></FilterOption><FilterOption count="33" label="201607"></FilterOption><FilterOption count="32" label="201601"></FilterOption><FilterOption count="32" label="201608"></FilterOption><FilterOption count="32" label="201703"></FilterOption><FilterOption count="32" label="201710"></FilterOption><FilterOption count="32" label="201806"></FilterOption><FilterOption count="31" label="201302"></FilterOption><FilterOption count="31" label="201609"></FilterOption><FilterOption count="31" label="201810"></FilterOption><FilterOption count="31" label="201812"></FilterOption><FilterOption count="31" label="201903"></FilterOption><FilterOption count="30" label="201311"></FilterOption><FilterOption count="30" label="201503"></FilterOption><FilterOption count="30" label="201506"></FilterOption><FilterOption count="30" label="201507"></FilterOption><FilterOption count="30" label="201706"></FilterOption><FilterOption count="30" label="201711"></FilterOption><FilterOption count="28" label="201305"></FilterOption><FilterOption count="28" label="201505"></FilterOption><FilterOption count="28" label="201605"></FilterOption><FilterOption count="28" label="201811"></FilterOption><FilterOption count="28" label="201902"></FilterOption><FilterOption count="27" label="201511"></FilterOption><FilterOption count="27" label="201805"></FilterOption><FilterOption count="26" label="201105"></FilterOption><FilterOption count="26" label="201210"></FilterOption><FilterOption count="26" label="201308"></FilterOption><FilterOption count="26" label="201310"></FilterOption><FilterOption count="26" label="201312"></FilterOption><FilterOption count="26" label="201502"></FilterOption><FilterOption count="26" label="201604"></FilterOption><FilterOption count="26" label="201701"></FilterOption><FilterOption count="26" label="201808"></FilterOption><FilterOption count="25" label="201307"></FilterOption><FilterOption count="25" label="201402"></FilterOption><FilterOption count="25" label="201408"></FilterOption><FilterOption count="25" label="201702"></FilterOption><FilterOption count="24" label="201106"></FilterOption><FilterOption count="24" label="201406"></FilterOption><FilterOption count="24" label="201612"></FilterOption><FilterOption count="24" label="201712"></FilterOption><FilterOption count="23" label="201207"></FilterOption><FilterOption count="23" label="201301"></FilterOption><FilterOption count="23" label="201501"></FilterOption><FilterOption count="23" label="201606"></FilterOption><FilterOption count="23" label="201611"></FilterOption><FilterOption count="22" label="201110"></FilterOption><FilterOption count="22" label="201203"></FilterOption><FilterOption count="22" label="201309"></FilterOption><FilterOption count="22" label="201403"></FilterOption><FilterOption count="22" label="201704"></FilterOption><FilterOption count="22" label="201707"></FilterOption><FilterOption count="21" label="200810"></FilterOption><FilterOption count="21" label="201004"></FilterOption><FilterOption count="21" label="201103"></FilterOption><FilterOption count="21" label="201112"></FilterOption><FilterOption count="21" label="201401"></FilterOption><FilterOption count="21" label="201404"></FilterOption><FilterOption count="21" label="201405"></FilterOption><FilterOption count="21" label="201508"></FilterOption><FilterOption count="20" label="200906"></FilterOption><FilterOption count="20" label="201001"></FilterOption><FilterOption count="20" label="201107"></FilterOption><FilterOption count="20" label="201201"></FilterOption><FilterOption count="20" label="201410"></FilterOption><FilterOption count="20" label="201804"></FilterOption><FilterOption count="19" label="200909"></FilterOption><FilterOption count="19" label="201005"></FilterOption><FilterOption count="19" label="201602"></FilterOption><FilterOption count="19" label="201610"></FilterOption><FilterOption count="18" label="200910"></FilterOption><FilterOption count="18" label="201010"></FilterOption><FilterOption count="18" label="201409"></FilterOption><FilterOption count="17" label="200904"></FilterOption><FilterOption count="17" label="201101"></FilterOption><FilterOption count="17" label="201102"></FilterOption><FilterOption count="17" label="201109"></FilterOption><FilterOption count="17" label="201303"></FilterOption><FilterOption count="17" label="201304"></FilterOption><FilterOption count="17" label="201306"></FilterOption><FilterOption count="17" label="201407"></FilterOption><FilterOption count="17" label="201411"></FilterOption><FilterOption count="17" label="201412"></FilterOption></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="5600" label="Company"></FilterOption><FilterOption id="ACA" count="1368" label="Academic"></FilterOption><FilterOption id="OTH" count="45" label="Others"></FilterOption><FilterOption id="GOV" count="43" label="Government"></FilterOption><FilterOption id="NGO" count="26" label="Non-Government"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="11"><FilterOption id="NSWE" count="6365" label="Northern, Southern &amp; Western Europe"></FilterOption><FilterOption id="USCA" count="3860" label="US &amp; Canada"></FilterOption><FilterOption id="EEUR" count="3500" label="Eastern Europe"></FilterOption><FilterOption id="EAPO" count="2188" label="East Asia &amp; Pacific Ocean"></FilterOption><FilterOption id="AUNZ" count="2132" label="Australia &amp; New Zealand"></FilterOption><FilterOption id="MENA" count="1889" label="Middle East &amp; North Africa"></FilterOption><FilterOption id="SOAM" count="1793" label="South America"></FilterOption><FilterOption id="CAAC" count="1407" label="Central America &amp; Caribbean"></FilterOption><FilterOption id="CSAF" count="912" label="Central &amp; Southern Africa"></FilterOption><FilterOption id="SOCA" count="599" label="Southern &amp; Central Asia"></FilterOption><FilterOption id="INDO" count="4" label="Indian Ocean"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="3634" count="307" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"></FilterOption><FilterOption id="3954" count="295" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"></FilterOption><FilterOption id="3617" count="283" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="10295" count="218" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"></FilterOption><FilterOption id="7126" count="193" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"></FilterOption><FilterOption id="7961" count="185" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"></FilterOption><FilterOption id="3623" count="161" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"></FilterOption><FilterOption id="3824" count="156" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"></FilterOption><FilterOption id="3952" count="151" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"></FilterOption><FilterOption id="7967" count="145" label="Solid tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3965" count="144" label="Breast tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3937" count="142" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="3530" count="131" label="Lymphoma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="461" count="122" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="3647" count="120" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3936" count="118" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="3525" count="118" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"></FilterOption><FilterOption id="502" count="115" label="Rheumatoid arthritis - Active Rheumatoid Arthritis"></FilterOption><FilterOption id="145" count="110" label="Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="103" count="108" label="Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="3966" count="106" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"></FilterOption><FilterOption id="3931" count="103" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="3564" count="102" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"></FilterOption><FilterOption id="12053" count="100" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="8073" count="90" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"></FilterOption><FilterOption id="3650" count="89" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"></FilterOption><FilterOption id="3814" count="84" label="Colorectal tumor - Subjects with Colon Cancer"></FilterOption><FilterOption id="513" count="84" label="Rheumatoid arthritis - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="7877" count="83" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"></FilterOption><FilterOption id="3938" count="81" label="Breast tumor - Subjects with Triple Negative Breast Cancer"></FilterOption><FilterOption id="3667" count="81" label="Melanoma - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3945" count="77" label="Breast tumor - Subjects with Stage III Breast Cancer"></FilterOption><FilterOption id="3956" count="75" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"></FilterOption><FilterOption id="7487" count="75" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="3500" count="72" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"></FilterOption><FilterOption id="3583" count="72" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"></FilterOption><FilterOption id="3813" count="71" label="Colorectal tumor - Subjects with Rectal Cancer"></FilterOption><FilterOption id="3977" count="71" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"></FilterOption><FilterOption id="3473" count="71" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"></FilterOption><FilterOption id="3926" count="70" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"></FilterOption><FilterOption id="3586" count="70" label="Prostate tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="8010" count="69" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"></FilterOption><FilterOption id="3778" count="68" label="Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma"></FilterOption><FilterOption id="3472" count="68" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"></FilterOption><FilterOption id="3680" count="67" label="Melanoma - Subjects with Stage IV Melanoma"></FilterOption><FilterOption id="100" count="67" label="Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent"></FilterOption><FilterOption id="3565" count="67" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"></FilterOption><FilterOption id="3774" count="66" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"></FilterOption><FilterOption id="3489" count="66" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"></FilterOption><FilterOption id="3923" count="66" label="Multiple myeloma - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="128" count="66" label="Multiple sclerosis - Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)"></FilterOption><FilterOption id="7415" count="65" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"></FilterOption><FilterOption id="7810" count="63" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"></FilterOption><FilterOption id="3637" count="63" label="Lung tumor - Subjects with Unresectable/In-operable Lung Cancer"></FilterOption><FilterOption id="538" count="63" label="Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy - Methotrexate"></FilterOption><FilterOption id="12845" count="62" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"></FilterOption><FilterOption id="10129" count="62" label="Lung tumor - Subjects with EGFR Positive Lung Cancer"></FilterOption><FilterOption id="3502" count="62" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"></FilterOption><FilterOption id="7960" count="62" label="Solid tumor - Subjects with Locally Advanced Solid Tumors"></FilterOption><FilterOption id="7107" count="60" label="HIV infection - Treatment Naive Subjects"></FilterOption><FilterOption id="4003" count="60" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"></FilterOption><FilterOption id="7879" count="60" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"></FilterOption><FilterOption id="12018" count="59" label="Prostate tumor - Subjects with adenocarcinoma of prostate"></FilterOption><FilterOption id="3932" count="58" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="3980" count="58" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"></FilterOption><FilterOption id="3999" count="58" label="Leukemia - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="102" count="58" label="Non-insulin dependent diabetes - Subjects with Good Glycemic Control"></FilterOption><FilterOption id="3860" count="57" label="Colorectal tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3736" count="56" label="Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers"></FilterOption><FilterOption id="562" count="56" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD"></FilterOption><FilterOption id="11954" count="55" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"></FilterOption><FilterOption id="8414" count="55" label="Pain - Subjects with Somatic Pain - Subjects with arthritic pain"></FilterOption><FilterOption id="500" count="55" label="Rheumatoid arthritis - Severe Rheumatoid Arthritis"></FilterOption><FilterOption id="561" count="54" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD"></FilterOption><FilterOption id="489" count="54" label="Hepatitis C virus infection - Treatment Naive Subjects"></FilterOption><FilterOption id="499" count="54" label="Rheumatoid arthritis - Moderate Rheumatoid Arthritis"></FilterOption><FilterOption id="161" count="53" label="Alzheimers disease - Subjects with Mild Alzheimer's Disease"></FilterOption><FilterOption id="7700" count="53" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="7108" count="53" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="11612" count="52" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects"></FilterOption><FilterOption id="3434" count="52" label="Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris"></FilterOption><FilterOption id="7966" count="52" label="Solid tumor - Subjects with Relapsed/Recurrent Solid Tumors"></FilterOption><FilterOption id="3950" count="51" label="Breast tumor - Subjects with Early Stage Breast Cancer"></FilterOption><FilterOption id="3944" count="51" label="Breast tumor - Subjects with Stage II Breast Cancer"></FilterOption><FilterOption id="7486" count="51" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with squamous cell lung cancer"></FilterOption><FilterOption id="108" count="51" label="Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity"></FilterOption><FilterOption id="201" count="49" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"></FilterOption><FilterOption id="3681" count="49" label="Melanoma - Subjects with Evidence of Metastasis"></FilterOption><FilterOption id="3698" count="49" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"></FilterOption><FilterOption id="7918" count="49" label="Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects"></FilterOption><FilterOption id="7402" count="49" label="Renal cell carcinoma - Subjects with Clear Cell Renal Cell Carcinoma"></FilterOption><FilterOption id="11424" count="48" label="Pancreas tumor - Subjects with Adenocarcinoma of Pancreas"></FilterOption><FilterOption id="9884" count="47" label="Hemophilia - Subjects with Severe Hemophilia"></FilterOption><FilterOption id="3501" count="47" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"></FilterOption><FilterOption id="7414" count="47" label="Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma"></FilterOption><FilterOption id="8387" count="46" label="Pain - Subjects with Chronic Pain"></FilterOption><FilterOption id="3452" count="45" label="Psoriasis - Subjects with Severe Psoriasis"></FilterOption><FilterOption id="8025" count="45" label="Stomach tumor - Subjects with adenocarcinoma of the gastroesophageal junction"></FilterOption><FilterOption id="9876" count="44" label="Hemophilia - Subjects with Hemophilia A"></FilterOption><FilterOption id="7962" count="44" label="Solid tumor - Subjects with Unresectable Solid Tumors"></FilterOption></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="125" label="201912"></FilterOption><FilterOption count="66" label="202012"></FilterOption><FilterOption count="65" label="201812"></FilterOption><FilterOption count="64" label="201906"></FilterOption><FilterOption count="64" label="202006"></FilterOption><FilterOption count="63" label="201909"></FilterOption><FilterOption count="61" label="201905"></FilterOption><FilterOption count="61" label="202003"></FilterOption><FilterOption count="57" label="201803"></FilterOption><FilterOption count="56" label="201907"></FilterOption><FilterOption count="55" label="201712"></FilterOption><FilterOption count="55" label="201910"></FilterOption><FilterOption count="50" label="201512"></FilterOption><FilterOption count="49" label="201612"></FilterOption><FilterOption count="47" label="201606"></FilterOption><FilterOption count="47" label="201704"></FilterOption><FilterOption count="47" label="201707"></FilterOption><FilterOption count="47" label="201808"></FilterOption><FilterOption count="47" label="201911"></FilterOption><FilterOption count="46" label="201904"></FilterOption><FilterOption count="46" label="202001"></FilterOption><FilterOption count="45" label="201809"></FilterOption><FilterOption count="45" label="201810"></FilterOption><FilterOption count="44" label="201908"></FilterOption><FilterOption count="44" label="202005"></FilterOption><FilterOption count="44" label="202007"></FilterOption><FilterOption count="43" label="201807"></FilterOption><FilterOption count="42" label="201603"></FilterOption><FilterOption count="42" label="201604"></FilterOption><FilterOption count="42" label="201609"></FilterOption><FilterOption count="42" label="201701"></FilterOption><FilterOption count="42" label="201805"></FilterOption><FilterOption count="42" label="201806"></FilterOption><FilterOption count="41" label="201703"></FilterOption><FilterOption count="41" label="201705"></FilterOption><FilterOption count="41" label="201706"></FilterOption><FilterOption count="41" label="201709"></FilterOption><FilterOption count="41" label="202002"></FilterOption><FilterOption count="40" label="201801"></FilterOption><FilterOption count="40" label="201901"></FilterOption><FilterOption count="39" label="201710"></FilterOption><FilterOption count="39" label="202009"></FilterOption><FilterOption count="38" label="201507"></FilterOption><FilterOption count="38" label="201903"></FilterOption><FilterOption count="38" label="202106"></FilterOption><FilterOption count="37" label="201610"></FilterOption><FilterOption count="37" label="201811"></FilterOption><FilterOption count="37" label="202010"></FilterOption><FilterOption count="36" label="201505"></FilterOption><FilterOption count="36" label="201506"></FilterOption><FilterOption count="36" label="201605"></FilterOption><FilterOption count="36" label="201607"></FilterOption><FilterOption count="36" label="201611"></FilterOption><FilterOption count="36" label="202004"></FilterOption><FilterOption count="36" label="202112"></FilterOption><FilterOption count="35" label="201303"></FilterOption><FilterOption count="35" label="201804"></FilterOption><FilterOption count="35" label="202104"></FilterOption><FilterOption count="35" label="202109"></FilterOption><FilterOption count="34" label="201402"></FilterOption><FilterOption count="34" label="201404"></FilterOption><FilterOption count="33" label="201103"></FilterOption><FilterOption count="33" label="201310"></FilterOption><FilterOption count="33" label="201409"></FilterOption><FilterOption count="33" label="201502"></FilterOption><FilterOption count="33" label="201510"></FilterOption><FilterOption count="33" label="201511"></FilterOption><FilterOption count="33" label="201602"></FilterOption><FilterOption count="33" label="202011"></FilterOption><FilterOption count="32" label="201410"></FilterOption><FilterOption count="32" label="201711"></FilterOption><FilterOption count="31" label="201309"></FilterOption><FilterOption count="31" label="201407"></FilterOption><FilterOption count="30" label="201206"></FilterOption><FilterOption count="30" label="201305"></FilterOption><FilterOption count="30" label="201403"></FilterOption><FilterOption count="30" label="201702"></FilterOption><FilterOption count="30" label="202103"></FilterOption><FilterOption count="29" label="201105"></FilterOption><FilterOption count="29" label="201708"></FilterOption><FilterOption count="28" label="201112"></FilterOption><FilterOption count="28" label="201205"></FilterOption><FilterOption count="28" label="201209"></FilterOption><FilterOption count="28" label="201302"></FilterOption><FilterOption count="28" label="201412"></FilterOption><FilterOption count="28" label="202008"></FilterOption><FilterOption count="28" label="202101"></FilterOption><FilterOption count="27" label="201503"></FilterOption><FilterOption count="26" label="200807"></FilterOption><FilterOption count="26" label="201011"></FilterOption><FilterOption count="26" label="201212"></FilterOption><FilterOption count="26" label="201304"></FilterOption><FilterOption count="26" label="201401"></FilterOption><FilterOption count="26" label="201504"></FilterOption><FilterOption count="26" label="201601"></FilterOption><FilterOption count="26" label="202108"></FilterOption><FilterOption count="25" label="200906"></FilterOption><FilterOption count="25" label="200912"></FilterOption><FilterOption count="25" label="201007"></FilterOption><FilterOption count="25" label="201203"></FilterOption></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="ES" count="6306" label="Spain"></FilterOption><FilterOption id="DE" count="3719" label="Germany"></FilterOption><FilterOption id="US" count="3593" label="US"></FilterOption><FilterOption id="FR" count="3479" label="France"></FilterOption><FilterOption id="IT" count="3414" label="Italy"></FilterOption><FilterOption id="GB" count="3210" label="UK"></FilterOption><FilterOption id="CA" count="2652" label="Canada"></FilterOption><FilterOption id="BE" count="2572" label="Belgium"></FilterOption><FilterOption id="PL" count="2415" label="Poland"></FilterOption><FilterOption id="AU" count="2095" label="Australia"></FilterOption><FilterOption id="NL" count="2066" label="Netherlands"></FilterOption><FilterOption id="RU" count="1803" label="Russian Federation"></FilterOption><FilterOption id="HU" count="1736" label="Hungary"></FilterOption><FilterOption id="CZ" count="1707" label="Czech Republic"></FilterOption><FilterOption id="AT" count="1589" label="Austria"></FilterOption><FilterOption id="SE" count="1474" label="Sweden"></FilterOption><FilterOption id="KR" count="1440" label="South Korea"></FilterOption><FilterOption id="IL" count="1391" label="Israel"></FilterOption><FilterOption id="DK" count="1296" label="Denmark"></FilterOption><FilterOption id="BR" count="1245" label="Brazil"></FilterOption><FilterOption id="AR" count="1180" label="Argentina"></FilterOption><FilterOption id="CH" count="1148" label="Switzerland"></FilterOption><FilterOption id="MX" count="1136" label="Mexico"></FilterOption><FilterOption id="TW" count="1098" label="Taiwan"></FilterOption><FilterOption id="GR" count="1063" label="Greece"></FilterOption><FilterOption id="RO" count="1025" label="Romania"></FilterOption><FilterOption id="PT" count="1020" label="Portugal"></FilterOption><FilterOption id="JP" count="980" label="Japan"></FilterOption><FilterOption id="TR" count="906" label="Turkey"></FilterOption><FilterOption id="ZA" count="897" label="South Africa"></FilterOption><FilterOption id="FI" count="857" label="Finland"></FilterOption><FilterOption id="BG" count="828" label="Bulgaria"></FilterOption><FilterOption id="SK" count="751" label="Slovakia"></FilterOption><FilterOption id="UA" count="734" label="Ukraine"></FilterOption><FilterOption id="NO" count="710" label="Norway"></FilterOption><FilterOption id="IE" count="661" label="Ireland"></FilterOption><FilterOption id="NZ" count="577" label="New Zealand"></FilterOption><FilterOption id="IN" count="574" label="India"></FilterOption><FilterOption id="CL" count="573" label="Chile"></FilterOption><FilterOption id="CN" count="555" label="China"></FilterOption><FilterOption id="SG" count="537" label="Singapore"></FilterOption><FilterOption id="HK" count="528" label="Hong Kong"></FilterOption><FilterOption id="TH" count="477" label="Thailand"></FilterOption><FilterOption id="CO" count="465" label="Colombia"></FilterOption><FilterOption id="RS" count="440" label="Serbia"></FilterOption><FilterOption id="LT" count="437" label="Lithuania"></FilterOption><FilterOption id="PR" count="434" label="Puerto Rico"></FilterOption><FilterOption id="HR" count="409" label="Croatia"></FilterOption><FilterOption id="PE" count="405" label="Peru"></FilterOption><FilterOption id="EE" count="395" label="Estonia"></FilterOption><FilterOption id="LV" count="378" label="Latvia"></FilterOption><FilterOption id="MY" count="373" label="Malaysia"></FilterOption><FilterOption id="PH" count="287" label="Philippines"></FilterOption><FilterOption id="X5" count="238" label="Europe"></FilterOption><FilterOption id="SI" count="199" label="Slovenia"></FilterOption><FilterOption id="GE" count="107" label="Georgia"></FilterOption><FilterOption id="EG" count="105" label="Egypt"></FilterOption><FilterOption id="BY" count="103" label="Belarus"></FilterOption><FilterOption id="SA" count="101" label="Saudi Arabia"></FilterOption><FilterOption id="BA" count="99" label="Bosnia and Herzegovina"></FilterOption><FilterOption id="GT" count="99" label="Guatemala"></FilterOption><FilterOption id="PA" count="95" label="Panama"></FilterOption><FilterOption id="LB" count="94" label="Lebanon"></FilterOption><FilterOption id="XD" count="89" label="North America"></FilterOption><FilterOption id="VN" count="78" label="Vietnam"></FilterOption><FilterOption id="X2" count="72" label="Asia"></FilterOption><FilterOption id="CR" count="65" label="Costa Rica"></FilterOption><FilterOption id="KP" count="57" label="North Korea"></FilterOption><FilterOption id="IS" count="50" label="Iceland"></FilterOption><FilterOption id="VE" count="50" label="Venezuela"></FilterOption><FilterOption id="MK" count="45" label="Macedonia, The Former Yugoslav Republic of"></FilterOption><FilterOption id="TN" count="44" label="Tunisia"></FilterOption><FilterOption id="LU" count="42" label="Luxembourg"></FilterOption><FilterOption id="XE" count="42" label="South America"></FilterOption><FilterOption id="EU" count="41" label="EU"></FilterOption><FilterOption id="AE" count="40" label="United Arab Emirates"></FilterOption><FilterOption id="ID" count="36" label="Indonesia"></FilterOption><FilterOption id="DO" count="33" label="Dominican Republic"></FilterOption><FilterOption id="EC" count="33" label="Ecuador"></FilterOption><FilterOption id="MD" count="33" label="Moldova, Republic of"></FilterOption><FilterOption id="PK" count="33" label="Pakistan"></FilterOption><FilterOption id="JO" count="28" label="Jordan"></FilterOption><FilterOption id="DZ" count="23" label="Algeria"></FilterOption><FilterOption id="MA" count="22" label="Morocco"></FilterOption><FilterOption id="CY" count="19" label="Cyprus"></FilterOption><FilterOption id="KZ" count="15" label="Kazakhstan"></FilterOption><FilterOption id="UY" count="15" label="Uruguay"></FilterOption><FilterOption id="SV" count="14" label="El Salvador"></FilterOption><FilterOption id="ME" count="14" label="Montenegro"></FilterOption><FilterOption id="MT" count="13" label="Malta"></FilterOption><FilterOption id="KW" count="12" label="Kuwait"></FilterOption><FilterOption id="LK" count="12" label="Sri Lanka"></FilterOption><FilterOption id="XW" count="11" label="Western Europe"></FilterOption><FilterOption id="BS" count="10" label="Bahamas"></FilterOption><FilterOption id="MC" count="10" label="Monaco"></FilterOption><FilterOption id="AS" count="9" label="American Samoa"></FilterOption><FilterOption id="QA" count="9" label="Qatar"></FilterOption><FilterOption id="X0" count="8" label="Africa"></FilterOption><FilterOption id="AL" count="8" label="Albania"></FilterOption><FilterOption id="OM" count="8" label="Oman"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="17"><FilterOption id="EAMAA" count="5754" label="Middle-aged Adults (45-64 yrs)"></FilterOption><FilterOption id="EAYAD" count="5705" label="Young Adults (18-44 yrs)"></FilterOption><FilterOption id="EAAAD" count="5521" label="Aged Adults (65-79 yrs)"></FilterOption><FilterOption id="EAELD" count="4723" label="Elderly Adults (80 and over)"></FilterOption><FilterOption id="EAADL" count="635" label="Adolescents (13-17 yrs)"></FilterOption><FilterOption id="EACHI" count="568" label="Children (6-12 yrs)"></FilterOption><FilterOption id="EGFEM" count="557" label="Female"></FilterOption><FilterOption id="EAPRE" count="343" label="Preschool Children (2-5 yrs)"></FilterOption><FilterOption id="EGMAL" count="266" label="Male"></FilterOption><FilterOption id="EVHVA" count="257" label="Healthy volunteers accepted"></FilterOption><FilterOption id="EAINF" count="245" label="Infants (6-23 months)"></FilterOption><FilterOption id="EANEW" count="195" label="Newborn Infants (up to 5 months)"></FilterOption><FilterOption id="ECASI" count="68" label="Asian Ancestry"></FilterOption><FilterOption id="ECJAP" count="66" label="Japanese Ancestry"></FilterOption><FilterOption id="ECEUR" count="41" label="European Ancestry"></FilterOption><FilterOption id="EVHVO" count="26" label="Healthy volunteers only"></FilterOption><FilterOption id="ECAFR" count="13" label="African Ancestry"></FilterOption></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="27"><FilterOption id="SSTINV" count="5997" label="Interventional"></FilterOption><FilterOption id="SIPTRE" count="5593" label="Treatment"></FilterOption><FilterOption id="SIARND" count="4358" label="Randomized"></FilterOption><FilterOption id="SISPRL" count="4357" label="Parallel Assignment"></FilterOption><FilterOption id="SIMOPN" count="3063" label="Open Label"></FilterOption><FilterOption id="SIMMBD" count="2673" label="Multiple Blind"></FilterOption><FilterOption id="SICPLC" count="2308" label="Placebo Control"></FilterOption><FilterOption id="SICACT" count="1458" label="Active Control"></FilterOption><FilterOption id="SISSNG" count="1253" label="Single Group Assignment"></FilterOption><FilterOption id="SIANON" count="1199" label="Non-Randomized"></FilterOption><FilterOption id="SICNOC" count="896" label="No Control"></FilterOption><FilterOption id="SSTOBS" count="518" label="Observational"></FilterOption><FilterOption id="SIPPRE" count="377" label="Prevention"></FilterOption><FilterOption id="SOTPRO" count="371" label="Prospective"></FilterOption><FilterOption id="SOSCOH" count="326" label="Cohort"></FilterOption><FilterOption id="SIMSBD" count="185" label="Single Blind"></FilterOption><FilterOption id="SISXOV" count="130" label="Crossover Assignment"></FilterOption><FilterOption id="SOTRET" count="114" label="Retrospective"></FilterOption><FilterOption id="SODXSC" count="45" label="Cross-sectional"></FilterOption><FilterOption id="SOSCSC" count="42" label="Case Control"></FilterOption><FilterOption id="SICDSC" count="25" label="Dose Comparison"></FilterOption><FilterOption id="SIPDIA" count="24" label="Diagnosis"></FilterOption><FilterOption id="SODLNG" count="23" label="Longitudinal"></FilterOption><FilterOption id="SICHST" count="21" label="Historical Control"></FilterOption><FilterOption id="SISFCT" count="18" label="Factorial Assignment"></FilterOption><FilterOption id="SISEAA" count="3" label="Expanded Access Assignment"></FilterOption><FilterOption id="SOSDEF" count="2" label="Defined Population"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="4021" label="ClinicalTrials.gov and others"></FilterOption><FilterOption id="CTGOV" count="2265" label="ClinicalTrials.gov only"></FilterOption><FilterOption id="OTHERS" count="180" label="Others only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="2280" label="Anticancer"></FilterOption><FilterOption id="2953" count="1514" label="Anti-inflammatory"></FilterOption><FilterOption id="55685" count="1163" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="62255" count="1101" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="991" count="815" label="Antiviral"></FilterOption><FilterOption id="1589" count="671" label="Apoptosis stimulator"></FilterOption><FilterOption id="767" count="637" label="Cell cycle inhibitor"></FilterOption><FilterOption id="61" count="591" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="7293" count="524" label="Synergist"></FilterOption><FilterOption id="393" count="492" label="Immunostimulant"></FilterOption><FilterOption id="7761" count="469" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="140" count="371" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="50" count="342" label="Anticancer alkylating agent"></FilterOption><FilterOption id="1569" count="318" label="Anticancer antimetabolite"></FilterOption><FilterOption id="1596" count="297" label="Immunomodulator"></FilterOption><FilterOption id="15184" count="281" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="2946" count="279" label="Analgesic"></FilterOption><FilterOption id="399" count="255" label="Hypoglycemic agent"></FilterOption><FilterOption id="396" count="244" label="Immunosuppressant"></FilterOption><FilterOption id="2657" count="239" label="Antihypertensive"></FilterOption><FilterOption id="2576" count="234" label="Microtubule stabilizer"></FilterOption><FilterOption id="2575" count="217" label="Microtubule inhibitor"></FilterOption><FilterOption id="1615" count="202" label="Neuroprotectant"></FilterOption><FilterOption id="2660" count="201" label="Vasoprotectant"></FilterOption><FilterOption id="70" count="155" label="Anticonvulsant agent"></FilterOption><FilterOption id="1594" count="128" label="Antibacterial"></FilterOption><FilterOption id="2659" count="124" label="Cardioprotectant"></FilterOption><FilterOption id="646" count="117" label="Bronchodilator"></FilterOption><FilterOption id="12378" count="110" label="Prophylactic vaccine"></FilterOption><FilterOption id="2947" count="109" label="Antiparkinsonian"></FilterOption><FilterOption id="2941" count="107" label="Antidepressant"></FilterOption><FilterOption id="284" count="95" label="Nootropic agent"></FilterOption><FilterOption id="2667" count="93" label="Antiarteriosclerotic"></FilterOption><FilterOption id="659" count="91" label="Coagulation inhibitor"></FilterOption><FilterOption id="695" count="89" label="Metastasis inhibitor"></FilterOption><FilterOption id="449" count="84" label="Antiarrhythmic agent"></FilterOption><FilterOption id="439" count="84" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="750" count="82" label="DNA intercalator"></FilterOption><FilterOption id="610" count="79" label="Hematopoietic stimulator"></FilterOption><FilterOption id="382" count="79" label="TNF alpha synthesis inhibitor"></FilterOption><FilterOption id="388" count="79" label="Vasodilator"></FilterOption><FilterOption id="59620" count="77" label="Unspecified drug target"></FilterOption><FilterOption id="2943" count="74" label="Antipsychotic"></FilterOption><FilterOption id="805" count="73" label="Folate modulator"></FilterOption><FilterOption id="71" count="70" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="747" count="70" label="HIV replication inhibitor"></FilterOption><FilterOption id="62254" count="69" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="12379" count="67" label="Therapeutic vaccine"></FilterOption><FilterOption id="664" count="66" label="Fibrosuppressant"></FilterOption><FilterOption id="539" count="61" label="Immunotoxin"></FilterOption><FilterOption id="2942" count="60" label="Anxiolytic"></FilterOption><FilterOption id="12372" count="59" label="Protein subunit vaccine"></FilterOption><FilterOption id="968" count="58" label="Coagulation stimulator"></FilterOption><FilterOption id="1470" count="56" label="Respiratory system agent"></FilterOption><FilterOption id="72" count="55" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="38206" count="54" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="312" count="54" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="55684" count="52" label="Anticancer antibody"></FilterOption><FilterOption id="1332" count="51" label="Gastrointestinal system agent"></FilterOption><FilterOption id="15319" count="48" label="Hepatitis C virus replication inhibitor"></FilterOption><FilterOption id="15187" count="48" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="89" count="46" label="Bone resorption inhibitor"></FilterOption><FilterOption id="15128" count="45" label="Ophthalmological agent"></FilterOption><FilterOption id="2954" count="44" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="7292" count="44" label="Vulnerary agent"></FilterOption><FilterOption id="1538" count="42" label="Bacterial protein synthesis inhibitor"></FilterOption><FilterOption id="285" count="42" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="12371" count="42" label="Subunit vaccine"></FilterOption><FilterOption id="7760" count="42" label="T-lymphocyte inhibitor"></FilterOption><FilterOption id="3189" count="41" label="Corticosteroid agonist"></FilterOption><FilterOption id="1532" count="38" label="Viral replication inhibitor"></FilterOption><FilterOption id="2970" count="35" label="Anti-emetic"></FilterOption><FilterOption id="104" count="34" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="1748" count="32" label="Fungicide"></FilterOption><FilterOption id="12367" count="30" label="Inactivated viral vaccine"></FilterOption><FilterOption id="463" count="30" label="Ribosome binding agent"></FilterOption><FilterOption id="3" count="29" label="5-HT uptake inhibitor"></FilterOption><FilterOption id="5580" count="29" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="12596" count="29" label="Osteoclast inhibitor"></FilterOption><FilterOption id="937" count="28" label="Androgen synthesis inhibitor"></FilterOption><FilterOption id="5704" count="28" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="5710" count="28" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="38439" count="28" label="DPP IV inhibitor antidiabetic product"></FilterOption><FilterOption id="12364" count="26" label="Live attenuated viral vaccine"></FilterOption><FilterOption id="74" count="25" label="Antioxidant agent"></FilterOption><FilterOption id="7294" count="25" label="Antisense oligonucleotide inhibitor"></FilterOption><FilterOption id="2939" count="25" label="CNS modulator"></FilterOption><FilterOption id="137" count="25" label="Diuretic agent"></FilterOption><FilterOption id="7220" count="25" label="Neoplasm diagnostic agent"></FilterOption><FilterOption id="15148" count="25" label="Ocular antineovascularisation agent"></FilterOption><FilterOption id="3272" count="24" label="Growth hormone release inhibitor"></FilterOption><FilterOption id="15180" count="24" label="Topical antipruritic product"></FilterOption><FilterOption id="1570" count="23" label="Allergen"></FilterOption><FilterOption id="7018" count="23" label="Antihypertriglyceridemic agent"></FilterOption><FilterOption id="11593" count="23" label="DNA repair inhibitor"></FilterOption><FilterOption id="38212" count="23" label="Human insulin intermediate acting product"></FilterOption><FilterOption id="1590" count="22" label="Apoptosis inhibitor"></FilterOption><FilterOption id="1540" count="22" label="Macrolide antibiotic"></FilterOption><FilterOption id="12370" count="22" label="Recombinant viral vector vaccine"></FilterOption><FilterOption id="966" count="21" label="Cardiac agent"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="1748" label="Unspecified"></FilterOption><FilterOption id="YES" count="1227" label="Yes"></FilterOption><FilterOption id="NO" count="456" label="No"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8712" count="217" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8489" count="206" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8481" count="195" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8719" count="188" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8663" count="184" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8998" count="161" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="8738" count="154" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8522" count="153" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="15312" count="149" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8505" count="142" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8713" count="136" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8514" count="125" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8639" count="120" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8513" count="114" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="9153" count="114" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="7538" count="114" label="Lymphoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9122" count="104" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="9215" count="101" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="7547" count="101" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8721" count="99" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7611" count="99" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="15207" count="98" label="Solid tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8187" count="95" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"></FilterOption><FilterOption id="15212" count="95" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="8996" count="90" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8722" count="89" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="1503" count="89" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="8720" count="88" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7879" count="88" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9213" count="86" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="7680" count="85" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="9218" count="84" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="8640" count="84" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="8430" count="83" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="15218" count="82" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8151" count="81" label="Colorectal tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="9247" count="80" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="8523" count="80" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="7563" count="79" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8078" count="77" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="3900" count="77" label="Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response"></FilterOption><FilterOption id="7569" count="76" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8516" count="73" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8519" count="73" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"></FilterOption><FilterOption id="22595" count="72" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="6863" count="72" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="8163" count="70" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8189" count="70" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="1345" count="70" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="15287" count="68" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="2622" count="66" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="26033" count="66" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="6940" count="65" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="10828" count="65" label="Ovary tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7354" count="64" label="Multiple myeloma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8555" count="62" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="6924" count="61" label="Melanoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="7908" count="59" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8651" count="59" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="6919" count="59" label="Melanoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="10830" count="58" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="37159" count="56" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="7564" count="56" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="4000" count="56" label="Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)"></FilterOption><FilterOption id="8759" count="55" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="10939" count="55" label="Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="13357" count="55" label="Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="8725" count="54" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8451" count="54" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="15215" count="54" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7393" count="53" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"></FilterOption><FilterOption id="25959" count="53" label="Pain - Assessment of Functional Disability/Physical Function"></FilterOption><FilterOption id="8999" count="52" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"></FilterOption><FilterOption id="7367" count="52" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="1626" count="52" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="13352" count="52" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="11717" count="51" label="Bladder cancer - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7679" count="51" label="Lymphoma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7045" count="51" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="10540" count="51" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="3884" count="51" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 50 Response"></FilterOption><FilterOption id="8744" count="50" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="1624" count="50" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8997" count="49" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="3736" count="49" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="7909" count="49" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8641" count="49" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="7049" count="49" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="12156" count="49" label="Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="8508" count="48" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="3885" count="48" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 70 Response"></FilterOption><FilterOption id="28074" count="47" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"></FilterOption><FilterOption id="7360" count="47" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="11722" count="46" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8563" count="46" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="25874" count="46" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"></FilterOption><FilterOption id="25986" count="46" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)"></FilterOption><FilterOption id="11728" count="45" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="8745" count="45" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"></FilterOption><FilterOption id="7027" count="45" label="Melanoma - Assessment of adverse events"></FilterOption></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1211" count="637" label="Alanine transaminase"></FilterOption><FilterOption id="12058" count="569" label="Total body mass"></FilterOption><FilterOption id="2527" count="547" label="Aspartate aminotransferase"></FilterOption><FilterOption id="1236" count="453" label="Hemoglobin"></FilterOption><FilterOption id="213" count="441" label="Creatinine"></FilterOption><FilterOption id="2054" count="438" label="Blood platelets"></FilterOption><FilterOption id="1904" count="416" label="Heart rate"></FilterOption><FilterOption id="46" count="404" label="C-reactive protein"></FilterOption><FilterOption id="1735" count="376" label="Glucose"></FilterOption><FilterOption id="1925" count="362" label="Neutrophils"></FilterOption><FilterOption id="2586" count="343" label="Blood pressure"></FilterOption><FilterOption id="2387" count="340" label="Bilirubin"></FilterOption><FilterOption id="3" count="330" label="HER2"></FilterOption><FilterOption id="330" count="308" label="Systolic blood pressure"></FilterOption><FilterOption id="125" count="306" label="Leukocyte count"></FilterOption><FilterOption id="217" count="272" label="Triglycerides"></FilterOption><FilterOption id="332" count="270" label="Diastolic blood pressure"></FilterOption><FilterOption id="133" count="268" label="Total cholesterol"></FilterOption><FilterOption id="152" count="262" label="Low-density lipoprotein cholesterol"></FilterOption><FilterOption id="4806" count="254" label="Lymphocytes"></FilterOption><FilterOption id="28899" count="253" label="Alkaline phosphatase"></FilterOption><FilterOption id="289" count="249" label="Hemoglobin A, glycosylated"></FilterOption><FilterOption id="153" count="234" label="High-density lipoprotein cholesterol"></FilterOption><FilterOption id="118" count="223" label="Albumin"></FilterOption><FilterOption id="1857" count="216" label="T-cell surface glycoprotein CD4"></FilterOption><FilterOption id="8" count="210" label="Epidermal growth factor receptor"></FilterOption><FilterOption id="824" count="201" label="Programmed cell death 1 ligand 1"></FilterOption><FilterOption id="7895" count="194" label="Estimated glomerular filtration rate"></FilterOption><FilterOption id="44216" count="187" label="Body temperature"></FilterOption><FilterOption id="113" count="182" label="Body Mass Index"></FilterOption><FilterOption id="5" count="179" label="Estrogen receptor"></FilterOption><FilterOption id="1880" count="168" label="T-Helper Lymphocytes"></FilterOption><FilterOption id="2098" count="161" label="Potassium"></FilterOption><FilterOption id="2713" count="155" label="Forced expiratory volume"></FilterOption><FilterOption id="2417" count="152" label="Calcium"></FilterOption><FilterOption id="176" count="151" label="Interleukin-6"></FilterOption><FilterOption id="148" count="151" label="QT interval"></FilterOption><FilterOption id="2662" count="150" label="Sodium"></FilterOption><FilterOption id="8458" count="149" label="gamma-Glutamyltransferase"></FilterOption><FilterOption id="14767" count="141" label="Lipids"></FilterOption><FilterOption id="3447" count="141" label="T-cell surface glycoprotein CD8 alpha chain"></FilterOption><FilterOption id="8024" count="139" label="Creatine kinase"></FilterOption><FilterOption id="4522" count="138" label="Erythrocytes"></FilterOption><FilterOption id="6" count="130" label="Progesterone receptor"></FilterOption><FilterOption id="1289" count="126" label="Tumor mass"></FilterOption><FilterOption id="1221" count="125" label="Hematocrit"></FilterOption><FilterOption id="248" count="123" label="Eosinophils"></FilterOption><FilterOption id="52" count="123" label="GTPase KRas"></FilterOption><FilterOption id="30214" count="122" label="Joint swelling"></FilterOption><FilterOption id="46506" count="121" label="T-Lymphocytes"></FilterOption><FilterOption id="17697" count="120" label="Body height"></FilterOption><FilterOption id="6663" count="118" label="B-lymphocytes"></FilterOption><FilterOption id="46505" count="116" label="Cytotoxic T-Lymphocytes"></FilterOption><FilterOption id="30217" count="116" label="Joint tenderness"></FilterOption><FilterOption id="7033" count="113" label="Lipase"></FilterOption><FilterOption id="2358" count="113" label="Urea nitrogen"></FilterOption><FilterOption id="36136" count="112" label="Cytokines"></FilterOption><FilterOption id="44218" count="112" label="Human immunodeficiency virus RNA"></FilterOption><FilterOption id="1945" count="111" label="Left ventricular ejection fraction"></FilterOption><FilterOption id="82" count="110" label="B-Raf proto-oncogene serine/threonine-protein kinase"></FilterOption><FilterOption id="147" count="106" label="Six-minute walk distance"></FilterOption><FilterOption id="38" count="105" label="Prostate-specific antigen"></FilterOption><FilterOption id="106" count="101" label="N-terminal Pro Brain Natriuretic Peptide"></FilterOption><FilterOption id="274" count="101" label="Tumor necrosis factor"></FilterOption><FilterOption id="154" count="98" label="Lactate dehydrogenase"></FilterOption><FilterOption id="10260" count="98" label="Respiratory frequency"></FilterOption><FilterOption id="808" count="97" label="Insulin"></FilterOption><FilterOption id="44186" count="94" label="Hepatitis C virus RNA"></FilterOption><FilterOption id="288" count="93" label="Uric acid"></FilterOption><FilterOption id="1912" count="92" label="Forced Vital Capacity"></FilterOption><FilterOption id="8097" count="90" label="Monocytes"></FilterOption><FilterOption id="5700" count="87" label="ALK receptor"></FilterOption><FilterOption id="781" count="87" label="Erythrocyte sedimentation rate"></FilterOption><FilterOption id="18315" count="84" label="Visual acuity"></FilterOption><FilterOption id="3374" count="83" label="Bone mineral density"></FilterOption><FilterOption id="9807" count="81" label="Basophils"></FilterOption><FilterOption id="1183" count="78" label="Urinary albumin to creatinine ratio"></FilterOption><FilterOption id="252" count="77" label="Interferon gamma"></FilterOption><FilterOption id="11857" count="77" label="Transaminases"></FilterOption><FilterOption id="11114" count="75" label="Brain"></FilterOption><FilterOption id="6993" count="74" label="Alpha-amylase 1"></FilterOption><FilterOption id="418" count="74" label="Waist circumference"></FilterOption><FilterOption id="7" count="73" label="Antigen KI-67"></FilterOption><FilterOption id="3247" count="73" label="Chlorides"></FilterOption><FilterOption id="1731" count="72" label="B-lymphocyte antigen CD20"></FilterOption><FilterOption id="3451" count="72" label="Immunoglobulin G"></FilterOption><FilterOption id="12516" count="71" label="Urinary protein"></FilterOption><FilterOption id="2626" count="69" label="Total protein"></FilterOption><FilterOption id="19714" count="68" label="Muscle strength"></FilterOption><FilterOption id="3083" count="68" label="Phosphate"></FilterOption><FilterOption id="2382" count="68" label="Phosphorus"></FilterOption><FilterOption id="215" count="65" label="Apolipoprotein B-100"></FilterOption><FilterOption id="22" count="65" label="Breast cancer type 1 susceptibility protein"></FilterOption><FilterOption id="41" count="64" label="Breast cancer type 2 susceptibility protein"></FilterOption><FilterOption id="64" count="61" label="Circulating Tumor Cells"></FilterOption><FilterOption id="10684" count="60" label="Blood cells"></FilterOption><FilterOption id="71" count="60" label="CA-125 antigen"></FilterOption><FilterOption id="92" count="60" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"></FilterOption><FilterOption id="214" count="57" label="Apolipoprotein A-I"></FilterOption><FilterOption id="2515" count="57" label="Magnesium"></FilterOption></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="6"><FilterOption id="SIEEFC" count="5866" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="5676" label="Safety"></FilterOption><FilterOption id="SIEPCK" count="2717" label="Pharmacokinetics"></FilterOption><FilterOption id="SIEPCD" count="1574" label="Pharmacodynamics"></FilterOption><FilterOption id="SIEBAV" count="26" label="Bioavailability"></FilterOption><FilterOption id="SIEBEQ" count="24" label="Bioequivalence"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3803" count="171" label="paclitaxel"></FilterOption><FilterOption id="44383" count="152" label="carboplatin"></FilterOption><FilterOption id="3199" count="126" label="gemcitabine"></FilterOption><FilterOption id="8047" count="103" label="bevacizumab"></FilterOption><FilterOption id="2953" count="99" label="docetaxel"></FilterOption><FilterOption id="54804" count="93" label="nivolumab"></FilterOption><FilterOption id="6736" count="87" label="rituximab"></FilterOption><FilterOption id="3792" count="83" label="oxaliplatin"></FilterOption><FilterOption id="12205" count="75" label="capecitabine"></FilterOption><FilterOption id="5369" count="71" label="ribavirin"></FilterOption><FilterOption id="72699" count="70" label="atezolizumab"></FilterOption><FilterOption id="70667" count="66" label="pembrolizumab"></FilterOption><FilterOption id="3536" count="65" label="pemetrexed disodium"></FilterOption><FilterOption id="6386" count="65" label="trastuzumab"></FilterOption><FilterOption id="2871" count="60" label="irinotecan"></FilterOption><FilterOption id="7310" count="59" label="ritonavir"></FilterOption><FilterOption id="23625" count="56" label="peginterferon alfa-2a"></FilterOption><FilterOption id="36630" count="52" label="ipilimumab"></FilterOption><FilterOption id="29016" count="47" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="15954" count="44" label="bortezomib"></FilterOption><FilterOption id="6050" count="44" label="metformin hydrochloride"></FilterOption><FilterOption id="10388" count="43" label="cetuximab"></FilterOption><FilterOption id="3072" count="41" label="etoposide phosphate"></FilterOption><FilterOption id="27572" count="36" label="lenalidomide"></FilterOption><FilterOption id="81193" count="34" label="durvalumab"></FilterOption><FilterOption id="13340" count="33" label="everolimus"></FilterOption><FilterOption id="47000" count="32" label="bendamustine"></FilterOption><FilterOption id="11961" count="32" label="erlotinib"></FilterOption><FilterOption id="3313" count="31" label="fulvestrant"></FilterOption><FilterOption id="2784" count="31" label="letrozole"></FilterOption><FilterOption id="6156" count="25" label="fludarabine"></FilterOption><FilterOption id="28532" count="25" label="pertuzumab"></FilterOption><FilterOption id="10309" count="24" label="abiraterone"></FilterOption><FilterOption id="3669" count="24" label="mycophenolate mofetil"></FilterOption><FilterOption id="53227" count="24" label="obinutuzumab"></FilterOption><FilterOption id="32981" count="23" label="darunavir"></FilterOption><FilterOption id="7934" count="22" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="13022" count="22" label="epirubicin"></FilterOption><FilterOption id="55237" count="22" label="ibrutinib"></FilterOption><FilterOption id="3081" count="21" label="exemestane"></FilterOption><FilterOption id="33591" count="21" label="lapatinib"></FilterOption><FilterOption id="4529" count="21" label="temozolomide"></FilterOption><FilterOption id="53200" count="20" label="daratumumab"></FilterOption><FilterOption id="4510" count="20" label="tacrolimus"></FilterOption><FilterOption id="6408" count="20" label="vinorelbine"></FilterOption><FilterOption id="56544" count="19" label="cobimetinib"></FilterOption><FilterOption id="12646" count="19" label="panitumumab"></FilterOption><FilterOption id="37370" count="18" label="azacitidine"></FilterOption><FilterOption id="71886" count="18" label="ribavirin (oral tablet, HCV), Roche"></FilterOption><FilterOption id="14681" count="17" label="lopinavir + ritonavir"></FilterOption><FilterOption id="27696" count="16" label="pomalidomide"></FilterOption><FilterOption id="96193" count="16" label="spartalizumab"></FilterOption><FilterOption id="12973" count="16" label="sunitinib"></FilterOption><FilterOption id="70895" count="16" label="venetoclax"></FilterOption><FilterOption id="15254" count="15" label="atazanavir"></FilterOption><FilterOption id="2836" count="15" label="clopidogrel"></FilterOption><FilterOption id="58741" count="15" label="daclatasvir"></FilterOption><FilterOption id="45902" count="15" label="ramucirumab"></FilterOption><FilterOption id="55288" count="15" label="trametinib"></FilterOption><FilterOption id="72538" count="14" label="abemaciclib"></FilterOption><FilterOption id="48181" count="14" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="45841" count="14" label="lenvatinib mesylate"></FilterOption><FilterOption id="16063" count="14" label="olaparib"></FilterOption><FilterOption id="10271" count="14" label="palbociclib"></FilterOption><FilterOption id="65360" count="14" label="ribociclib"></FilterOption><FilterOption id="49219" count="14" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="45562" count="14" label="tremelimumab"></FilterOption><FilterOption id="61901" count="13" label="buparlisib"></FilterOption><FilterOption id="54601" count="13" label="carfilzomib"></FilterOption><FilterOption id="53133" count="13" label="dabrafenib"></FilterOption><FilterOption id="3474" count="13" label="lamivudine"></FilterOption><FilterOption id="39069" count="13" label="simeprevir"></FilterOption><FilterOption id="29831" count="13" label="sorafenib"></FilterOption><FilterOption id="14163" count="12" label="adalimumab"></FilterOption><FilterOption id="3321" count="12" label="anastrozole"></FilterOption><FilterOption id="5999" count="12" label="ciclosporin, Novartis"></FilterOption><FilterOption id="10172" count="12" label="efavirenz"></FilterOption><FilterOption id="54488" count="12" label="raltegravir"></FilterOption><FilterOption id="10096" count="12" label="telaprevir"></FilterOption><FilterOption id="12731" count="12" label="tipranavir"></FilterOption><FilterOption id="2807" count="11" label="atorvastatin"></FilterOption><FilterOption id="83065" count="11" label="avelumab"></FilterOption><FilterOption id="61668" count="11" label="faldaprevir"></FilterOption><FilterOption id="83873" count="11" label="osimertinib"></FilterOption><FilterOption id="65416" count="11" label="sofosbuvir"></FilterOption><FilterOption id="14493" count="11" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="65353" count="10" label="alpelisib"></FilterOption><FilterOption id="51160" count="10" label="nintedanib"></FilterOption><FilterOption id="44314" count="10" label="tamoxifen"></FilterOption><FilterOption id="54469" count="10" label="vemurafenib"></FilterOption><FilterOption id="39209" count="9" label="axitinib"></FilterOption><FilterOption id="55305" count="9" label="binimetinib"></FilterOption><FilterOption id="59062" count="9" label="dolutegravir"></FilterOption><FilterOption id="53981" count="9" label="enzalutamide"></FilterOption><FilterOption id="3130" count="9" label="filgrastim"></FilterOption><FilterOption id="11603" count="9" label="gefitinib"></FilterOption><FilterOption id="59460" count="9" label="isatuximab"></FilterOption><FilterOption id="11519" count="9" label="mitoxantrone"></FilterOption><FilterOption id="50341" count="9" label="neratinib"></FilterOption><FilterOption id="4126" count="9" label="pioglitazone"></FilterOption></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="2542" label="Other Publications"></FilterOption><FilterOption id="PR" count="2427" label="Press Releases"></FilterOption><FilterOption id="SERIAL" count="2315" label="Serial Publications"></FilterOption><FilterOption id="CORPORATE" count="598" label="Corporate Publications"></FilterOption><FilterOption id="CONFERENCE" count="556" label="Conference Reports"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="54804" count="46" label="nivolumab"></FilterOption><FilterOption id="14163" count="36" label="adalimumab"></FilterOption><FilterOption id="55275" count="29" label="secukinumab"></FilterOption><FilterOption id="72699" count="26" label="atezolizumab"></FilterOption><FilterOption id="4567" count="24" label="etanercept"></FilterOption><FilterOption id="81193" count="23" label="durvalumab"></FilterOption><FilterOption id="70667" count="22" label="pembrolizumab"></FilterOption><FilterOption id="32677" count="22" label="rivaroxaban"></FilterOption><FilterOption id="16063" count="21" label="olaparib"></FilterOption><FilterOption id="45499" count="21" label="tofacitinib citrate (oral, inflammation), Pfizer"></FilterOption><FilterOption id="74726" count="21" label="upadacitinib"></FilterOption><FilterOption id="24343" count="20" label="dabigatran etexilate"></FilterOption><FilterOption id="6259" count="20" label="tocilizumab (intravenous), Roche/Chugai"></FilterOption><FilterOption id="13340" count="18" label="everolimus"></FilterOption><FilterOption id="12973" count="18" label="sunitinib"></FilterOption><FilterOption id="52967" count="17" label="apixaban"></FilterOption><FilterOption id="11961" count="17" label="erlotinib"></FilterOption><FilterOption id="27572" count="17" label="lenalidomide"></FilterOption><FilterOption id="83873" count="17" label="osimertinib"></FilterOption><FilterOption id="43738" count="17" label="pazopanib"></FilterOption><FilterOption id="8047" count="16" label="bevacizumab"></FilterOption><FilterOption id="53981" count="16" label="enzalutamide"></FilterOption><FilterOption id="10154" count="16" label="fingolimod"></FilterOption><FilterOption id="35644" count="16" label="methoxy polyethylene glycol-epoetin beta"></FilterOption><FilterOption id="58782" count="16" label="sacubitril + valsartan trisodium hemipentahydrate"></FilterOption><FilterOption id="6850" count="15" label="infliximab"></FilterOption><FilterOption id="17814" count="15" label="pregabalin"></FilterOption><FilterOption id="6736" count="15" label="rituximab"></FilterOption><FilterOption id="2953" count="14" label="docetaxel"></FilterOption><FilterOption id="29831" count="14" label="sorafenib"></FilterOption><FilterOption id="44897" count="13" label="apremilast"></FilterOption><FilterOption id="59098" count="13" label="baricitinib"></FilterOption><FilterOption id="12205" count="13" label="capecitabine"></FilterOption><FilterOption id="3089" count="13" label="eptacog alfa (activated)"></FilterOption><FilterOption id="14681" count="13" label="lopinavir + ritonavir"></FilterOption><FilterOption id="8165" count="13" label="tiotropium bromide"></FilterOption><FilterOption id="36669" count="13" label="trastuzumab emtansine"></FilterOption><FilterOption id="48946" count="12" label="dasatinib"></FilterOption><FilterOption id="10606" count="12" label="eltrombopag"></FilterOption><FilterOption id="55237" count="12" label="ibrutinib"></FilterOption><FilterOption id="3803" count="12" label="paclitaxel"></FilterOption><FilterOption id="77337" count="12" label="risankizumab"></FilterOption><FilterOption id="42858" count="12" label="ustekinumab"></FilterOption><FilterOption id="54449" count="11" label="afatinib"></FilterOption><FilterOption id="47733" count="11" label="canakinumab"></FilterOption><FilterOption id="65240" count="11" label="evolocumab"></FilterOption><FilterOption id="42857" count="11" label="golimumab"></FilterOption><FilterOption id="36630" count="11" label="ipilimumab"></FilterOption><FilterOption id="51388" count="11" label="nilotinib"></FilterOption><FilterOption id="36332" count="11" label="ticagrelor"></FilterOption><FilterOption id="69858" count="10" label="ceritinib"></FilterOption><FilterOption id="52192" count="10" label="dapagliflozin propanediol"></FilterOption><FilterOption id="58762" count="10" label="empagliflozin"></FilterOption><FilterOption id="6050" count="10" label="metformin hydrochloride"></FilterOption><FilterOption id="54624" count="10" label="regorafenib"></FilterOption><FilterOption id="72538" count="9" label="abemaciclib"></FilterOption><FilterOption id="37592" count="9" label="brivaracetam"></FilterOption><FilterOption id="15593" count="9" label="eculizumab"></FilterOption><FilterOption id="51255" count="9" label="edoxaban"></FilterOption><FilterOption id="67629" count="9" label="filgotinib"></FilterOption><FilterOption id="14336" count="9" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="47941" count="9" label="GSK-1437173A"></FilterOption><FilterOption id="64060" count="9" label="guselkumab"></FilterOption><FilterOption id="9313" count="9" label="lanreotide"></FilterOption><FilterOption id="52854" count="9" label="macitentan"></FilterOption><FilterOption id="51160" count="9" label="nintedanib"></FilterOption><FilterOption id="54662" count="9" label="ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis"></FilterOption><FilterOption id="29717" count="8" label="aliskiren"></FilterOption><FilterOption id="5871" count="8" label="bosentan"></FilterOption><FilterOption id="50935" count="8" label="cabozantinib S-malate"></FilterOption><FilterOption id="55798" count="8" label="crizotinib"></FilterOption><FilterOption id="49721" count="8" label="denosumab"></FilterOption><FilterOption id="28773" count="8" label="eribulin mesylate"></FilterOption><FilterOption id="32355" count="8" label="indacaterol"></FilterOption><FilterOption id="62451" count="8" label="ixekizumab"></FilterOption><FilterOption id="25049" count="8" label="laquinimod"></FilterOption><FilterOption id="3669" count="8" label="mycophenolate mofetil"></FilterOption><FilterOption id="4151" count="8" label="pramipexole"></FilterOption><FilterOption id="8713" count="8" label="sildenafil citrate"></FilterOption><FilterOption id="6386" count="8" label="trastuzumab"></FilterOption><FilterOption id="2765" count="8" label="zoledronic acid"></FilterOption><FilterOption id="69066" count="7" label="alectinib"></FilterOption><FilterOption id="18425" count="7" label="ambrisentan"></FilterOption><FilterOption id="7781" count="7" label="aripiprazole"></FilterOption><FilterOption id="100097" count="7" label="bictegravir + emtricitabine + tenofovir alafenamide (HIV-1 infection), Gilead"></FilterOption><FilterOption id="28035" count="7" label="cabazitaxel"></FilterOption><FilterOption id="21138" count="7" label="certolizumab pegol"></FilterOption><FilterOption id="53133" count="7" label="dabrafenib"></FilterOption><FilterOption id="61317" count="7" label="daprodustat (oral, anemia), GlaxoSmithKline"></FilterOption><FilterOption id="54082" count="7" label="fremanezumab"></FilterOption><FilterOption id="3199" count="7" label="gemcitabine"></FilterOption><FilterOption id="37613" count="7" label="maraviroc"></FilterOption><FilterOption id="48638" count="7" label="ocrelizumab"></FilterOption><FilterOption id="56776" count="7" label="SHP-647"></FilterOption><FilterOption id="2716" count="6" label="alemtuzumab"></FilterOption><FilterOption id="31831" count="6" label="belimumab"></FilterOption><FilterOption id="98856" count="6" label="BMS-986165"></FilterOption><FilterOption id="30379" count="6" label="bosutinib"></FilterOption><FilterOption id="57592" count="6" label="canagliflozin"></FilterOption><FilterOption id="59953" count="6" label="capmatinib"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="100"><FilterOption id="44383" count="107" label="carboplatin"></FilterOption><FilterOption id="3803" count="81" label="paclitaxel"></FilterOption><FilterOption id="3199" count="63" label="gemcitabine"></FilterOption><FilterOption id="2953" count="43" label="docetaxel"></FilterOption><FilterOption id="8047" count="42" label="bevacizumab"></FilterOption><FilterOption id="3792" count="42" label="oxaliplatin"></FilterOption><FilterOption id="6736" count="39" label="rituximab"></FilterOption><FilterOption id="3536" count="37" label="pemetrexed disodium"></FilterOption><FilterOption id="6386" count="34" label="trastuzumab"></FilterOption><FilterOption id="12205" count="33" label="capecitabine"></FilterOption><FilterOption id="6050" count="24" label="metformin hydrochloride"></FilterOption><FilterOption id="7310" count="24" label="ritonavir"></FilterOption><FilterOption id="3072" count="21" label="etoposide phosphate"></FilterOption><FilterOption id="2871" count="20" label="irinotecan"></FilterOption><FilterOption id="49219" count="20" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="29016" count="19" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="15954" count="15" label="bortezomib"></FilterOption><FilterOption id="47000" count="14" label="bendamustine"></FilterOption><FilterOption id="6408" count="14" label="vinorelbine"></FilterOption><FilterOption id="15254" count="13" label="atazanavir"></FilterOption><FilterOption id="32981" count="12" label="darunavir"></FilterOption><FilterOption id="10252" count="12" label="insulin glargine"></FilterOption><FilterOption id="10309" count="11" label="abiraterone"></FilterOption><FilterOption id="10388" count="11" label="cetuximab"></FilterOption><FilterOption id="2836" count="11" label="clopidogrel"></FilterOption><FilterOption id="13022" count="11" label="epirubicin"></FilterOption><FilterOption id="23625" count="11" label="peginterferon alfa-2a"></FilterOption><FilterOption id="14163" count="10" label="adalimumab"></FilterOption><FilterOption id="10172" count="10" label="efavirenz"></FilterOption><FilterOption id="6156" count="10" label="fludarabine"></FilterOption><FilterOption id="27572" count="10" label="lenalidomide"></FilterOption><FilterOption id="8832" count="9" label="glimepiride"></FilterOption><FilterOption id="48181" count="9" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="3669" count="9" label="mycophenolate mofetil"></FilterOption><FilterOption id="44375" count="9" label="warfarin"></FilterOption><FilterOption id="10411" count="8" label="insulin aspart"></FilterOption><FilterOption id="11519" count="8" label="mitoxantrone"></FilterOption><FilterOption id="3081" count="7" label="exemestane"></FilterOption><FilterOption id="33591" count="7" label="lapatinib"></FilterOption><FilterOption id="27696" count="7" label="pomalidomide"></FilterOption><FilterOption id="44384" count="6" label="ceftriaxone"></FilterOption><FilterOption id="59062" count="6" label="dolutegravir"></FilterOption><FilterOption id="7934" count="6" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="11961" count="6" label="erlotinib"></FilterOption><FilterOption id="13340" count="6" label="everolimus"></FilterOption><FilterOption id="2784" count="6" label="letrozole"></FilterOption><FilterOption id="5369" count="6" label="ribavirin"></FilterOption><FilterOption id="4510" count="6" label="tacrolimus"></FilterOption><FilterOption id="3321" count="5" label="anastrozole"></FilterOption><FilterOption id="13928" count="5" label="enoxaparin sodium"></FilterOption><FilterOption id="3474" count="5" label="lamivudine"></FilterOption><FilterOption id="14681" count="5" label="lopinavir + ritonavir"></FilterOption><FilterOption id="53227" count="5" label="obinutuzumab"></FilterOption><FilterOption id="28532" count="5" label="pertuzumab"></FilterOption><FilterOption id="14493" count="5" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="36332" count="5" label="ticagrelor"></FilterOption><FilterOption id="12150" count="5" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"></FilterOption><FilterOption id="37370" count="4" label="azacitidine"></FilterOption><FilterOption id="54601" count="4" label="carfilzomib"></FilterOption><FilterOption id="62275" count="4" label="cobicistat"></FilterOption><FilterOption id="5907" count="4" label="duloxetine"></FilterOption><FilterOption id="17518" count="4" label="escitalopram"></FilterOption><FilterOption id="3353" count="4" label="insulin lispro"></FilterOption><FilterOption id="21374" count="4" label="pegfilgrastim"></FilterOption><FilterOption id="71886" count="4" label="ribavirin (oral tablet, HCV), Roche"></FilterOption><FilterOption id="44401" count="4" label="vancomycin"></FilterOption><FilterOption id="72699" count="3" label="atezolizumab"></FilterOption><FilterOption id="5999" count="3" label="ciclosporin, Novartis"></FilterOption><FilterOption id="44370" count="3" label="clindamycin"></FilterOption><FilterOption id="72148" count="3" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"></FilterOption><FilterOption id="13239" count="3" label="decitabine"></FilterOption><FilterOption id="4728" count="3" label="emtricitabine"></FilterOption><FilterOption id="30682" count="3" label="etravirine"></FilterOption><FilterOption id="11367" count="3" label="ezetimibe"></FilterOption><FilterOption id="7286" count="3" label="goserelin acetate"></FilterOption><FilterOption id="3616" count="3" label="meropenem"></FilterOption><FilterOption id="3700" count="3" label="nevirapine"></FilterOption><FilterOption id="54804" count="3" label="nivolumab"></FilterOption><FilterOption id="3750" count="3" label="ondansetron"></FilterOption><FilterOption id="70667" count="3" label="pembrolizumab"></FilterOption><FilterOption id="4126" count="3" label="pioglitazone"></FilterOption><FilterOption id="54488" count="3" label="raltegravir"></FilterOption><FilterOption id="52857" count="3" label="rilpivirine hydrochloride"></FilterOption><FilterOption id="4259" count="3" label="saquinavir"></FilterOption><FilterOption id="15183" count="3" label="sertraline"></FilterOption><FilterOption id="44314" count="3" label="tamoxifen"></FilterOption><FilterOption id="44316" count="3" label="zidovudine"></FilterOption><FilterOption id="6242" count="2" label="abacavir"></FilterOption><FilterOption id="2500" count="2" label="amlodipine"></FilterOption><FilterOption id="7867" count="2" label="amprenavir"></FilterOption><FilterOption id="7781" count="2" label="aripiprazole"></FilterOption><FilterOption id="2807" count="2" label="atorvastatin"></FilterOption><FilterOption id="11141" count="2" label="basiliximab"></FilterOption><FilterOption id="16915" count="2" label="calcium levofolinate"></FilterOption><FilterOption id="69973" count="2" label="dolutegravir + lamivudine + abacavir (HIV), ViiV"></FilterOption><FilterOption id="59624" count="2" label="dulaglutide"></FilterOption><FilterOption id="51371" count="2" label="elvitegravir"></FilterOption><FilterOption id="25880" count="2" label="enteric-coated mycophenolate sodium, Novartis"></FilterOption><FilterOption id="28773" count="2" label="eribulin mesylate"></FilterOption><FilterOption id="4567" count="2" label="etanercept"></FilterOption></Filter><Filter label="Trial Category" name="trialCategory" total="18"><FilterOption id="4" count="4318" label="Small molecule"></FilterOption><FilterOption id="3" count="2411" label="Biological"></FilterOption><FilterOption id="8" count="356" label="Medical device"></FilterOption><FilterOption id="9" count="236" label="Medical procedure"></FilterOption><FilterOption id="16" count="200" label="Behavioral intervention"></FilterOption><FilterOption id="5" count="192" label="Vaccine"></FilterOption><FilterOption id="11" count="132" label="Dietary supplement"></FilterOption><FilterOption id="15" count="119" label="Radiation therapy"></FilterOption><FilterOption id="6" count="88" label="Cell therapy"></FilterOption><FilterOption id="7" count="78" label="Gene therapy"></FilterOption><FilterOption id="18" count="55" label="Pathophysiology"></FilterOption><FilterOption id="14" count="43" label="Diagnostic"></FilterOption><FilterOption id="17" count="32" label="Biomarker identification"></FilterOption><FilterOption id="10" count="8" label="Borderline product"></FilterOption><FilterOption id="2" count="5" label="Drug"></FilterOption><FilterOption id="19" count="3" label="Surgical procedure"></FilterOption><FilterOption id="13" count="2" label="Hospital solutions"></FilterOption><FilterOption id="12" count="1" label="Herbal preparation"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="YES" count="3446" label="Yes"></FilterOption><FilterOption id="NO" count="3084" label="No"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="67136" count="249" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="740" count="240" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="3848" count="224" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="3808" count="205" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="3846" count="193" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="3850" count="181" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="14007" count="164" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="372" count="163" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="5085" count="154" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="3756" count="147" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3806" count="126" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="48492" count="125" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="12521" count="119" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="948" count="111" label="PDGF receptor antagonist"></FilterOption><FilterOption id="142" count="110" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="3816" count="107" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="1722" count="107" label="VEGF receptor antagonist"></FilterOption><FilterOption id="48489" count="101" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="3754" count="100" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3562" count="99" label="Jak1 tyrosine kinase inhibitor"></FilterOption><FilterOption id="10240" count="97" label="mTOR inhibitor"></FilterOption><FilterOption id="3688" count="95" label="FGF3 receptor antagonist"></FilterOption><FilterOption id="721" count="92" label="TNF binding agent"></FilterOption><FilterOption id="3682" count="91" label="FGF1 receptor antagonist"></FilterOption><FilterOption id="138" count="90" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="141" count="90" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="5482" count="89" label="Cytotoxic T-lymphocyte protein-4 inhibitor"></FilterOption><FilterOption id="3154" count="87" label="CSF-1 antagonist"></FilterOption><FilterOption id="1016" count="87" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="1832" count="87" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="204" count="86" label="HIV protease inhibitor"></FilterOption><FilterOption id="385" count="84" label="Protein tyrosine kinase inhibitor"></FilterOption><FilterOption id="768" count="82" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="381" count="82" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="4548" count="81" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="135" count="75" label="DHFR inhibitor"></FilterOption><FilterOption id="120" count="73" label="Factor Xa antagonist"></FilterOption><FilterOption id="181" count="71" label="GAR transformylase inhibitor"></FilterOption><FilterOption id="214" count="71" label="Interferon alpha 2 ligand"></FilterOption><FilterOption id="38283" count="71" label="Poly ADP ribose polymerase 1 inhibitor"></FilterOption><FilterOption id="374" count="71" label="Transferase inhibitor"></FilterOption><FilterOption id="3685" count="68" label="FGF2 receptor antagonist"></FilterOption><FilterOption id="38286" count="68" label="Poly ADP ribose polymerase 2 inhibitor"></FilterOption><FilterOption id="7424" count="67" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="40" count="66" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="4917" count="66" label="Proteasome inhibitor"></FilterOption><FilterOption id="12349" count="64" label="Hepatitis C virus NS3 protease inhibitor"></FilterOption><FilterOption id="76" count="63" label="Aromatase inhibitor"></FilterOption><FilterOption id="76090" count="62" label="mTOR complex 1 inhibitor"></FilterOption><FilterOption id="13571" count="61" label="Bcr protein inhibitor"></FilterOption><FilterOption id="675" count="61" label="Hepatocyte growth factor receptor antagonist"></FilterOption><FilterOption id="471" count="61" label="IL-6 receptor antagonist"></FilterOption><FilterOption id="3584" count="60" label="Lck tyrosine kinase inhibitor"></FilterOption><FilterOption id="3576" count="59" label="Src tyrosine kinase inhibitor"></FilterOption><FilterOption id="8805" count="58" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="4314" count="57" label="Cyclin-dependent kinase-4 inhibitor"></FilterOption><FilterOption id="4318" count="57" label="Cyclin-dependent kinase-6 inhibitor"></FilterOption><FilterOption id="7588" count="57" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="629" count="54" label="Inosine monophosphate dehydrogenase inhibitor"></FilterOption><FilterOption id="4762" count="54" label="MEK-1 protein kinase inhibitor"></FilterOption><FilterOption id="4764" count="54" label="MEK-2 protein kinase inhibitor"></FilterOption><FilterOption id="2585" count="52" label="Glucagon-like peptide 1 receptor agonist"></FilterOption><FilterOption id="2507" count="51" label="PARP inhibitor"></FilterOption><FilterOption id="3524" count="50" label="Abl tyrosine kinase inhibitor"></FilterOption><FilterOption id="4010" count="50" label="Calcineurin inhibitor"></FilterOption><FilterOption id="286" count="50" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="23014" count="50" label="Insulin ligand"></FilterOption><FilterOption id="400" count="50" label="Insulin receptor agonist"></FilterOption><FilterOption id="1833" count="47" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="3834" count="47" label="Tek tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3592" count="46" label="Btk tyrosine kinase inhibitor"></FilterOption><FilterOption id="76469" count="45" label="26S proteasome complex inhibitor"></FilterOption><FilterOption id="168" count="45" label="FGF receptor antagonist"></FilterOption><FilterOption id="1575" count="44" label="Phosphoinositide 3-kinase inhibitor"></FilterOption><FilterOption id="4550" count="44" label="Raf 1 protein kinase inhibitor"></FilterOption><FilterOption id="498" count="44" label="Sodium channel inhibitor"></FilterOption><FilterOption id="205" count="43" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="3252" count="43" label="Insulin-like growth factor 1 receptor antagonist"></FilterOption><FilterOption id="60" count="42" label="Androgen receptor antagonist"></FilterOption><FilterOption id="262" count="42" label="Muscarinic M3 receptor antagonist"></FilterOption><FilterOption id="770" count="41" label="Endothelin ET-A receptor antagonist"></FilterOption><FilterOption id="38289" count="41" label="Poly ADP ribose polymerase 3 inhibitor"></FilterOption><FilterOption id="43842" count="40" label="Hepatitis C virus protein NS5A inhibitor"></FilterOption><FilterOption id="541" count="40" label="Tubulin receptor antagonist"></FilterOption><FilterOption id="115" count="38" label="Factor VIII agonist"></FilterOption><FilterOption id="4802" count="38" label="IL-17 antagonist"></FilterOption><FilterOption id="3564" count="38" label="Jak2 tyrosine kinase inhibitor"></FilterOption><FilterOption id="3796" count="38" label="MET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="4020" count="38" label="Sodium glucose transporter-2 inhibitor"></FilterOption><FilterOption id="511" count="38" label="TNF antagonist"></FilterOption><FilterOption id="64" count="37" label="Angiotensin II receptor antagonist"></FilterOption><FilterOption id="3758" count="37" label="Erbb3 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3818" count="37" label="Ret tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3760" count="36" label="Erbb4 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="12358" count="36" label="Hepatitis C virus NS5B polymerase inhibitor"></FilterOption><FilterOption id="4913" count="36" label="P2Y12 purinoceptor antagonist"></FilterOption><FilterOption id="3736" count="35" label="Anaplastic lymphoma kinase receptor inhibitor"></FilterOption><FilterOption id="9748" count="35" label="IL-23 antagonist"></FilterOption><FilterOption id="1689" count="35" label="VEGF-A ligand inhibitor"></FilterOption><FilterOption id="111" count="34" label="Factor IIa antagonist"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="18767" count="55" label="Pfizer Inc"></FilterOption><FilterOption id="1013295" count="54" label="Astellas Pharma Inc"></FilterOption><FilterOption id="28355" count="54" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1059823" count="50" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="1009547" count="47" label="Sanofi SA"></FilterOption><FilterOption id="19446" count="46" label="Roche Holding AG"></FilterOption><FilterOption id="20300" count="43" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="15065" count="42" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="14190" count="40" label="AstraZeneca plc"></FilterOption><FilterOption id="1017818" count="38" label="Instituto de Salud Carlos III"></FilterOption><FilterOption id="23137" count="34" label="Novartis AG"></FilterOption><FilterOption id="19453" count="32" label="Genentech Inc"></FilterOption><FilterOption id="18681" count="29" label="Ono Pharmaceutical Co Ltd"></FilterOption><FilterOption id="17810" count="28" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="19214" count="27" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="15331" count="25" label="Celgene Corp"></FilterOption><FilterOption id="20519" count="24" label="National Cancer Institute"></FilterOption><FilterOption id="14109" count="22" label="Amgen Inc"></FilterOption><FilterOption id="14455" count="22" label="Bayer AG"></FilterOption><FilterOption id="1101929" count="21" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="1067538" count="21" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1033116" count="21" label="PAREXEL International"></FilterOption><FilterOption id="1057369" count="20" label="La Paz University Hospital (Madrid)"></FilterOption><FilterOption id="18077" count="18" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="20452" count="18" label="UCB SA"></FilterOption><FilterOption id="1065900" count="17" label="Apices Soluciones, S.L."></FilterOption><FilterOption id="26178" count="17" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="1055006" count="17" label="Ministry of Health, Spain"></FilterOption><FilterOption id="1072507" count="16" label="AbbVie Inc"></FilterOption><FilterOption id="19620" count="16" label="Eisai Inc"></FilterOption><FilterOption id="1059977" count="14" label="European Commission"></FilterOption><FilterOption id="18440" count="14" label="Myriad Genetics Inc"></FilterOption><FilterOption id="1042255" count="13" label="Breast International Group"></FilterOption><FilterOption id="1045910" count="13" label="Hospital Clinico San Carlos"></FilterOption><FilterOption id="18101" count="13" label="Merck KGaA"></FilterOption><FilterOption id="1116693" count="13" label="Productos Roche, S.A. de C.V."></FilterOption><FilterOption id="1003065" count="12" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="17332" count="12" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="24652" count="12" label="Shire plc"></FilterOption><FilterOption id="1084506" count="11" label="European Network of Gynaecological Oncological Trial Groups"></FilterOption><FilterOption id="23119" count="11" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1006639" count="11" label="Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="1033989" count="11" label="Pharmaceutical Product Development LLC"></FilterOption><FilterOption id="1067340" count="11" label="Pivotal SL"></FilterOption><FilterOption id="25554" count="11" label="Seattle Genetics Inc"></FilterOption><FilterOption id="1063946" count="11" label="Syneos Health Inc"></FilterOption><FilterOption id="13601" count="10" label="Abbott Laboratories"></FilterOption><FilterOption id="1056444" count="10" label="Foundation Medicine Inc"></FilterOption><FilterOption id="1041702" count="10" label="Gynecologic Oncology Group"></FilterOption><FilterOption id="17216" count="10" label="Incyte Corp"></FilterOption><FilterOption id="1005244" count="9" label="Biogen Inc"></FilterOption><FilterOption id="14881" count="9" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="15414" count="9" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="22676" count="9" label="Exelixis Inc"></FilterOption><FilterOption id="1070222" count="9" label="Fundación Mutua Madrileña"></FilterOption><FilterOption id="1040862" count="9" label="Hospital General Universitario Gregorio Marañon"></FilterOption><FilterOption id="1033112" count="9" label="Hospital Universitario 12 de Octubre"></FilterOption><FilterOption id="1056709" count="9" label="ICON Clinical Research"></FilterOption><FilterOption id="1100315" count="9" label="PRA Health Sciences"></FilterOption><FilterOption id="20348" count="9" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="21082" count="9" label="Walter and Eliza Hall Institute of Medical Research"></FilterOption><FilterOption id="25902" count="8" label="Array BioPharma Inc"></FilterOption><FilterOption id="1079783" count="8" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"></FilterOption><FilterOption id="27741" count="8" label="Galapagos NV"></FilterOption><FilterOption id="16450" count="8" label="Gilead Sciences Inc"></FilterOption><FilterOption id="29481" count="8" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"></FilterOption><FilterOption id="1014884" count="8" label="Medivation Inc"></FilterOption><FilterOption id="19063" count="8" label="Pharmacyclics Inc"></FilterOption><FilterOption id="1026270" count="8" label="Servicio Regional De Salud De La Consejeria De Salud De La Comunidad De Madrid"></FilterOption><FilterOption id="19864" count="7" label="Adir &amp; Co"></FilterOption><FilterOption id="1017506" count="7" label="Daiichi Sankyo Co Ltd"></FilterOption><FilterOption id="1039423" count="7" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="1040940" count="7" label="Hospital Universitari de Bellvitge"></FilterOption><FilterOption id="1072601" count="7" label="Hospital Universitario Virgen de la Arrixa"></FilterOption><FilterOption id="1144568" count="7" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="1097931" count="6" label="Andalusian Initiative for Advanced Therapies"></FilterOption><FilterOption id="21283" count="6" label="Astellas Pharma Europe BV"></FilterOption><FilterOption id="1018807" count="6" label="Covance Inc"></FilterOption><FilterOption id="1048337" count="6" label="Duke Clinical Research Institute"></FilterOption><FilterOption id="1039086" count="6" label="Germans Trias i Pujol Hospital"></FilterOption><FilterOption id="1104124" count="6" label="GlaxoSmithKline LLC"></FilterOption><FilterOption id="17416" count="6" label="Janssen LP"></FilterOption><FilterOption id="21404" count="6" label="MorphoSys AG"></FilterOption><FilterOption id="1045801" count="6" label="The European Union"></FilterOption><FilterOption id="1061163" count="5" label="Abbott Vascular"></FilterOption><FilterOption id="23948" count="5" label="Assistance Publique Hopitaux de Paris"></FilterOption><FilterOption id="22123" count="5" label="Cleveland Clinic Foundation"></FilterOption><FilterOption id="1091345" count="5" label="Complejo Hospitalario de Navarra"></FilterOption><FilterOption id="1069026" count="5" label="Effice Servicios Para la Investigacion"></FilterOption><FilterOption id="1039403" count="5" label="German Federal Ministry of Education and Research"></FilterOption><FilterOption id="19461" count="5" label="Hoffmann-La Roche Inc"></FilterOption><FilterOption id="25599" count="5" label="Novartis Pharma AG"></FilterOption><FilterOption id="20556" count="5" label="Universidad Complutense de Madrid"></FilterOption><FilterOption id="23505" count="5" label="University College London"></FilterOption><FilterOption id="1125317" count="4" label="ADIR Association"></FilterOption><FilterOption id="14438" count="4" label="Baxter Healthcare Corp"></FilterOption><FilterOption id="27847" count="4" label="Boston Scientific Corp"></FilterOption><FilterOption id="29469" count="4" label="Cancer Research UK"></FilterOption><FilterOption id="1045739" count="4" label="Chiltern International Inc."></FilterOption><FilterOption id="1013107" count="4" label="CNIC - Fundacion Centro National de Investigaciones Cardiovasculares Carlos III"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="100"><FilterOption id="1545" count="765" label="Anticancer"></FilterOption><FilterOption id="767" count="286" label="Cell cycle inhibitor"></FilterOption><FilterOption id="2953" count="273" label="Anti-inflammatory"></FilterOption><FilterOption id="140" count="218" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="55685" count="216" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="991" count="208" label="Antiviral"></FilterOption><FilterOption id="1569" count="194" label="Anticancer antimetabolite"></FilterOption><FilterOption id="50" count="184" label="Anticancer alkylating agent"></FilterOption><FilterOption id="62255" count="178" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="2576" count="134" label="Microtubule stabilizer"></FilterOption><FilterOption id="61" count="131" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="1589" count="121" label="Apoptosis stimulator"></FilterOption><FilterOption id="2575" count="119" label="Microtubule inhibitor"></FilterOption><FilterOption id="2660" count="116" label="Vasoprotectant"></FilterOption><FilterOption id="7293" count="76" label="Synergist"></FilterOption><FilterOption id="399" count="75" label="Hypoglycemic agent"></FilterOption><FilterOption id="2946" count="72" label="Analgesic"></FilterOption><FilterOption id="15184" count="58" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="1594" count="57" label="Antibacterial"></FilterOption><FilterOption id="1596" count="52" label="Immunomodulator"></FilterOption><FilterOption id="396" count="52" label="Immunosuppressant"></FilterOption><FilterOption id="805" count="46" label="Folate modulator"></FilterOption><FilterOption id="646" count="43" label="Bronchodilator"></FilterOption><FilterOption id="659" count="41" label="Coagulation inhibitor"></FilterOption><FilterOption id="104" count="40" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="2657" count="39" label="Antihypertensive"></FilterOption><FilterOption id="747" count="38" label="HIV replication inhibitor"></FilterOption><FilterOption id="393" count="36" label="Immunostimulant"></FilterOption><FilterOption id="7761" count="36" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="750" count="35" label="DNA intercalator"></FilterOption><FilterOption id="15187" count="35" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="38206" count="33" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="2659" count="32" label="Cardioprotectant"></FilterOption><FilterOption id="38215" count="27" label="Human insulin long acting product"></FilterOption><FilterOption id="610" count="26" label="Hematopoietic stimulator"></FilterOption><FilterOption id="12378" count="26" label="Prophylactic vaccine"></FilterOption><FilterOption id="2954" count="25" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="70" count="24" label="Anticonvulsant agent"></FilterOption><FilterOption id="3189" count="24" label="Corticosteroid agonist"></FilterOption><FilterOption id="62254" count="23" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="1615" count="22" label="Neuroprotectant"></FilterOption><FilterOption id="382" count="22" label="TNF alpha synthesis inhibitor"></FilterOption><FilterOption id="2667" count="20" label="Antiarteriosclerotic"></FilterOption><FilterOption id="312" count="20" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="2941" count="18" label="Antidepressant"></FilterOption><FilterOption id="2947" count="18" label="Antiparkinsonian"></FilterOption><FilterOption id="38211" count="17" label="Human insulin fast acting product"></FilterOption><FilterOption id="71" count="16" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="1538" count="16" label="Bacterial protein synthesis inhibitor"></FilterOption><FilterOption id="1479" count="16" label="RNA synthesis modulator"></FilterOption><FilterOption id="2970" count="15" label="Anti-emetic"></FilterOption><FilterOption id="1535" count="15" label="Beta lactam antibiotic"></FilterOption><FilterOption id="89" count="15" label="Bone resorption inhibitor"></FilterOption><FilterOption id="73547" count="15" label="Carbapenem"></FilterOption><FilterOption id="664" count="15" label="Fibrosuppressant"></FilterOption><FilterOption id="38205" count="14" label="Sulphonylurea antidiabetic product"></FilterOption><FilterOption id="1532" count="14" label="Viral replication inhibitor"></FilterOption><FilterOption id="3" count="13" label="5-HT uptake inhibitor"></FilterOption><FilterOption id="2942" count="13" label="Anxiolytic"></FilterOption><FilterOption id="3246" count="13" label="Insulin release stimulator"></FilterOption><FilterOption id="463" count="13" label="Ribosome binding agent"></FilterOption><FilterOption id="72" count="12" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="2943" count="12" label="Antipsychotic"></FilterOption><FilterOption id="32411" count="12" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="1129" count="12" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="285" count="12" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="15148" count="12" label="Ocular antineovascularisation agent"></FilterOption><FilterOption id="7760" count="12" label="T-lymphocyte inhibitor"></FilterOption><FilterOption id="937" count="11" label="Androgen synthesis inhibitor"></FilterOption><FilterOption id="12596" count="11" label="Osteoclast inhibitor"></FilterOption><FilterOption id="388" count="11" label="Vasodilator"></FilterOption><FilterOption id="968" count="10" label="Coagulation stimulator"></FilterOption><FilterOption id="284" count="10" label="Nootropic agent"></FilterOption><FilterOption id="439" count="10" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="1748" count="9" label="Fungicide"></FilterOption><FilterOption id="12367" count="9" label="Inactivated viral vaccine"></FilterOption><FilterOption id="12375" count="9" label="Toxoid vaccine"></FilterOption><FilterOption id="1537" count="8" label="Cephalosporin"></FilterOption><FilterOption id="12373" count="8" label="Polysaccharide subunit vaccine"></FilterOption><FilterOption id="62253" count="7" label="Anticancer hormone"></FilterOption><FilterOption id="3984" count="7" label="Bacterial nucleic acid synthesis inhibitor"></FilterOption><FilterOption id="15128" count="7" label="Ophthalmological agent"></FilterOption><FilterOption id="12372" count="7" label="Protein subunit vaccine"></FilterOption><FilterOption id="12371" count="7" label="Subunit vaccine"></FilterOption><FilterOption id="1540" count="6" label="Macrolide antibiotic"></FilterOption><FilterOption id="563" count="6" label="Microtubule modulator"></FilterOption><FilterOption id="882" count="5" label="5-HETE modulator"></FilterOption><FilterOption id="1541" count="5" label="Aminoglycoside antibiotic"></FilterOption><FilterOption id="449" count="5" label="Antiarrhythmic agent"></FilterOption><FilterOption id="7018" count="5" label="Antihypertriglyceridemic agent"></FilterOption><FilterOption id="5704" count="5" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="5710" count="5" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="5580" count="5" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="871" count="5" label="GABA modulator"></FilterOption><FilterOption id="614" count="5" label="Lipid uptake inhibitor"></FilterOption><FilterOption id="12364" count="5" label="Live attenuated viral vaccine"></FilterOption><FilterOption id="695" count="5" label="Metastasis inhibitor"></FilterOption><FilterOption id="2955" count="5" label="Non-steroidal anti-inflammatory"></FilterOption><FilterOption id="15180" count="5" label="Topical antipruritic product"></FilterOption><FilterOption id="59620" count="5" label="Unspecified drug target"></FilterOption></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="3276" label="Proteomic"></FilterOption><FilterOption id="38" count="3151" label="Genomic"></FilterOption><FilterOption id="31" count="1773" label="Physiological"></FilterOption><FilterOption id="32" count="1488" label="Biochemical"></FilterOption><FilterOption id="75" count="1159" label="Cellular"></FilterOption><FilterOption id="39" count="722" label="Anthropomorphic"></FilterOption><FilterOption id="40" count="669" label="Structural (imaging)"></FilterOption></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="3548" label="Therapeutic effect marker"></FilterOption><FilterOption id="1571666123" count="1493" label="Disease marker"></FilterOption><FilterOption id="730490367" count="1257" label="Toxic effect marker"></FilterOption><FilterOption id="3242045531" count="22" label="Not determined"></FilterOption></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="3803" count="177" label="paclitaxel"></FilterOption><FilterOption id="44383" count="154" label="carboplatin"></FilterOption><FilterOption id="3199" count="127" label="gemcitabine"></FilterOption><FilterOption id="54804" count="118" label="nivolumab"></FilterOption><FilterOption id="8047" count="113" label="bevacizumab"></FilterOption><FilterOption id="2953" count="109" label="docetaxel"></FilterOption><FilterOption id="6736" count="96" label="rituximab"></FilterOption><FilterOption id="72699" count="90" label="atezolizumab"></FilterOption><FilterOption id="12205" count="86" label="capecitabine"></FilterOption><FilterOption id="3792" count="85" label="oxaliplatin"></FilterOption><FilterOption id="70667" count="85" label="pembrolizumab"></FilterOption><FilterOption id="5369" count="73" label="ribavirin"></FilterOption><FilterOption id="3536" count="71" label="pemetrexed disodium"></FilterOption><FilterOption id="6386" count="71" label="trastuzumab"></FilterOption><FilterOption id="36630" count="62" label="ipilimumab"></FilterOption><FilterOption id="7310" count="62" label="ritonavir"></FilterOption><FilterOption id="2871" count="61" label="irinotecan"></FilterOption><FilterOption id="23625" count="59" label="peginterferon alfa-2a"></FilterOption><FilterOption id="29016" count="54" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="6050" count="53" label="metformin hydrochloride"></FilterOption><FilterOption id="27572" count="51" label="lenalidomide"></FilterOption><FilterOption id="13340" count="48" label="everolimus"></FilterOption><FilterOption id="81193" count="47" label="durvalumab"></FilterOption><FilterOption id="11961" count="47" label="erlotinib"></FilterOption><FilterOption id="10388" count="46" label="cetuximab"></FilterOption><FilterOption id="15954" count="45" label="bortezomib"></FilterOption><FilterOption id="14163" count="44" label="adalimumab"></FilterOption><FilterOption id="3072" count="43" label="etoposide phosphate"></FilterOption><FilterOption id="3313" count="35" label="fulvestrant"></FilterOption><FilterOption id="2784" count="35" label="letrozole"></FilterOption><FilterOption id="16063" count="34" label="olaparib"></FilterOption><FilterOption id="12973" count="34" label="sunitinib"></FilterOption><FilterOption id="47000" count="32" label="bendamustine"></FilterOption><FilterOption id="3669" count="31" label="mycophenolate mofetil"></FilterOption><FilterOption id="55275" count="29" label="secukinumab"></FilterOption><FilterOption id="55237" count="28" label="ibrutinib"></FilterOption><FilterOption id="14681" count="28" label="lopinavir + ritonavir"></FilterOption><FilterOption id="29831" count="28" label="sorafenib"></FilterOption><FilterOption id="10309" count="26" label="abiraterone"></FilterOption><FilterOption id="4567" count="26" label="etanercept"></FilterOption><FilterOption id="53227" count="26" label="obinutuzumab"></FilterOption><FilterOption id="28532" count="26" label="pertuzumab"></FilterOption><FilterOption id="6259" count="26" label="tocilizumab (intravenous), Roche/Chugai"></FilterOption><FilterOption id="32981" count="25" label="darunavir"></FilterOption><FilterOption id="6156" count="25" label="fludarabine"></FilterOption><FilterOption id="33591" count="25" label="lapatinib"></FilterOption><FilterOption id="32677" count="25" label="rivaroxaban"></FilterOption><FilterOption id="74726" count="25" label="upadacitinib"></FilterOption><FilterOption id="7934" count="24" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="3081" count="24" label="exemestane"></FilterOption><FilterOption id="83873" count="24" label="osimertinib"></FilterOption><FilterOption id="4510" count="24" label="tacrolimus"></FilterOption><FilterOption id="4529" count="24" label="temozolomide"></FilterOption><FilterOption id="53981" count="23" label="enzalutamide"></FilterOption><FilterOption id="43738" count="23" label="pazopanib"></FilterOption><FilterOption id="24343" count="22" label="dabigatran etexilate"></FilterOption><FilterOption id="53200" count="22" label="daratumumab"></FilterOption><FilterOption id="13022" count="22" label="epirubicin"></FilterOption><FilterOption id="12646" count="22" label="panitumumab"></FilterOption><FilterOption id="45499" count="22" label="tofacitinib citrate (oral, inflammation), Pfizer"></FilterOption><FilterOption id="37370" count="21" label="azacitidine"></FilterOption><FilterOption id="6408" count="21" label="vinorelbine"></FilterOption><FilterOption id="72538" count="20" label="abemaciclib"></FilterOption><FilterOption id="56544" count="20" label="cobimetinib"></FilterOption><FilterOption id="27696" count="20" label="pomalidomide"></FilterOption><FilterOption id="54488" count="20" label="raltegravir"></FilterOption><FilterOption id="49219" count="20" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="36332" count="20" label="ticagrelor"></FilterOption><FilterOption id="52967" count="19" label="apixaban"></FilterOption><FilterOption id="15254" count="19" label="atazanavir"></FilterOption><FilterOption id="2836" count="19" label="clopidogrel"></FilterOption><FilterOption id="45841" count="19" label="lenvatinib mesylate"></FilterOption><FilterOption id="51160" count="19" label="nintedanib"></FilterOption><FilterOption id="10271" count="19" label="palbociclib"></FilterOption><FilterOption id="71886" count="19" label="ribavirin (oral tablet, HCV), Roche"></FilterOption><FilterOption id="45562" count="19" label="tremelimumab"></FilterOption><FilterOption id="48946" count="18" label="dasatinib"></FilterOption><FilterOption id="45902" count="18" label="ramucirumab"></FilterOption><FilterOption id="96193" count="18" label="spartalizumab"></FilterOption><FilterOption id="36669" count="18" label="trastuzumab emtansine"></FilterOption><FilterOption id="83065" count="17" label="avelumab"></FilterOption><FilterOption id="10606" count="17" label="eltrombopag"></FilterOption><FilterOption id="6850" count="17" label="infliximab"></FilterOption><FilterOption id="17814" count="17" label="pregabalin"></FilterOption><FilterOption id="58782" count="17" label="sacubitril + valsartan trisodium hemipentahydrate"></FilterOption><FilterOption id="14493" count="17" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="8165" count="17" label="tiotropium bromide"></FilterOption><FilterOption id="70895" count="17" label="venetoclax"></FilterOption><FilterOption id="54449" count="16" label="afatinib"></FilterOption><FilterOption id="39209" count="16" label="axitinib"></FilterOption><FilterOption id="61901" count="16" label="buparlisib"></FilterOption><FilterOption id="50935" count="16" label="cabozantinib S-malate"></FilterOption><FilterOption id="53133" count="16" label="dabrafenib"></FilterOption><FilterOption id="59062" count="16" label="dolutegravir"></FilterOption><FilterOption id="10154" count="16" label="fingolimod"></FilterOption><FilterOption id="35644" count="16" label="methoxy polyethylene glycol-epoetin beta"></FilterOption><FilterOption id="65360" count="16" label="ribociclib"></FilterOption><FilterOption id="55288" count="16" label="trametinib"></FilterOption><FilterOption id="2807" count="15" label="atorvastatin"></FilterOption><FilterOption id="47733" count="15" label="canakinumab"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="8489" count="118" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8713" count="112" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15287" count="103" label="Solid tumor - Assessment of adverse events"></FilterOption><FilterOption id="15293" count="100" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="9153" count="99" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="3736" count="90" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"></FilterOption><FilterOption id="9213" count="87" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="8481" count="80" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="6863" count="79" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"></FilterOption><FilterOption id="9155" count="73" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8505" count="71" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="1359" count="69" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="8719" count="60" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="2622" count="60" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="7547" count="56" label="Lymphoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="9008" count="55" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8998" count="55" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="8523" count="55" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8721" count="54" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8163" count="54" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8513" count="52" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="7569" count="52" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="9247" count="51" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="10830" count="51" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="15312" count="51" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8514" count="50" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="7563" count="50" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="15212" count="49" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"></FilterOption><FilterOption id="15285" count="49" label="Solid tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="7908" count="41" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="3883" count="41" label="Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response"></FilterOption><FilterOption id="7704" count="40" label="Lymphoma - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="15286" count="40" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="8436" count="39" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="8670" count="39" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"></FilterOption><FilterOption id="7360" count="39" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8720" count="38" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="15309" count="37" label="Solid tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8187" count="36" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"></FilterOption><FilterOption id="2" count="35" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="8639" count="35" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="10545" count="35" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="3900" count="35" label="Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response"></FilterOption><FilterOption id="8744" count="34" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="7680" count="33" label="Lymphoma - Assessment of adverse events"></FilterOption><FilterOption id="10243" count="33" label="Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of venous thrombosis/thromboembolism"></FilterOption><FilterOption id="8714" count="32" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="22595" count="32" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="8555" count="32" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8640" count="32" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="1358" count="32" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="25874" count="32" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"></FilterOption><FilterOption id="8430" count="31" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="7879" count="31" label="Leukemia - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7564" count="31" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="22545" count="30" label="End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels"></FilterOption><FilterOption id="7891" count="30" label="Leukemia - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8140" count="30" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"></FilterOption><FilterOption id="1561" count="30" label="Non-insulin dependent diabetes - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="7045" count="30" label="Prostate tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="7049" count="30" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="2492" count="29" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="2619" count="29" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"></FilterOption><FilterOption id="8078" count="29" label="Leukemia - Assessment of adverse events"></FilterOption><FilterOption id="25875" count="29" label="Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]"></FilterOption><FilterOption id="13344" count="29" label="Pancreas tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="4144" count="29" label="Rheumatoid arthritis - Assessment of adverse events"></FilterOption><FilterOption id="26827" count="29" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="17220" count="28" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"></FilterOption><FilterOption id="8996" count="28" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="23916" count="28" label="Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)"></FilterOption><FilterOption id="23051" count="28" label="Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)"></FilterOption><FilterOption id="6940" count="28" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"></FilterOption><FilterOption id="7367" count="28" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="4139" count="28" label="Rheumatoid arthritis - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="2292" count="27" label="Alzheimers disease - Cognitive, Global and Functional Assessments - Alzheimer's disease assessment scale - cognition (ADAS-cog)"></FilterOption><FilterOption id="3809" count="27" label="Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="26033" count="27" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="2981" count="26" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="8641" count="26" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="1548" count="26" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="1540" count="26" label="Non-insulin dependent diabetes - Assessment of Stroke"></FilterOption><FilterOption id="11728" count="25" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"></FilterOption><FilterOption id="8754" count="25" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8556" count="25" label="Lung tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="15215" count="25" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="37159" count="24" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="9122" count="24" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="2515" count="24" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="8077" count="24" label="Leukemia - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="10914" count="24" label="Ovary tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"></FilterOption><FilterOption id="10895" count="24" label="Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="17461" count="24" label="Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="10247" count="24" label="Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of pulmonary embolism(PE)"></FilterOption><FilterOption id="9310" count="23" label="Breast tumor - Imaging/Radiological Assessments"></FilterOption><FilterOption id="4283" count="23" label="Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response"></FilterOption><FilterOption id="12048" count="23" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8663" count="23" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="7489" count="23" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"></FilterOption><FilterOption id="25959" count="23" label="Pain - Assessment of Functional Disability/Physical Function"></FilterOption></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="23137" count="419" label="Novartis AG"></FilterOption><FilterOption id="19446" count="404" label="Roche Holding AG"></FilterOption><FilterOption id="18767" count="356" label="Pfizer Inc"></FilterOption><FilterOption id="28355" count="327" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="15065" count="241" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="14190" count="238" label="AstraZeneca plc"></FilterOption><FilterOption id="17810" count="219" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="26178" count="189" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="14455" count="155" label="Bayer AG"></FilterOption><FilterOption id="1059823" count="153" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="1009547" count="147" label="Sanofi SA"></FilterOption><FilterOption id="1067538" count="144" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1144568" count="134" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="14881" count="132" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="1072507" count="127" label="AbbVie Inc"></FilterOption><FilterOption id="15331" count="126" label="Celgene Corp"></FilterOption><FilterOption id="14109" count="116" label="Amgen Inc"></FilterOption><FilterOption id="1091809" count="108" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="25599" count="107" label="Novartis Pharma AG"></FilterOption><FilterOption id="16450" count="101" label="Gilead Sciences Inc"></FilterOption><FilterOption id="1013295" count="98" label="Astellas Pharma Inc"></FilterOption><FilterOption id="19453" count="93" label="Genentech Inc"></FilterOption><FilterOption id="18614" count="87" label="Novo Nordisk A/S"></FilterOption><FilterOption id="30062" count="82" label="AstraZeneca AB"></FilterOption><FilterOption id="29218" count="78" label="AbbVie Deutschland GmbH &amp; Co KG"></FilterOption><FilterOption id="15133" count="76" label="Bristol-Myers Squibb International Corp"></FilterOption><FilterOption id="1121088" count="72" label="Novartis Farmaceutica SA"></FilterOption><FilterOption id="1038736" count="64" label="PETHEMA Foundation"></FilterOption><FilterOption id="1057369" count="63" label="La Paz University Hospital (Madrid)"></FilterOption><FilterOption id="20300" count="60" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="22546" count="55" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="13601" count="53" label="Abbott Laboratories"></FilterOption><FilterOption id="1003983" count="51" label="Bayer HealthCare AG"></FilterOption><FilterOption id="23119" count="50" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="20452" count="48" label="UCB SA"></FilterOption><FilterOption id="24652" count="47" label="Shire plc"></FilterOption><FilterOption id="15414" count="46" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1017818" count="46" label="Instituto de Salud Carlos III"></FilterOption><FilterOption id="1005244" count="45" label="Biogen Inc"></FilterOption><FilterOption id="19620" count="45" label="Eisai Inc"></FilterOption><FilterOption id="18101" count="45" label="Merck KGaA"></FilterOption><FilterOption id="1045910" count="43" label="Hospital Clinico San Carlos"></FilterOption><FilterOption id="1119200" count="43" label="Sanofi-Aventis Research and Development"></FilterOption><FilterOption id="1050515" count="43" label="ViiV Healthcare Ltd"></FilterOption><FilterOption id="1110770" count="41" label="Novartis Farma SpA"></FilterOption><FilterOption id="19214" count="41" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="20348" count="41" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="1040862" count="40" label="Hospital General Universitario Gregorio Marañon"></FilterOption><FilterOption id="1042061" count="40" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="22586" count="39" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="17839" count="39" label="Eli Lilly SA"></FilterOption><FilterOption id="17216" count="38" label="Incyte Corp"></FilterOption><FilterOption id="1087775" count="36" label="Novartis Oncology"></FilterOption><FilterOption id="1145220" count="35" label="GlaxoSmithKline Research &amp; Development Ltd"></FilterOption><FilterOption id="17332" count="34" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="18077" count="34" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="27053" count="33" label="Glaxo Group Research Ltd"></FilterOption><FilterOption id="18681" count="33" label="Ono Pharmaceutical Co Ltd"></FilterOption><FilterOption id="17259" count="32" label="Ipsen"></FilterOption><FilterOption id="19461" count="31" label="Hoffmann-La Roche Inc"></FilterOption><FilterOption id="20556" count="31" label="Universidad Complutense de Madrid"></FilterOption><FilterOption id="23780" count="30" label="Actelion Ltd"></FilterOption><FilterOption id="15121" count="30" label="Bristol-Myers Squibb Belgium SA"></FilterOption><FilterOption id="1122528" count="30" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="1020322" count="29" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="24166" count="29" label="GlaxoSmithKline Biologicals"></FilterOption><FilterOption id="1039423" count="29" label="Hospital Clinic of Barcelona"></FilterOption><FilterOption id="1079538" count="29" label="Instituto de Investigación Hospital Universitario La Paz"></FilterOption><FilterOption id="1103352" count="28" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="1044292" count="28" label="Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="21991" count="28" label="Takeda Oncology"></FilterOption><FilterOption id="20519" count="27" label="National Cancer Institute"></FilterOption><FilterOption id="1110884" count="26" label="Biogen Idec Research Ltd"></FilterOption><FilterOption id="22563" count="26" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="1035512" count="26" label="EMD Serono Inc"></FilterOption><FilterOption id="1003570" count="26" label="Janssen R&amp;D (Ireland)"></FilterOption><FilterOption id="18008" count="26" label="MedImmune LLC"></FilterOption><FilterOption id="16299" count="26" label="Sanofi Genzyme"></FilterOption><FilterOption id="14112" count="26" label="Wyeth"></FilterOption><FilterOption id="1006639" count="25" label="Hospital Universitario Ramon y Cajal"></FilterOption><FilterOption id="22554" count="24" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="1092773" count="24" label="Hospital Puerta de Hierro Majadahonda"></FilterOption><FilterOption id="1003065" count="24" label="Hospital Vall D'Hebron"></FilterOption><FilterOption id="14913" count="23" label="Eisai Ltd"></FilterOption><FilterOption id="29481" count="23" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"></FilterOption><FilterOption id="21283" count="22" label="Astellas Pharma Europe BV"></FilterOption><FilterOption id="27847" count="22" label="Boston Scientific Corp"></FilterOption><FilterOption id="1033112" count="22" label="Hospital Universitario 12 de Octubre"></FilterOption><FilterOption id="1095980" count="22" label="NOVARTIS FARMACEUTICA, S.A. DE C.V."></FilterOption><FilterOption id="22598" count="22" label="Unilfarma Lda"></FilterOption><FilterOption id="DOL1000131" count="22" label="Universidad Autonoma de Madrid"></FilterOption><FilterOption id="1007052" count="22" label="Universidad Europea De Madrid"></FilterOption><FilterOption id="25902" count="21" label="Array BioPharma Inc"></FilterOption><FilterOption id="1101929" count="21" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="1055006" count="21" label="Ministry of Health, Spain"></FilterOption><FilterOption id="1033116" count="21" label="PAREXEL International"></FilterOption><FilterOption id="22555" count="20" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="27108" count="20" label="Glaxo SA"></FilterOption><FilterOption id="25554" count="20" label="Seattle Genetics Inc"></FilterOption><FilterOption id="1065900" count="19" label="Apices Soluciones, S.L."></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="214" label="2019-01-24"></FilterOption><FilterOption count="128" label="2019-01-25"></FilterOption><FilterOption count="105" label="2019-01-26"></FilterOption><FilterOption count="102" label="2019-07-03"></FilterOption><FilterOption count="99" label="2018-10-14"></FilterOption><FilterOption count="99" label="2019-03-07"></FilterOption><FilterOption count="98" label="2019-06-27"></FilterOption><FilterOption count="97" label="2018-10-15"></FilterOption><FilterOption count="91" label="2019-06-28"></FilterOption><FilterOption count="90" label="2019-06-26"></FilterOption><FilterOption count="86" label="2019-06-07"></FilterOption><FilterOption count="84" label="2019-06-20"></FilterOption><FilterOption count="83" label="2019-06-25"></FilterOption><FilterOption count="82" label="2019-07-01"></FilterOption><FilterOption count="80" label="2019-07-02"></FilterOption><FilterOption count="77" label="2018-10-12"></FilterOption><FilterOption count="75" label="2019-06-17"></FilterOption><FilterOption count="73" label="2019-06-21"></FilterOption><FilterOption count="70" label="2019-06-06"></FilterOption><FilterOption count="68" label="2019-06-12"></FilterOption><FilterOption count="68" label="2019-06-14"></FilterOption><FilterOption count="67" label="2018-10-13"></FilterOption><FilterOption count="58" label="2019-06-19"></FilterOption><FilterOption count="56" label="2019-06-18"></FilterOption><FilterOption count="53" label="2013-12-02"></FilterOption><FilterOption count="49" label="2019-06-10"></FilterOption><FilterOption count="46" label="2019-06-13"></FilterOption><FilterOption count="45" label="2019-05-31"></FilterOption><FilterOption count="43" label="2018-10-16"></FilterOption><FilterOption count="40" label="2019-06-11"></FilterOption><FilterOption count="40" label="2019-06-24"></FilterOption><FilterOption count="38" label="2019-05-15"></FilterOption><FilterOption count="38" label="2019-05-17"></FilterOption><FilterOption count="38" label="2019-05-22"></FilterOption><FilterOption count="38" label="2019-05-23"></FilterOption><FilterOption count="35" label="2018-07-07"></FilterOption><FilterOption count="32" label="2019-02-07"></FilterOption><FilterOption count="32" label="2019-05-24"></FilterOption><FilterOption count="31" label="2018-06-09"></FilterOption><FilterOption count="31" label="2019-05-27"></FilterOption><FilterOption count="31" label="2019-06-22"></FilterOption><FilterOption count="28" label="2019-04-05"></FilterOption><FilterOption count="28" label="2019-06-04"></FilterOption><FilterOption count="27" label="2019-04-11"></FilterOption><FilterOption count="26" label="2018-11-27"></FilterOption><FilterOption count="26" label="2018-12-12"></FilterOption><FilterOption count="26" label="2019-05-30"></FilterOption><FilterOption count="26" label="2019-06-03"></FilterOption><FilterOption count="25" label="2019-06-08"></FilterOption><FilterOption count="24" label="2018-12-14"></FilterOption><FilterOption count="23" label="2018-12-05"></FilterOption><FilterOption count="23" label="2019-05-07"></FilterOption><FilterOption count="23" label="2019-06-05"></FilterOption><FilterOption count="22" label="2019-03-21"></FilterOption><FilterOption count="22" label="2019-04-25"></FilterOption><FilterOption count="21" label="2018-06-23"></FilterOption><FilterOption count="21" label="2018-11-13"></FilterOption><FilterOption count="21" label="2019-03-20"></FilterOption><FilterOption count="21" label="2019-04-09"></FilterOption><FilterOption count="21" label="2019-04-23"></FilterOption><FilterOption count="21" label="2019-05-09"></FilterOption><FilterOption count="21" label="2019-05-10"></FilterOption><FilterOption count="21" label="2019-05-21"></FilterOption><FilterOption count="20" label="2018-11-16"></FilterOption><FilterOption count="20" label="2018-12-13"></FilterOption><FilterOption count="19" label="2018-06-02"></FilterOption><FilterOption count="19" label="2018-11-30"></FilterOption><FilterOption count="19" label="2019-03-01"></FilterOption><FilterOption count="19" label="2019-05-13"></FilterOption><FilterOption count="18" label="2018-01-23"></FilterOption><FilterOption count="18" label="2018-04-28"></FilterOption><FilterOption count="18" label="2018-11-29"></FilterOption><FilterOption count="18" label="2019-02-06"></FilterOption><FilterOption count="18" label="2019-02-21"></FilterOption><FilterOption count="18" label="2019-03-29"></FilterOption><FilterOption count="18" label="2019-04-15"></FilterOption><FilterOption count="18" label="2019-04-17"></FilterOption><FilterOption count="18" label="2019-05-02"></FilterOption><FilterOption count="18" label="2019-05-14"></FilterOption><FilterOption count="18" label="2019-06-15"></FilterOption><FilterOption count="18" label="2019-06-29"></FilterOption><FilterOption count="17" label="2018-06-30"></FilterOption><FilterOption count="17" label="2018-11-17"></FilterOption><FilterOption count="17" label="2018-11-20"></FilterOption><FilterOption count="17" label="2018-11-22"></FilterOption><FilterOption count="17" label="2018-12-10"></FilterOption><FilterOption count="17" label="2018-12-20"></FilterOption><FilterOption count="17" label="2019-05-16"></FilterOption><FilterOption count="16" label="2018-05-23"></FilterOption><FilterOption count="16" label="2018-05-26"></FilterOption><FilterOption count="16" label="2018-05-29"></FilterOption><FilterOption count="16" label="2018-11-23"></FilterOption><FilterOption count="16" label="2019-02-22"></FilterOption><FilterOption count="16" label="2019-03-22"></FilterOption><FilterOption count="16" label="2019-05-03"></FilterOption><FilterOption count="16" label="2019-05-29"></FilterOption><FilterOption count="15" label="2018-01-24"></FilterOption><FilterOption count="15" label="2018-05-19"></FilterOption><FilterOption count="15" label="2018-12-18"></FilterOption><FilterOption count="15" label="2019-02-04"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="151" label="201912"></FilterOption><FilterOption count="89" label="202012"></FilterOption><FilterOption count="70" label="202112"></FilterOption><FilterOption count="66" label="201812"></FilterOption><FilterOption count="63" label="201906"></FilterOption><FilterOption count="62" label="202006"></FilterOption><FilterOption count="61" label="202003"></FilterOption><FilterOption count="59" label="201512"></FilterOption><FilterOption count="55" label="201909"></FilterOption><FilterOption count="54" label="201910"></FilterOption><FilterOption count="52" label="201712"></FilterOption><FilterOption count="52" label="202007"></FilterOption><FilterOption count="49" label="201905"></FilterOption><FilterOption count="48" label="201907"></FilterOption><FilterOption count="47" label="202005"></FilterOption><FilterOption count="46" label="201612"></FilterOption><FilterOption count="46" label="201710"></FilterOption><FilterOption count="46" label="201803"></FilterOption><FilterOption count="46" label="201805"></FilterOption><FilterOption count="46" label="202001"></FilterOption><FilterOption count="44" label="201801"></FilterOption><FilterOption count="44" label="201904"></FilterOption><FilterOption count="43" label="201811"></FilterOption><FilterOption count="43" label="202106"></FilterOption><FilterOption count="42" label="201604"></FilterOption><FilterOption count="42" label="201706"></FilterOption><FilterOption count="42" label="201806"></FilterOption><FilterOption count="42" label="201911"></FilterOption><FilterOption count="42" label="202002"></FilterOption><FilterOption count="41" label="201808"></FilterOption><FilterOption count="40" label="201701"></FilterOption><FilterOption count="40" label="202009"></FilterOption><FilterOption count="39" label="201312"></FilterOption><FilterOption count="39" label="201412"></FilterOption><FilterOption count="39" label="201901"></FilterOption><FilterOption count="38" label="201704"></FilterOption><FilterOption count="38" label="201903"></FilterOption><FilterOption count="38" label="201908"></FilterOption><FilterOption count="37" label="201112"></FilterOption><FilterOption count="37" label="202010"></FilterOption><FilterOption count="37" label="202101"></FilterOption><FilterOption count="36" label="201310"></FilterOption><FilterOption count="36" label="201709"></FilterOption><FilterOption count="36" label="201809"></FilterOption><FilterOption count="36" label="201810"></FilterOption><FilterOption count="36" label="202004"></FilterOption><FilterOption count="36" label="202109"></FilterOption><FilterOption count="35" label="201506"></FilterOption><FilterOption count="35" label="201611"></FilterOption><FilterOption count="35" label="201705"></FilterOption><FilterOption count="35" label="202011"></FilterOption><FilterOption count="34" label="201212"></FilterOption><FilterOption count="34" label="201606"></FilterOption><FilterOption count="34" label="201807"></FilterOption><FilterOption count="34" label="202102"></FilterOption><FilterOption count="34" label="202107"></FilterOption><FilterOption count="33" label="201504"></FilterOption><FilterOption count="33" label="201605"></FilterOption><FilterOption count="33" label="201711"></FilterOption><FilterOption count="32" label="201103"></FilterOption><FilterOption count="32" label="201508"></FilterOption><FilterOption count="32" label="202008"></FilterOption><FilterOption count="32" label="202212"></FilterOption><FilterOption count="31" label="201203"></FilterOption><FilterOption count="31" label="201303"></FilterOption><FilterOption count="31" label="201401"></FilterOption><FilterOption count="31" label="201409"></FilterOption><FilterOption count="31" label="201503"></FilterOption><FilterOption count="31" label="201601"></FilterOption><FilterOption count="31" label="201707"></FilterOption><FilterOption count="31" label="201708"></FilterOption><FilterOption count="31" label="201902"></FilterOption><FilterOption count="31" label="202108"></FilterOption><FilterOption count="30" label="201304"></FilterOption><FilterOption count="30" label="201305"></FilterOption><FilterOption count="30" label="201501"></FilterOption><FilterOption count="30" label="201502"></FilterOption><FilterOption count="30" label="201507"></FilterOption><FilterOption count="30" label="201603"></FilterOption><FilterOption count="30" label="201610"></FilterOption><FilterOption count="30" label="201804"></FilterOption><FilterOption count="29" label="201209"></FilterOption><FilterOption count="29" label="201407"></FilterOption><FilterOption count="29" label="201505"></FilterOption><FilterOption count="29" label="201510"></FilterOption><FilterOption count="29" label="201607"></FilterOption><FilterOption count="29" label="201609"></FilterOption><FilterOption count="29" label="202104"></FilterOption><FilterOption count="29" label="202105"></FilterOption><FilterOption count="29" label="202203"></FilterOption><FilterOption count="28" label="201007"></FilterOption><FilterOption count="28" label="201105"></FilterOption><FilterOption count="28" label="201210"></FilterOption><FilterOption count="28" label="201301"></FilterOption><FilterOption count="28" label="201309"></FilterOption><FilterOption count="28" label="201402"></FilterOption><FilterOption count="28" label="201406"></FilterOption><FilterOption count="28" label="201703"></FilterOption><FilterOption count="27" label="201405"></FilterOption><FilterOption count="27" label="202103"></FilterOption></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="67" label="201703"></FilterOption><FilterOption count="65" label="201810"></FilterOption><FilterOption count="63" label="201806"></FilterOption><FilterOption count="59" label="201606"></FilterOption><FilterOption count="59" label="201701"></FilterOption><FilterOption count="58" label="201712"></FilterOption><FilterOption count="57" label="201511"></FilterOption><FilterOption count="56" label="201210"></FilterOption><FilterOption count="54" label="201506"></FilterOption><FilterOption count="53" label="201507"></FilterOption><FilterOption count="53" label="201610"></FilterOption><FilterOption count="52" label="201403"></FilterOption><FilterOption count="52" label="201410"></FilterOption><FilterOption count="52" label="201512"></FilterOption><FilterOption count="52" label="201804"></FilterOption><FilterOption count="51" label="201412"></FilterOption><FilterOption count="51" label="201611"></FilterOption><FilterOption count="50" label="201309"></FilterOption><FilterOption count="50" label="201704"></FilterOption><FilterOption count="49" label="201605"></FilterOption><FilterOption count="48" label="201211"></FilterOption><FilterOption count="48" label="201707"></FilterOption><FilterOption count="47" label="201310"></FilterOption><FilterOption count="47" label="201609"></FilterOption><FilterOption count="46" label="201401"></FilterOption><FilterOption count="46" label="201706"></FilterOption><FilterOption count="45" label="201411"></FilterOption><FilterOption count="45" label="201501"></FilterOption><FilterOption count="45" label="201509"></FilterOption><FilterOption count="45" label="201612"></FilterOption><FilterOption count="45" label="201802"></FilterOption><FilterOption count="44" label="201103"></FilterOption><FilterOption count="44" label="201106"></FilterOption><FilterOption count="44" label="201311"></FilterOption><FilterOption count="44" label="201603"></FilterOption><FilterOption count="44" label="201604"></FilterOption><FilterOption count="44" label="201702"></FilterOption><FilterOption count="43" label="200812"></FilterOption><FilterOption count="43" label="201711"></FilterOption><FilterOption count="43" label="201801"></FilterOption><FilterOption count="43" label="201805"></FilterOption><FilterOption count="43" label="201904"></FilterOption><FilterOption count="42" label="201301"></FilterOption><FilterOption count="42" label="201504"></FilterOption><FilterOption count="42" label="201803"></FilterOption><FilterOption count="42" label="201811"></FilterOption><FilterOption count="41" label="200909"></FilterOption><FilterOption count="41" label="201010"></FilterOption><FilterOption count="41" label="201112"></FilterOption><FilterOption count="41" label="201212"></FilterOption><FilterOption count="41" label="201607"></FilterOption><FilterOption count="41" label="201812"></FilterOption><FilterOption count="40" label="201110"></FilterOption><FilterOption count="40" label="201306"></FilterOption><FilterOption count="40" label="201510"></FilterOption><FilterOption count="40" label="201602"></FilterOption><FilterOption count="39" label="200904"></FilterOption><FilterOption count="39" label="201206"></FilterOption><FilterOption count="39" label="201312"></FilterOption><FilterOption count="39" label="201405"></FilterOption><FilterOption count="39" label="201601"></FilterOption><FilterOption count="39" label="201807"></FilterOption><FilterOption count="39" label="201903"></FilterOption><FilterOption count="38" label="200804"></FilterOption><FilterOption count="38" label="201304"></FilterOption><FilterOption count="38" label="201705"></FilterOption><FilterOption count="37" label="201109"></FilterOption><FilterOption count="37" label="201204"></FilterOption><FilterOption count="37" label="201205"></FilterOption><FilterOption count="36" label="201009"></FilterOption><FilterOption count="36" label="201111"></FilterOption><FilterOption count="36" label="201201"></FilterOption><FilterOption count="36" label="201308"></FilterOption><FilterOption count="36" label="201402"></FilterOption><FilterOption count="36" label="201406"></FilterOption><FilterOption count="36" label="201407"></FilterOption><FilterOption count="36" label="201709"></FilterOption><FilterOption count="35" label="200901"></FilterOption><FilterOption count="35" label="201012"></FilterOption><FilterOption count="35" label="201101"></FilterOption><FilterOption count="35" label="201102"></FilterOption><FilterOption count="35" label="201105"></FilterOption><FilterOption count="35" label="201203"></FilterOption><FilterOption count="35" label="201503"></FilterOption><FilterOption count="35" label="201505"></FilterOption><FilterOption count="34" label="201107"></FilterOption><FilterOption count="34" label="201209"></FilterOption><FilterOption count="33" label="200912"></FilterOption><FilterOption count="33" label="201001"></FilterOption><FilterOption count="33" label="201011"></FilterOption><FilterOption count="33" label="201404"></FilterOption><FilterOption count="33" label="201710"></FilterOption><FilterOption count="33" label="201901"></FilterOption><FilterOption count="33" label="201902"></FilterOption><FilterOption count="32" label="200810"></FilterOption><FilterOption count="32" label="201104"></FilterOption><FilterOption count="32" label="201303"></FilterOption><FilterOption count="32" label="201906"></FilterOption><FilterOption count="31" label="200611"></FilterOption><FilterOption count="31" label="200801"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="15"><FilterOption id="C3" count="2482" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="1337" label="Phase 2 Clinical"></FilterOption><FilterOption id="C4" count="671" label="Phase 4 Clinical"></FilterOption><FilterOption id="PNA" count="491" label="Phase Not Applicable"></FilterOption><FilterOption id="C12" count="312" label="Phase 1/Phase 2 Clinical"></FilterOption><FilterOption id="C1" count="268" label="Phase 1 Clinical"></FilterOption><FilterOption id="NS" count="219" label="Phase not specified"></FilterOption><FilterOption id="C3B" count="208" label="Phase 3b Clinical"></FilterOption><FilterOption id="C2B" count="175" label="Phase 2b Clinical"></FilterOption><FilterOption id="C23" count="138" label="Phase 2/Phase 3 Clinical"></FilterOption><FilterOption id="C1B" count="109" label="Phase 1b Clinical"></FilterOption><FilterOption id="C2A" count="87" label="Phase 2a Clinical"></FilterOption><FilterOption id="C3A" count="18" label="Phase 3a Clinical"></FilterOption><FilterOption id="C0" count="9" label="Phase 0 Clinical"></FilterOption><FilterOption id="C1A" count="6" label="Phase 1a Clinical"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="3976" count="326" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3977" count="326" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="3900" count="303" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="3957" count="288" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"></FilterOption><FilterOption id="4840" count="287" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4880" count="267" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4879" count="265" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3936" count="256" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"></FilterOption><FilterOption id="3940" count="225" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3938" count="220" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"></FilterOption><FilterOption id="584" count="197" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"></FilterOption><FilterOption id="3914" count="184" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="13096" count="177" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3537" count="165" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3538" count="165" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4483" count="157" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4032" count="154" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4024" count="153" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="22417" count="151" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"></FilterOption><FilterOption id="13110" count="148" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="13111" count="148" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="5418" count="147" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"></FilterOption><FilterOption id="13129" count="147" label="Solid tumor - Subjects with Treatment Refractory Disease"></FilterOption><FilterOption id="22381" count="146" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"></FilterOption><FilterOption id="4814" count="143" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="4074" count="140" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="4528" count="139" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="4527" count="138" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3935" count="135" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"></FilterOption><FilterOption id="5317" count="124" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"></FilterOption><FilterOption id="4894" count="122" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="4922" count="122" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="1751" count="122" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="4857" count="121" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="3539" count="120" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="3933" count="119" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage III lung cancer"></FilterOption><FilterOption id="4813" count="118" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="901" count="116" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="4073" count="115" label="Lung tumor - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="3989" count="113" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="3971" count="113" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"></FilterOption><FilterOption id="5086" count="110" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4106" count="110" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"></FilterOption><FilterOption id="4923" count="109" label="Breast tumor - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="607" count="109" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="5087" count="108" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="3548" count="108" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"></FilterOption><FilterOption id="4808" count="105" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="22262" count="103" label="Pain - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="7091" count="102" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4509" count="101" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"></FilterOption><FilterOption id="3987" count="100" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="4877" count="99" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"></FilterOption><FilterOption id="4817" count="97" label="Breast tumor - Postmenopausal Breast Cancer Women"></FilterOption><FilterOption id="4569" count="96" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"></FilterOption><FilterOption id="4041" count="96" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="3614" count="95" label="Lymphoma - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="3997" count="93" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="4856" count="91" label="Breast tumor - Subjects with Measurable Disease"></FilterOption><FilterOption id="3978" count="90" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4565" count="89" label="Colorectal tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4564" count="88" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="5088" count="88" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="8817" count="88" label="Pancreas tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4468" count="87" label="Colorectal tumor - Subjects with Colon Cancer"></FilterOption><FilterOption id="4467" count="86" label="Colorectal tumor - Subjects with Rectal Cancer"></FilterOption><FilterOption id="3642" count="86" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="32043" count="85" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"></FilterOption><FilterOption id="4169" count="85" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4170" count="85" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="13131" count="85" label="Solid tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4955" count="83" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"></FilterOption><FilterOption id="3609" count="83" label="Lymphoma - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="4864" count="81" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"></FilterOption><FilterOption id="4815" count="81" label="Breast tumor - Subjects with Triple Negative Breast Cancer"></FilterOption><FilterOption id="4895" count="80" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer hormonal therapy"></FilterOption><FilterOption id="4471" count="80" label="Colorectal tumor - Subjects with Measurable Disease - Subjects with measurable disease as per modified RECIST Criteria"></FilterOption><FilterOption id="4558" count="80" label="Colorectal tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="5074" count="80" label="Leukemia - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4827" count="78" label="Breast tumor - TNM Stage III Breast Cancer"></FilterOption><FilterOption id="5073" count="78" label="Leukemia - Subjects with Normal/Acceptable Organ Function - Subjects with normal/adequate liver function"></FilterOption><FilterOption id="4691" count="78" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4692" count="78" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="13132" count="78" label="Solid tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="8263" count="77" label="Ovary tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4397" count="76" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4162" count="76" label="Melanoma - Subjects with Diagnosis of Melanoma - Subjects with histological diagnosis of melanoma"></FilterOption><FilterOption id="22416" count="75" label="Breast tumor - Subjects with Unresectable Breast Cancer"></FilterOption><FilterOption id="4398" count="75" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="6663" count="75" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="4098" count="75" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Subjects recovered from all prior therapies and/or their toxic/adverse effects"></FilterOption><FilterOption id="13133" count="75" label="Solid tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4893" count="73" label="Breast tumor - Subjects with History of Anti Cancer Therapy"></FilterOption><FilterOption id="4981" count="72" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"></FilterOption><FilterOption id="3755" count="72" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"></FilterOption><FilterOption id="3448" count="71" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"></FilterOption><FilterOption id="3622" count="71" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="3628" count="71" label="Lymphoma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4139" count="71" label="Melanoma - Subjects with Stage IV Melanoma"></FilterOption><FilterOption id="8264" count="71" label="Ovary tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="100"><FilterOption id="2953" count="50" label="docetaxel"></FilterOption><FilterOption id="3803" count="34" label="paclitaxel"></FilterOption><FilterOption id="3199" count="25" label="gemcitabine"></FilterOption><FilterOption id="12205" count="22" label="capecitabine"></FilterOption><FilterOption id="13928" count="19" label="enoxaparin sodium"></FilterOption><FilterOption id="7413" count="18" label="darbepoetin alfa"></FilterOption><FilterOption id="3313" count="17" label="fulvestrant"></FilterOption><FilterOption id="44375" count="16" label="warfarin"></FilterOption><FilterOption id="11961" count="15" label="erlotinib"></FilterOption><FilterOption id="37370" count="14" label="azacitidine"></FilterOption><FilterOption id="6736" count="14" label="rituximab"></FilterOption><FilterOption id="14163" count="13" label="adalimumab"></FilterOption><FilterOption id="70667" count="13" label="pembrolizumab"></FilterOption><FilterOption id="29831" count="13" label="sorafenib"></FilterOption><FilterOption id="12973" count="13" label="sunitinib"></FilterOption><FilterOption id="8165" count="13" label="tiotropium bromide"></FilterOption><FilterOption id="10252" count="12" label="insulin glargine"></FilterOption><FilterOption id="4577" count="12" label="topotecan"></FilterOption><FilterOption id="11460" count="11" label="imatinib"></FilterOption><FilterOption id="2784" count="11" label="letrozole"></FilterOption><FilterOption id="4529" count="11" label="temozolomide"></FilterOption><FilterOption id="44401" count="11" label="vancomycin"></FilterOption><FilterOption id="6408" count="11" label="vinorelbine"></FilterOption><FilterOption id="2807" count="10" label="atorvastatin"></FilterOption><FilterOption id="7934" count="9" label="doxorubicin (liposomal, STEALTH), Alza"></FilterOption><FilterOption id="6050" count="9" label="metformin hydrochloride"></FilterOption><FilterOption id="3536" count="9" label="pemetrexed disodium"></FilterOption><FilterOption id="4567" count="8" label="etanercept"></FilterOption><FilterOption id="3081" count="8" label="exemestane"></FilterOption><FilterOption id="14336" count="8" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="3360" count="8" label="interferon beta-1a, Biogen"></FilterOption><FilterOption id="14493" count="8" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="3321" count="7" label="anastrozole"></FilterOption><FilterOption id="6850" count="7" label="infliximab"></FilterOption><FilterOption id="54804" count="7" label="nivolumab"></FilterOption><FilterOption id="22395" count="7" label="ranibizumab"></FilterOption><FilterOption id="42858" count="7" label="ustekinumab"></FilterOption><FilterOption id="28773" count="6" label="eribulin mesylate"></FilterOption><FilterOption id="13340" count="6" label="everolimus"></FilterOption><FilterOption id="2871" count="6" label="irinotecan"></FilterOption><FilterOption id="3616" count="6" label="meropenem"></FilterOption><FilterOption id="13460" count="6" label="oseltamivir"></FilterOption><FilterOption id="10488" count="6" label="tolterodine"></FilterOption><FilterOption id="2836" count="5" label="clopidogrel"></FilterOption><FilterOption id="13239" count="5" label="decitabine"></FilterOption><FilterOption id="53981" count="5" label="enzalutamide"></FilterOption><FilterOption id="3159" count="5" label="fluticasone propionate"></FilterOption><FilterOption id="5267" count="5" label="leuprorelin acetate"></FilterOption><FilterOption id="5148" count="5" label="liraglutide"></FilterOption><FilterOption id="12978" count="5" label="moxifloxacin"></FilterOption><FilterOption id="42299" count="5" label="ofatumumab"></FilterOption><FilterOption id="43738" count="5" label="pazopanib"></FilterOption><FilterOption id="9702" count="5" label="recombinant interferon beta-1a, Merck Serono"></FilterOption><FilterOption id="44312" count="5" label="salmeterol"></FilterOption><FilterOption id="8713" count="5" label="sildenafil citrate"></FilterOption><FilterOption id="4513" count="5" label="tamsulosin hydrochloride"></FilterOption><FilterOption id="53547" count="4" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"></FilterOption><FilterOption id="72699" count="4" label="atezolizumab"></FilterOption><FilterOption id="8047" count="4" label="bevacizumab"></FilterOption><FilterOption id="44697" count="4" label="carbamazepine (extended-release), Novartis"></FilterOption><FilterOption id="44388" count="4" label="carbidopa + levodopa"></FilterOption><FilterOption id="10388" count="4" label="cetuximab"></FilterOption><FilterOption id="5999" count="4" label="ciclosporin, Novartis"></FilterOption><FilterOption id="55798" count="4" label="crizotinib"></FilterOption><FilterOption id="2992" count="4" label="donepezil hydrochloride"></FilterOption><FilterOption id="67892" count="4" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"></FilterOption><FilterOption id="3350" count="4" label="Fluarix"></FilterOption><FilterOption id="11603" count="4" label="gefitinib"></FilterOption><FilterOption id="55237" count="4" label="ibrutinib"></FilterOption><FilterOption id="36630" count="4" label="ipilimumab"></FilterOption><FilterOption id="31620" count="4" label="octocog alfa, Baxalta"></FilterOption><FilterOption id="23625" count="4" label="peginterferon alfa-2a"></FilterOption><FilterOption id="12420" count="4" label="rosuvastatin"></FilterOption><FilterOption id="44313" count="4" label="simvastatin"></FilterOption><FilterOption id="50038" count="4" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"></FilterOption><FilterOption id="11232" count="4" label="tobramycin (nebulized), Novartis"></FilterOption><FilterOption id="2773" count="4" label="valsartan"></FilterOption><FilterOption id="6747" count="3" label="adefovir dipivoxil"></FilterOption><FilterOption id="2500" count="3" label="amlodipine"></FilterOption><FilterOption id="2509" count="3" label="anagrelide"></FilterOption><FilterOption id="15954" count="3" label="bortezomib"></FilterOption><FilterOption id="44383" count="3" label="carboplatin"></FilterOption><FilterOption id="4728" count="3" label="emtricitabine"></FilterOption><FilterOption id="44289" count="3" label="enalapril"></FilterOption><FilterOption id="7607" count="3" label="follitropin alfa"></FilterOption><FilterOption id="6140" count="3" label="formoterol"></FilterOption><FilterOption id="8710" count="3" label="glatiramer acetate"></FilterOption><FilterOption id="6621" count="3" label="Havrix"></FilterOption><FilterOption id="11036" count="3" label="linezolid"></FilterOption><FilterOption id="14681" count="3" label="lopinavir + ritonavir"></FilterOption><FilterOption id="3669" count="3" label="mycophenolate mofetil"></FilterOption><FilterOption id="29016" count="3" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="8747" count="3" label="palivizumab"></FilterOption><FilterOption id="17814" count="3" label="pregabalin"></FilterOption><FilterOption id="4234" count="3" label="risedronate sodium"></FilterOption><FilterOption id="55275" count="3" label="secukinumab"></FilterOption><FilterOption id="15478" count="3" label="solifenacin"></FilterOption><FilterOption id="49219" count="3" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="6386" count="3" label="trastuzumab"></FilterOption><FilterOption id="15130" count="3" label="vinflunine"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="372" count="99" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="5085" count="63" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="740" count="52" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="3808" count="51" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="1016" count="49" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="374" count="49" label="Transferase inhibitor"></FilterOption><FilterOption id="142" count="48" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="135" count="47" label="DHFR inhibitor"></FilterOption><FilterOption id="1832" count="47" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="181" count="46" label="GAR transformylase inhibitor"></FilterOption><FilterOption id="3848" count="46" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="12521" count="45" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="3846" count="45" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="3756" count="44" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="138" count="43" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="721" count="41" label="TNF binding agent"></FilterOption><FilterOption id="141" count="38" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="3850" count="38" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="76" count="35" label="Aromatase inhibitor"></FilterOption><FilterOption id="23014" count="35" label="Insulin ligand"></FilterOption><FilterOption id="400" count="35" label="Insulin receptor agonist"></FilterOption><FilterOption id="48492" count="34" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="381" count="34" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="8805" count="33" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="3816" count="31" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="40" count="29" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="3806" count="29" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="204" count="29" label="HIV protease inhibitor"></FilterOption><FilterOption id="768" count="29" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="948" count="29" label="PDGF receptor antagonist"></FilterOption><FilterOption id="262" count="28" label="Muscarinic M3 receptor antagonist"></FilterOption><FilterOption id="67136" count="26" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="7424" count="24" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="3754" count="24" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="1741" count="24" label="Low molecular weight heparin"></FilterOption><FilterOption id="286" count="22" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="111" count="22" label="Factor IIa antagonist"></FilterOption><FilterOption id="113" count="22" label="Factor IX antagonist"></FilterOption><FilterOption id="114" count="22" label="Factor VII antagonist"></FilterOption><FilterOption id="119" count="22" label="Factor X antagonist"></FilterOption><FilterOption id="4917" count="22" label="Proteasome inhibitor"></FilterOption><FilterOption id="1722" count="22" label="VEGF receptor antagonist"></FilterOption><FilterOption id="10583" count="22" label="Vitamin K epoxide reductase inhibitor"></FilterOption><FilterOption id="12162" count="21" label="Erythropoietin ligand"></FilterOption><FilterOption id="48489" count="21" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="4548" count="21" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="214" count="19" label="Interferon alpha 2 ligand"></FilterOption><FilterOption id="1833" count="19" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="76469" count="18" label="26S proteasome complex inhibitor"></FilterOption><FilterOption id="629" count="18" label="Inosine monophosphate dehydrogenase inhibitor"></FilterOption><FilterOption id="259" count="18" label="Muscarinic receptor antagonist"></FilterOption><FilterOption id="6512" count="17" label="DNA methyltransferase inhibitor"></FilterOption><FilterOption id="261" count="17" label="Muscarinic M1 receptor antagonist"></FilterOption><FilterOption id="4010" count="16" label="Calcineurin inhibitor"></FilterOption><FilterOption id="3154" count="16" label="CSF-1 antagonist"></FilterOption><FilterOption id="10240" count="16" label="mTOR inhibitor"></FilterOption><FilterOption id="4913" count="16" label="P2Y12 purinoceptor antagonist"></FilterOption><FilterOption id="2506" count="16" label="PARP modulator"></FilterOption><FilterOption id="57003" count="16" label="Peptidoglycan recognition protein inhibitor"></FilterOption><FilterOption id="4550" count="16" label="Raf 1 protein kinase inhibitor"></FilterOption><FilterOption id="3524" count="15" label="Abl tyrosine kinase inhibitor"></FilterOption><FilterOption id="7588" count="15" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="205" count="15" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="13571" count="14" label="Bcr protein inhibitor"></FilterOption><FilterOption id="71851" count="14" label="HIV GAG POL polyprotein inhibitor"></FilterOption><FilterOption id="12395" count="14" label="HIV GAG protein inhibitor"></FilterOption><FilterOption id="481" count="14" label="Interferon beta ligand"></FilterOption><FilterOption id="11778" count="13" label="PurH purine biosynthesis protein inhibitor"></FilterOption><FilterOption id="4542" count="13" label="Raf protein kinase inhibitor"></FilterOption><FilterOption id="814" count="13" label="Tubulin modulator"></FilterOption><FilterOption id="76090" count="12" label="mTOR complex 1 inhibitor"></FilterOption><FilterOption id="66340" count="12" label="Penicillin binding protein inhibitor"></FilterOption><FilterOption id="7025" count="12" label="Signal transduction inhibitor"></FilterOption><FilterOption id="15" count="11" label="5-HT 3 receptor antagonist"></FilterOption><FilterOption id="7472" count="11" label="Cytochrome P450 17 inhibitor"></FilterOption><FilterOption id="82444" count="11" label="DNA helicase inhibitor"></FilterOption><FilterOption id="51708" count="11" label="DNA polymerase alpha inhibitor"></FilterOption><FilterOption id="6830" count="11" label="DNA primase inhibitor"></FilterOption><FilterOption id="346" count="11" label="Ribonucleotide reductase inhibitor"></FilterOption><FilterOption id="18" count="10" label="ACE inhibitor"></FilterOption><FilterOption id="431" count="10" label="DNA gyrase inhibitor"></FilterOption><FilterOption id="2585" count="10" label="Glucagon-like peptide 1 receptor agonist"></FilterOption><FilterOption id="385" count="10" label="Protein tyrosine kinase inhibitor"></FilterOption><FilterOption id="60" count="9" label="Androgen receptor antagonist"></FilterOption><FilterOption id="64" count="9" label="Angiotensin II receptor antagonist"></FilterOption><FilterOption id="7418" count="9" label="Cytochrome P450 3 inhibitor"></FilterOption><FilterOption id="3688" count="9" label="FGF3 receptor antagonist"></FilterOption><FilterOption id="1092" count="9" label="GNRH receptor agonist"></FilterOption><FilterOption id="3584" count="9" label="Lck tyrosine kinase inhibitor"></FilterOption><FilterOption id="14007" count="9" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="13" count="8" label="5-HT 2 receptor antagonist"></FilterOption><FilterOption id="150" count="8" label="Dopamine D2 receptor antagonist"></FilterOption><FilterOption id="3682" count="8" label="FGF1 receptor antagonist"></FilterOption><FilterOption id="511" count="8" label="TNF antagonist"></FilterOption><FilterOption id="8222" count="8" label="Type II TNF receptor modulator"></FilterOption><FilterOption id="6515" count="7" label="Cytosine DNA methyltransferase inhibitor"></FilterOption><FilterOption id="1671" count="7" label="HIV integrase inhibitor"></FilterOption><FilterOption id="1584" count="7" label="IL-12 receptor antagonist"></FilterOption><FilterOption id="9748" count="7" label="IL-23 antagonist"></FilterOption><FilterOption id="516" count="7" label="Muscarinic M2 receptor antagonist"></FilterOption></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="1030" label="Diarrhea"></FilterOption><FilterOption id="226" count="941" label="Nausea"></FilterOption><FilterOption id="829" count="825" label="Fatigue"></FilterOption><FilterOption id="148" count="646" label="Headache"></FilterOption><FilterOption id="1991" count="622" label="Neutropenia"></FilterOption><FilterOption id="110" count="588" label="Emesis"></FilterOption><FilterOption id="17" count="566" label="Anemia"></FilterOption><FilterOption id="3020" count="408" label="Skin rash"></FilterOption><FilterOption id="3038" count="395" label="Appetite loss"></FilterOption><FilterOption id="324" count="388" label="Thrombocytopenia"></FilterOption><FilterOption id="1833" count="377" label="Fever"></FilterOption><FilterOption id="404" count="364" label="Constipation"></FilterOption><FilterOption id="2274" count="347" label="Rhinopharyngitis"></FilterOption><FilterOption id="178" count="296" label="Hypertension"></FilterOption><FilterOption id="516" count="277" label="Upper respiratory tract infection"></FilterOption><FilterOption id="3062" count="273" label="Death"></FilterOption><FilterOption id="360" count="256" label="Pneumonia"></FilterOption><FilterOption id="2439" count="252" label="Arthralgia"></FilterOption><FilterOption id="82" count="250" label="Cough"></FilterOption><FilterOption id="746" count="244" label="Infectious disease"></FilterOption><FilterOption id="3472" count="237" label="Abdominal pain"></FilterOption><FilterOption id="2400" count="222" label="Dyspnea"></FilterOption><FilterOption id="680" count="200" label="Leukopenia"></FilterOption><FilterOption id="3454" count="193" label="Dizziness"></FilterOption><FilterOption id="3221" count="192" label="Back pain"></FilterOption><FilterOption id="3795" count="189" label="Febrile neutropenia"></FilterOption><FilterOption id="402" count="182" label="Edema"></FilterOption><FilterOption id="279" count="177" label="Pruritus"></FilterOption><FilterOption id="1009" count="165" label="Urinary tract infection"></FilterOption><FilterOption id="20" count="154" label="Pain"></FilterOption><FilterOption id="13" count="150" label="Alopecia"></FilterOption><FilterOption id="1016" count="145" label="Stomatitis"></FilterOption><FilterOption id="1039" count="129" label="Myalgia"></FilterOption><FilterOption id="552" count="125" label="Bleeding"></FilterOption><FilterOption id="750" count="125" label="Insomnia"></FilterOption><FilterOption id="129" count="104" label="Gastrointestinal disease"></FilterOption><FilterOption id="259" count="104" label="Peripheral neuropathy"></FilterOption><FilterOption id="1821" count="103" label="Hyperglycemia"></FilterOption><FilterOption id="181" count="95" label="Hypokalemia"></FilterOption><FilterOption id="50" count="91" label="Bronchitis"></FilterOption><FilterOption id="1992" count="90" label="Lymphocytopenia"></FilterOption><FilterOption id="191" count="80" label="Influenza virus infection"></FilterOption><FilterOption id="1078" count="77" label="Lung embolism"></FilterOption><FilterOption id="1063" count="77" label="Xerostomia"></FilterOption><FilterOption id="3073" count="74" label="Drowsiness"></FilterOption><FilterOption id="2576" count="74" label="Dysgeusia"></FilterOption><FilterOption id="224" count="74" label="Myocardial infarction"></FilterOption><FilterOption id="2955" count="74" label="Weight loss"></FilterOption><FilterOption id="114" count="66" label="Sepsis"></FilterOption><FilterOption id="445" count="65" label="Hypoglycemia"></FilterOption><FilterOption id="408" count="65" label="Hypotension"></FilterOption><FilterOption id="182" count="64" label="Hypothyroidism"></FilterOption><FilterOption id="432" count="61" label="Dyspepsia"></FilterOption><FilterOption id="2024" count="59" label="Erythema"></FilterOption><FilterOption id="93" count="57" label="Depression"></FilterOption><FilterOption id="505" count="56" label="Hypersensitivity"></FilterOption><FilterOption id="277" count="55" label="Proteinuria"></FilterOption><FilterOption id="2434" count="55" label="Vertigo"></FilterOption><FilterOption id="1263" count="54" label="Mucositis"></FilterOption><FilterOption id="3050" count="51" label="Chill"></FilterOption><FilterOption id="1835" count="51" label="Epistaxis"></FilterOption><FilterOption id="2440" count="51" label="Musculoskeletal pain"></FilterOption><FilterOption id="1072" count="48" label="Colitis"></FilterOption><FilterOption id="69" count="48" label="Renal failure"></FilterOption><FilterOption id="55" count="47" label="Cardiac failure"></FilterOption><FilterOption id="3868" count="47" label="Xerosis"></FilterOption><FilterOption id="1280" count="45" label="Hypophosphatemia"></FilterOption><FilterOption id="25" count="44" label="Anxiety disorder"></FilterOption><FilterOption id="2954" count="42" label="Weight gain"></FilterOption><FilterOption id="574" count="41" label="Deep vein thrombosis"></FilterOption><FilterOption id="94" count="40" label="Dermatitis"></FilterOption><FilterOption id="1256" count="40" label="Hyponatremia"></FilterOption><FilterOption id="1542" count="39" label="Atrial fibrillation"></FilterOption><FilterOption id="2195" count="39" label="Gastroenteritis"></FilterOption><FilterOption id="172" count="39" label="Hyperbilirubinemia"></FilterOption><FilterOption id="678" count="38" label="Neuropathy"></FilterOption><FilterOption id="2529" count="37" label="Hot flashes"></FilterOption><FilterOption id="65" count="37" label="Stroke"></FilterOption><FilterOption id="1559" count="36" label="Congestive heart failure"></FilterOption><FilterOption id="358" count="36" label="Muscle spasm"></FilterOption><FilterOption id="325" count="36" label="Thromboembolism"></FilterOption><FilterOption id="626" count="35" label="Heart disease"></FilterOption><FilterOption id="668" count="35" label="Muscle weakness"></FilterOption><FilterOption id="453" count="33" label="Pharyngitis"></FilterOption><FilterOption id="2733" count="32" label="Hypomagnesemia"></FilterOption><FilterOption id="250" count="32" label="Pancreatitis"></FilterOption><FilterOption id="95" count="31" label="Dermatological disease"></FilterOption><FilterOption id="392" count="31" label="Varicella zoster virus infection"></FilterOption><FilterOption id="154" count="30" label="Hepatitis"></FilterOption><FilterOption id="188" count="30" label="Inflammatory disease"></FilterOption><FilterOption id="509" count="29" label="Respiratory tract infection"></FilterOption><FilterOption id="2184" count="28" label="Gastrointestinal bleeding"></FilterOption><FilterOption id="444" count="28" label="Hypocalcemia"></FilterOption><FilterOption id="286" count="27" label="Renal disease"></FilterOption><FilterOption id="1876" count="27" label="Syncope"></FilterOption><FilterOption id="2291" count="26" label="Hematuria"></FilterOption><FilterOption id="201" count="26" label="Liver disease"></FilterOption><FilterOption id="1091" count="25" label="Bone injury"></FilterOption><FilterOption id="174" count="25" label="Hypercholesterolemia"></FilterOption><FilterOption id="2738" count="25" label="Hyperkalemia"></FilterOption></Filter></Filters><NormalizedQuery>Madrid</NormalizedQuery><SearchResults><Trial Id="225671"><Indications><Indication>Premature labor</Indication></Indications><CompaniesCollaborator><Company>Universidad Complutense de Madrid</Company></CompaniesCollaborator><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-04-02T00:00:00Z</DateChangeLast><DateEnd>2014-07-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>HULP3551</Identifier><Identifier>NCT02192996</Identifier><Identifier>UNIVERSIDAD COMPLUTENSE MADRID</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bifidobacterium breve alone</Intervention><Intervention>Lactobacillus salivarius alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>5</PatientCountEnrollment><Phase>Phase 0 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>null</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study</TitleDisplay><BiomarkerNames><BiomarkerName>Birth weight </BiomarkerName><BiomarkerName> C-C motif chemokine 2 </BiomarkerName><BiomarkerName> C-C motif chemokine 4 </BiomarkerName><BiomarkerName> Granulocyte colony-stimulating factor </BiomarkerName><BiomarkerName> Granulocyte-macrophage colony-stimulating factor </BiomarkerName><BiomarkerName> Growth-regulated alpha protein </BiomarkerName><BiomarkerName> Immunoglobulin A </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-12 </BiomarkerName><BiomarkerName> Interleukin-13 </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Interleukin-4 </BiomarkerName><BiomarkerName> Interleukin-5 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-7 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Miguel Saenz de Pipaon, PhD. MD.</Name></ContactNames></Trial><Trial Id="254264"><Indications><Indication>Asthma</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2016-09-30T00:00:00Z</DateEnd><DateStart>2015-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02690831</Identifier><Identifier>UNIVERSIDAD AUTONOMA DE MADRID</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Inspiratory muscle training (IMT) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Inspiratory muscle training (IMT) alone</Intervention><Intervention>Manual therapy and motor control exercise alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to assess if an intervention of manual therapy and motor control exercises combined with an inspiratory muscle training program was more effective than an inspiratory muscle training program alone in increasing the maximum inspiratory pressure in patients with asthma. In addition, the study pretends to evaluate the changes caused by the intervention regarding possible postural changes and thoracic diameter.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Spirometry Unspecified</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Patients With Asthma</TitleDisplay><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="345639"><Indications><Indication>End stage renal disease</Indication><Indication>Kidney dialysis</Indication></Indications><CompaniesCollaborator><Company>Fundacion Renal Inigo Alvarez De Toledo</Company><Company>Universidad Europea De Madrid</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Politecnica de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2015-10-30T00:00:00Z</DateEnd><DateStart>2014-07-22T00:00:00Z</DateStart><Identifiers><Identifier>MARGARITA PÉREZ RUIZ</Identifier><Identifier>MGGROSS</Identifier><Identifier>NCT03579537</Identifier><Identifier>UNIVERSIDAD POLITÉCNICA MADRID</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Intradyalisis alone</Intervention><Intervention>exercise programe alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the trial was to study the effects of exercise on physical fitness among hemodialysis patients with chronic kidney disease. Regular physical exercise was adapted to the situation of the patient with hemodialysis to help improve the quality of life of the patient.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Anthropometric Assessments</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Anxiety by Protocol Specified Scales - Assessment by Spielberger State-Trait Anxiety Inventory (STAI)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Hormone Levels - Assessment of Parathyroid hormone (PTH)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of calcium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of plasma potassium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of sodium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of iron status</EndpointIndex><EndpointIndex>End stage renal disease - Functional Assessment</EndpointIndex><EndpointIndex>End stage renal disease - Hematological Assessments - Assessment of hematocrit</EndpointIndex><EndpointIndex>End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels</EndpointIndex><EndpointIndex>End stage renal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>End stage renal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Exercise on Physical Fitness Among Hemodialysis Patients With Chronic Kidney Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body fat percentage </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Chlorides </BiomarkerName><BiomarkerName> Fat mass </BiomarkerName><BiomarkerName> Ferritin </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Iron </BiomarkerName><BiomarkerName> Klotho </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> Parathyroid hormone </BiomarkerName><BiomarkerName> Phosphorus </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Six-minute walk distance </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Total iron binding capacity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-07-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="380601"><Indications><Indication>Streptococcus pneumoniae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Prophylactic vaccine</Action><Action>Subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein conjugated</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2016-04-30T00:00:00Z</DateEnd><DateStart>2007-05-01T00:00:00Z</DateStart><Identifiers><Identifier>HERACLES</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Prevnar 13 alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The aim of the study was to describe the population impact of the 13-valent pneumococcal conjugate vaccine ( PCV-13 ) on invasive pneumococcal disease (IPD) in children &amp;lt; 15 years of age in the Community of &lt;b&gt;Madrid&lt;/b&gt;, Spain [ 2151809 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TitleDisplay>HERACLES: An observational, clinical surveillance study to determine the Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years in Madrid, Spain</TitleDisplay><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>108 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="341503"><Indications><Indication>Cognitive disorder</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-13T00:00:00Z</DateChangeLast><DateEnd>2023-09-30T00:00:00Z</DateEnd><DateStart>2016-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT03541135</Identifier><Identifier>SENIORS-ENRICA II</Identifier><Identifier>Sen-ENRICAII</Identifier></Identifiers><PatientCountEnrollment>2800</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Community-living subjects in the region of &lt;b&gt;Madrid&lt;/b&gt;, Spain, aged &amp;gt;/= 65 years will be included and observed in this study.... Non-institutionalized residents in the region of &lt;b&gt;Madrid&lt;/b&gt;, Spain Age &amp;gt;/= 65 years</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Physical Examination - Muscle strength/activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Neurological Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Physical Performance Battery Score (SPPB)</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function - Assessment of daily activity/Work disability</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Mortality/Death Rates - Assessment of mortality</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function - Assessment of memory and learning</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of motor function</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Sen-ENRICAII: Study on Cardiovascular Health, Nutrition and Physical Functioning in Older Adults in Spain</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Cognitive disorder</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial stiffness </BiomarkerName><BiomarkerName> Augmentation index </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Gait </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> Pulse wave velocity </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>92 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando Rodríguez-Artalejo, MD, PhD</Name><Name>Jose R Banegas, MD, PhD</Name></ContactNames></Trial><Trial Id="313748"><Indications><Indication>Female infertility</Indication></Indications><ActionsPrimaryInterventionsControl><Action>GNRH receptor agonist</Action><Action>GNRH receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>GNRH receptor agonist</Action><Action>GNRH receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Proceptive</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Proceptive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2017-12-01T00:00:00Z</DateStart><Identifiers><Identifier>1702-MAD-014-MC</Identifier><Identifier>NCT03291821</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional ovarian stimulation alone</Intervention><Intervention>embryo freezing alone</Intervention><Intervention>embryo thawing alone</Intervention><Intervention>embryo transfer alone</Intervention><Intervention>intracytoplasmic sperm injection alone</Intervention><Intervention>ovarian puncture alone</Intervention><Intervention>trophectoderm biopsy alone</Intervention><Intervention>Variable regimens including Meriofert , cetrorelix , ganirelix acetate , human menopausal gonadotrophin , triptorelin pamoate</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>double ovarian stimulation (DuoStim) alone</Intervention><Intervention>embryo freezing alone</Intervention><Intervention>embryo thawing alone</Intervention><Intervention>embryo transfer alone</Intervention><Intervention>intracytoplasmic sperm injection alone</Intervention><Intervention>ovarian puncture alone</Intervention><Intervention>trophectoderm biopsy alone</Intervention><Intervention>Variable regimens including Meriofert , cetrorelix , ganirelix acetate , human menopausal gonadotrophin , triptorelin pamoate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>136</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Signed informed consent Age 35 to 42 years Patients from the IVI &lt;b&gt;madrid&lt;/b&gt; undergoing controlled ovarian hyperstimulation cycle including PGT analysis for infertility treatment BMI 18 to 30 kg/m2 Suspicion of suboptimal or poor response: AMH&amp;lt; 1.5 ng/ml AFC&amp;lt; 8 FSH&gt; 10 Poor response in a previous cycle (defined as&amp;lt</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo</EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of embryo implantation rate</EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of number of embryos transferred</EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes - Assessment of number of oocytes fertilised</EndpointIndex><EndpointIndex>Infertility - Assessment of Ovarian Function - Assessment of ovarian stimulation</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy - Assessment of pregnancy loss</EndpointIndex><EndpointIndex>Infertility - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Infertility - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Infertility - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART)</PatientSegment><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando Bronet</Name><Name>Gustavo N Cecchino, M.D.</Name><Name>Javier MS Romero, M.D.</Name><Name>Juan A Garcia Velasco, M.D., Ph.D.</Name><Name>Maria Cerrillo, M.D., Ph.D.</Name><Name>Maria Cruz</Name><Name>Mónica T Paredes</Name></ContactNames></Trial><Trial Id="348161"><Indications><Indication>HIV infection</Indication><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital General Universitario Gregorio Marañon</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-09-05T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>paritaprevir + ritonavir + ombitasvir + dasabuvir (oral, HCV infection) AbbVie alone</Intervention><Intervention>sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead alone</Intervention><Intervention>Variable regimens including Daklinza , ribavirin , simeprevir , sofosbuvir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2369</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser> The aim of this observational study was to evaluate treatment outcomes of interferon-free direct-acting antiviral agent-based therapy in patients with human immunodeficiency virus/hepatitis C virus (HCV)-coinfection enrolled in a prospective &lt;b&gt;Madrid&lt;/b&gt; coinfection registry [ 2058860 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><TitleDisplay>A real-world, Madrid coinfection registry finding study on the effect of all-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in patients with human immunodeficiency virus/HCV-coinfection</TitleDisplay><BiomarkerNames><BiomarkerName>Hepatitis C virus RNA </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial><Trial Id="374084"><Indications><Indication>Myalgia</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-22T00:00:00Z</DateChangeLast><DateEnd>2019-06-20T00:00:00Z</DateEnd><DateStart>2019-03-12T00:00:00Z</DateStart><Identifiers><Identifier>NCT03872063</Identifier><Identifier>RADO</Identifier></Identifiers><InterventionsControlDisplay><Intervention>eccentric exercises alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>eccentric exercises alone</Intervention><Intervention>myofascial induction technique alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Volleyball players Both gender Age range of 18 to 35 years Compete in a federated team in the Community of &lt;b&gt;Madrid&lt;/b&gt;</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment by Global Assessment Scales - Visual analogue scales (VAS) for local and general pain/overall disease activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Myofascial Induction and Eccentric Exercises in Volleyball Players</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Shoulder motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rubén Cuesta-Barriuso, PhD</Name></ContactNames></Trial><Trial Id="204979"><Indications><Indication>Cystic fibrosis</Indication></Indications><CompaniesCollaborator><Company>Hospital Infantil Universitario Nino Jesus</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-15T00:00:00Z</DateChangeLast><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>CFTRAINING</Identifier><Identifier>KID'STRAININGCF</Identifier><Identifier>NCT01706445</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Aerobic training alone</Intervention><Intervention>Inspiratory muscle training alone</Intervention><Intervention>Strength training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Boy/girl aged 6 to 17 years Living in the &lt;b&gt;Madrid&lt;/b&gt; area</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exercise Capacity/Tolerance - Assessment of muscle strength</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Combined Inspiratory Muscle and 'Whole Muscle' Training in Children With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Maximal oxygen uptake</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-07-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial><Trial Id="377117"><Indications><Indication>Factor VIII deficiency</Indication><Indication>Musculoskeletal disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor VIII agonist</Action><Action>Factor VIII modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Blood clotting modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-19T00:00:00Z</DateChangeLast><DateEnd>2020-12-15T00:00:00Z</DateEnd><DateStart>2019-09-02T00:00:00Z</DateStart><Identifiers><Identifier>LONGHEST</Identifier><Identifier>NCT03914209</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>efmoroctocog alfa alone</Intervention><Intervention>factor VIII therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This is a multicenter, observational clinical study. A total of 40 patients with hemophilia A will be included in this study. Patients will be recruited from five centers located in various regions of Spain (Community of &lt;b&gt;Madrid&lt;/b&gt;, Galicia, Community of Valenciana, Málaga and Vizcaya). The dependent variables will be: bleeding frequency (self-report of bleeding), changes in the dosage of factor VIII with EHL products ( rFVIIIFc ), pain (measured with the visual analog scale and a pressure Algometer)</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Clinical Symptoms - Assessment of bleeding episodes</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Co-morbidity - Assessment of hematologic diseases/disorders</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Exercise Capacity/Tolerance - Assessment of muscle strength</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss</EndpointIndex><EndpointIndex>Hemophilia - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Hemophilia - Assessment of pain</EndpointIndex><EndpointIndex>Hemophilia - Clinical Assessments - Assessment of neuropsychiatric function</EndpointIndex><EndpointIndex>Hemophilia - Patient Reported Outcomes/Quality of Life Assessments - Hemophilia Joint Health Score (HJHS)</EndpointIndex><EndpointIndex>Hemophilia - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Others - Healthy Subjects</PatientSegment><PatientSegment>Hemophilia - Subjects with Hemophilia A</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle strength </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-11-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rubén Cuesta-Barriuso, PhD</Name></ContactNames></Trial><Trial Id="204862"><Indications><Indication>Aneuploidy</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>MAD-FB-04-2010-01</Identifier><Identifier>NCT01164943</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>human FSH alone</Intervention><Intervention>recombinant follicle stimulating hormone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The aim of this study was to observe if there was a difference in aneuploidy rate and morphological oocyte parameters between different stimulation protocols.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Aneuploidy Rate and Stimulation Protocol: recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Oocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Agudo</Name><Name>Eva Martinez</Name><Name>Fernando Bronet</Name></ContactNames></Trial><Trial Id="257354"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-03-06T00:00:00Z</DateChangeLast><DateEnd>2018-09-30T00:00:00Z</DateEnd><DateStart>2017-04-01T00:00:00Z</DateStart><Identifiers><Identifier>1512-MAD-064-JGPROTOCOLOF-151</Identifier><Identifier>Mitenergy</Identifier><Identifier>NCT02727400</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>controlled ovarian stimulation alone</Intervention><Intervention>intracytoplasmic sperm injection alone</Intervention><Intervention>invitro fertilization alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The goal of this work is to analyze the mitochondrial function and energy production in oocyte donors compared with a group of women of advanced maternal age subject to a same ovarian stimulation protocol.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Case Control</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Infertility - Protocol Specified Other Endpoints - Other laboratory assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Mitenergy: Mitochondrial Energy Production in ART (Assisted Reproductive Technology)</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Others - Healthy Subjects</PatientSegment><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) - Women with in vitro fertilisation(IVF)</PatientSegment><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adenosine Triphosphate </BiomarkerName><BiomarkerName> Cytochrome c</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Juan A Garcia Velasco, MD</Name><Name>Juan A Garcia-Velasco, MD</Name><Name>Juan A Garcia-Velasco, MD, PhD</Name><Name>Juan Antonio A Garcia-Velasco, MD, PhD</Name><Name>Juan Antonio Garcia-Velasco, MD, PhD</Name></ContactNames></Trial><Trial Id="207556"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-04-10T00:00:00Z</DateChangeLast><DateEnd>2018-03-31T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>1405-MAD-020-JG</Identifier><Identifier>NCT02209168</Identifier></Identifiers><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to confirm the difference in ovarian reserve markers and serum vitamine D levels between infertile Indian, Arabian and Caucasian population.</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Infertility - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Infertility - Assessment of Ovarian Function - Assessment of ovarian follicle size/number</EndpointIndex><EndpointIndex>Infertility - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Differences in Ovarian Reserve Markers and Vitamin D Between Infertile Indian, Arabian and Caucasian Population</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) - Women with in vitro fertilisation(IVF)</PatientSegment><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) Failure</PatientSegment><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antral follicles </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Muellerian-inhibiting factor </BiomarkerName><BiomarkerName> Vitamin D</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>CARLOS IGLESIAS, MD</Name><Name>Carlos Iglesias, MD</Name></ContactNames></Trial><Trial Id="235377"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-22T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2015-10-31T00:00:00Z</DateStart><Identifiers><Identifier>1504-MAD-024-AR</Identifier><Identifier>BEMDON</Identifier><Identifier>NCT02503605</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Biosimilar recombinant FSH alone</Intervention><Intervention>Urinary FSH alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>130</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this study is to determine equivalence in terms of biological effectiveness of an ovarian stimulation protocol with biosimilar recombinant FSH stimulation protocol versus urinary FSH in oocyte donation program. The investigator's main objective is to perform a non-inferiority trial of biosimilar recombinant FSH product compared to a conventional ovarian stimulation protocol with urinary FSH in relation to the number of oocytes retrieved and the number of metaphase II oocytes.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>BEMDON: Biosimilar Versus Urinary Gonadotropins</TitleDisplay><BiomarkerNames><BiomarkerName>Estradiol </BiomarkerName><BiomarkerName> Granulosa cells </BiomarkerName><BiomarkerName> Oocytes </BiomarkerName><BiomarkerName> Progesterone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2016-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antonio Requena, MD, PhD</Name><Name>Antonio Requena, Md, PhD</Name><Name>María Cruz, PhD</Name></ContactNames></Trial><Trial Id="208033"><Indications><Indication>Female infertility</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Follicle stimulating hormone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Proceptive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Clinical IVI Alicante</Company><Company>Fundacion Instituto Valenciano de Infertilidad</Company></CompaniesCollaborator><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-10-13T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2014-10-31T00:00:00Z</DateStart><Identifiers><Identifier>1403-MAD-013-AR</Identifier><Identifier>NCT02213627</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>corifollitropin alfa alone</Intervention><Intervention>follitropin beta, Merck &amp; Co alone</Intervention><Intervention>human menopausal gonadotrophin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to determine if corifollitropin alfa (long-term gonadotropin administration) is effective in a controlled ovarian stimulation protocol in oocyte donors compared to daily gonadotropin administration ( recombinant FSH or HP-hMG [ Menopur ]).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Cycle Cancellation Rate</EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of embryo implantation rate</EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Infertility - Health Economic Assessments - Assessment of cost effectiveness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Use of Corifolitropin Alfa in Oocyte Donors</TitleDisplay><BiomarkerNames><BiomarkerName>Oocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antonio Requena, MD, PhD</Name><Name>Manuel Muñoz, MD, PhD</Name><Name>María Cruz, PhD</Name><Name>Pilar Alamá, MD, PhD</Name></ContactNames></Trial><Trial Id="282949"><Indications><Indication>Diabetic foot ulcer</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-05-10T00:00:00Z</DateEnd><DateStart>2016-12-10T00:00:00Z</DateStart><Identifiers><Identifier>NCT02995863</Identifier><Identifier>UCOMPLUTENSEMADRID</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Therapeutic Footwear alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Rigid Rocker Sole Footwear alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>73</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This research presented a randomized clinical trial which analyzes the efficacy of a rigid rocker sole in the reduction of the recurrence rate of plantar ulcers in diabetic foot patients. Investigators hypothesis was the use of a rigid rocker sole reduces the recurrence rate of diabetic foot ulcers in patients with peripheral neuropathy.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Arterial Stiffness &amp; Antiatherogenic Markers - Ankle-brachial index (ABI) [Ankle-Arm Blood Pressure Test]</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>This Research Hypothesizes That the Use of a Rigid Rocker Sole Reduces the Recurrence Rate of Diabetic Foot Ulcers in Patients With Peripheral Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Others - Healthy Subjects</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Foot Diseases - Subjects with diabetic foot ulcers</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Insulin dependent diabetes - Others - Healthy Subjects</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Diabetic Complications - Subjects with diabetic foot</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Others - Healthy Subjects</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Diabetic Complications - Subjects with diabetic foot</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ankle-brachial index</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mateo López Moral</Name></ContactNames></Trial><Trial Id="188956"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-04-23T00:00:00Z</DateChangeLast><DateEnd>2010-09-30T00:00:00Z</DateEnd><DateStart>2008-10-31T00:00:00Z</DateStart><Identifiers><Identifier>APPE</Identifier><Identifier>IVIMAD-LO-09-2008-01</Identifier><Identifier>NCT00870025</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>human chorionic gonadotropin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to evaluate the efficacy of human chorionic gonadotropin priming prior to controlled ovarian hyperstimulation in poor responder in vitro fertilization patients.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>APPE: Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) - Women with in vitro fertilisation(IVF)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Oocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Juan A Garcia-Velasco, MD, PhD</Name></ContactNames></Trial><Trial Id="198309"><Indications><Indication>Ovarian hyperstimulation syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GNRH receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-14T00:00:00Z</DateChangeLast><DateStart>2011-11-30T00:00:00Z</DateStart><Identifiers><Identifier>ERAMAD</Identifier><Identifier>MAD-AB-ERA-2011</Identifier><Identifier>NCT01500863</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>triptorelin alone</Intervention><Intervention>Variable regimens including estradiol valerate , hCG , progesterone , recombinant LH , triptorelin acetate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>35</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The investigators aimed to find out which protocol resembles the most the gene expression profile observed after hCG triggering and conventional luteal phase support, in order to choose it as the most adequate in terms of endometrium receptivity and safety (OHSS incidence).</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Endometriosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Endometriosis - Assessment of adverse events</EndpointIndex><EndpointIndex>Infertility - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Infertility - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>ERAMAD: Endometrial Receptivity After GnRH Agonist Triggering</TitleDisplay><PatientSegmentTerms><PatientSegment>Endometriosis - Subjects with History of/Scheduled for Disease Specific Therapy - Women with history of/scheduled for medical therapy</PatientSegment><PatientSegment>Endometriosis - Women with Protocol Specified Menstrual Status - Pre-menopausal subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alfonso Bermejo, MD</Name></ContactNames></Trial><Trial Id="330520"><Indications><Indication>Ovarian hyperstimulation syndrome</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antioxidant agent</Action><Action>Antiviral</Action><Action>Cardioprotectant</Action><Action>DNA modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-21T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2018-03-13T00:00:00Z</DateStart><Identifiers><Identifier>1401-MAD-004-IO</Identifier><Identifier>2014-003986-11</Identifier><Identifier>NCT03446625</Identifier><Identifier>RES-OHSS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>resveratrol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of the study is to evaluate the resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors. Randomized, clinical trial is to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition. Secondary objectives of the trial is to evaluate the effect of resveratrol on hemoconcentration, estradiol levels and ascitis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other gynecological disorder - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>RES-OHSS: Resveratrol as a Preventive Treatment of OHSS</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gynecological disorder - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Erythrocytes </BiomarkerName><BiomarkerName> Estradiol </BiomarkerName><BiomarkerName> Vascular endothelial growth factors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>IVI MADRID</Name><Name>Israel Ortega</Name><Name>Israel Ortega, MD</Name><Name>Juan A García-Velasco, MD</Name></ContactNames></Trial><Trial Id="196483"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Thymidylate synthase inhibitor</Action><Action>Topoisomerase I inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Monoclonal antibody murine</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-29T00:00:00Z</DateChangeLast><DateEnd>2011-10-31T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>C62 202-878</Identifier><Identifier>NCT01453257</Identifier><Identifier>TT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including bevacizumab , capecitabine , cetuximab , florouracil , irinotecan , leucovorin , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to demonstrate that the identification of therapeutic targets in real time and their prospectively use to customize the treatment to get a proportion of colorectal metastatic patients free of progression disease at 12 months of 50%.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TT: Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-Raf proto-oncogene serine/threonine-protein kinase </BiomarkerName><BiomarkerName> DNA excision repair protein ERCC-1 </BiomarkerName><BiomarkerName> DNA topoisomerase 1 </BiomarkerName><BiomarkerName> GTPase KRas </BiomarkerName><BiomarkerName> Phosphatidylinositol 3-Kinase </BiomarkerName><BiomarkerName> Thymidine phosphorylase </BiomarkerName><BiomarkerName> Thymidylate synthase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antonio Cubillo, Md PhD</Name></ContactNames></Trial><Trial Id="141661"><Indications><Indication>Bleeding</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-10-23T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-003218-17</Identifier><Identifier>NCT01881568</Identifier><Identifier>TRANEX1</Identifier><Identifier>TRANEX1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tranexamic acid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>79</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Adult patients (&gt; 18 years old) Patients scheduled for primary unilateral knee arthroplasty Patients for La Paz- Cantoblanco Hospital, &lt;b&gt;Madrid&lt;/b&gt;, Spain</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TRANEX1: Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA</TitleDisplay><BiomarkerNames><BiomarkerName>Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Enrique Gomez Barrena, PI</Name><Name>Norma Padilla</Name></ContactNames></Trial><Trial Id="373256"><Indications><Indication>Periodontitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Macrolide antibiotic</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-15T00:00:00Z</DateChangeLast><DateEnd>2019-07-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>ATB1</Identifier><Identifier>NCT03862456</Identifier></Identifiers><InterventionsControlDisplay><Intervention>metronidazole alone</Intervention><Intervention>periodontal surgery alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>azithromycin alone</Intervention><Intervention>periodontal surgery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The objective of this study is to determine whether, in subjects with non treated periodontitis (stage III and IV) positive to Porphyromonas gingivalis, the use of systemic antimicrobials (metronidazole versus azithromycin ) as an adjunctive treatment to periodontal surgery provides clinical and microbiological benefits.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Laboratory/Diagnostic Measures - Assessment of microbiological/serological parameters</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments - Assessment of probing pocket depth</EndpointIndex><EndpointIndex>Other mouth disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TitleDisplay>Metronidazole versus Azithromycin in Periodontal Surgery for Patients Positive to Porphyromonas Gingivalis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Periodontitis</PatientSegment><PatientSegment>Other mouth disease - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>78 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mariano Sanz</Name></ContactNames></Trial><Trial Id="374109"><Indications><Indication>Muscle disease</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-23T00:00:00Z</DateChangeLast><DateEnd>2019-06-20T00:00:00Z</DateEnd><DateStart>2019-03-12T00:00:00Z</DateStart><Identifiers><Identifier>NCT03872076</Identifier><Identifier>WATPLIO</Identifier></Identifiers><InterventionsControlDisplay><Intervention>isometric exercises with elastic band alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>isometric exercises with elastic band alone</Intervention><Intervention>plyometric exercise alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The objective of the study is to evaluate the effectiveness of plyometric exercises in the increase of quadriceps muscle strength, volume and stability dynamic in female athletic of water polo players from 18 to 25 years old.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Physical Examination - Muscle strength/activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Plyometric Exercises Versus Isometric Exercises With Theraband Elastic Band in Water Polo Players</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle </BiomarkerName><BiomarkerName> Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-05-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rubén Cuesta-Barriuso, PhD</Name></ContactNames></Trial><Trial Id="176203"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Thymidylate synthase inhibitor</Action><Action>Topoisomerase I inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-08T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2011-07-31T00:00:00Z</DateStart><Identifiers><Identifier>ANGIOSWITCH</Identifier><Identifier>ANGIOSWITCH2011</Identifier><Identifier>NCT02075086</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including bevacizumab , capecitabine , irinotecan , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this trial was to study angiogenic switch as predictor of response to chemotherapy in patients with metastatic colorectal cancer.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ANGIOSWITCH: Angiogenic Switch in Patients With Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer - Subjects with rectal adenocarcinoma</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with specific disease - Subjects with colon adenocarcinoma</PatientSegment><PatientSegment>Colorectal tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 7 </BiomarkerName><BiomarkerName> Eotaxin </BiomarkerName><BiomarkerName> Heparin-binding growth factor 2 </BiomarkerName><BiomarkerName> Hepatocyte growth factor </BiomarkerName><BiomarkerName> Interleukin-18 </BiomarkerName><BiomarkerName> Placenta growth factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antonio Cubillo, MD PhaD</Name><Name>Sofia Perea</Name></ContactNames></Trial><Trial Id="382645"><Indications><Indication>Metabolic syndrome X</Indication><Indication>Periodontitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Macrolide antibiotic</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Colgate-Palmolive Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-31T00:00:00Z</DateChangeLast><DateEnd>2018-07-31T00:00:00Z</DateEnd><DateStart>2012-11-28T00:00:00Z</DateStart><Identifiers><Identifier>12/206 CEIC HOSPITAL CLÍNICO</Identifier><Identifier>NCT03960216</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Supragingival Prophylaxis alone</Intervention><Intervention>chlorhexidine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Scaling and root planning alone</Intervention><Intervention>ultrasonic scaler, Minipiezon Electromedical Systems EMS, Nyon, Switzerland alone</Intervention><Intervention>azithromycin plus chlorhexidine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this trial was to evaluate the effect of intensive periodontal therapy (IPT) in patients with MetS and severe periodontitis.</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of HbA1c levels</EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of TNF</EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of interleukins</EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of Laboratory/Diagnostic Measures - Assessment of fibrinogen levels</EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Metabolic syndrome X - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Metabolic syndrome X - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Metabolic syndrome X - Protocol Specified Other Endpoints - Changes in microbiota</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Plasma fibrinogen</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Laboratory/Diagnostic Measures - Assessment of microbiological/serological parameters</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Safety and Tolerability - Assessment of bleeding</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments - Assessment of probing pocket depth</EndpointIndex><EndpointIndex>Other mouth disease - Glycemic Control Analysis</EndpointIndex><EndpointIndex>Other mouth disease - Intravascular Ultrasound (IVUS)/Intracoronary Ultrasound (ICUS) Parameters - Plaque index (PI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Periodontal Therapy in Patients with Metabolic Syndrome (MetS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Periodontitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alpha-1-antitrypsin </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Fibrinogen </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>68 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mariano Sanz</Name></ContactNames></Trial><Trial Id="373892"><Indications><Indication>Hernia</Indication><Indication>Lower back pain</Indication><Indication>Sciatica</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-25T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2019-04-01T00:00:00Z</DateStart><Identifiers><Identifier>19/044-E_TESIS</Identifier><Identifier>NCT03880370</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>flexibility test alone</Intervention><Intervention>functional tests alone</Intervention><Intervention>questionnaires alone</Intervention><Intervention>ultrasound imaging alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This is a control-case study. It has been designed to determine if there is a relationship between the cross sectional (thickness), through RUSI ultrasound, of the abdominal muscles, lumbar and hip muscles with the results of the functional tests, to determine its relevance in patients with low back pain and/or ciatalgia and lumbar disc herniation in non-professional athletes. The secondary objectives of the study will be to know if there is a relationship between the results of ultrasound</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Case Control</Term></TermsDesign><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment by Global Assessment Scales - Visual analogue scales (VAS) for local and general pain/overall disease activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Other Measures of Pain Quality</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Physical Examination - Physical activity assessment</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Oswestry Disability Index (ODI)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Roland–Morris Disability Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Relationship Of Lumbopelvic Musculature With Functional Tests In Non-Professional Athletes With Lumbar Disc Herniation</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain - Subjects with low back pain</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain - Subjects with lumbar disc herniation</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with sciatic pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with back pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle </BiomarkerName><BiomarkerName> Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Diego Miñambres Martin, Pt</Name><Name>Gustavo Plaza Manzano, Pt PhD</Name></ContactNames></Trial><Trial Id="192526"><Indications><Indication>Pancreas tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action><Action>Thymidylate synthase inhibitor</Action><Action>Topoisomerase I inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-06-02T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2011-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-001017-13</Identifier><Identifier>CNIO-GI-01-2011</Identifier><Identifier>NCT01394120</Identifier><Identifier>TARGTHPANC 001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including capecitabine , erlotinib , fluorouracil , gemcitabine , irinotecan , leucovorin calcium , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this trial is to evaluate the efficacy of selected treatment for pancreatic cancer patients based on the determination of therapeutic targets. The therapeutic target-driven treatment efficacy will be compared to the prospective treatment of a control group of patients treated at the discretion of the physician-researcher</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Adenocarcinoma of Pancreas</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ana Ruiz</Name><Name>Antonio Cubillo</Name><Name>Barbara Angulo</Name><Name>Eduardo Garcia-Rico</Name><Name>Eduardo Garcia-rico</Name><Name>Elena Garcia</Name><Name>Emilio Vicente</Name><Name>Emilio de Vicente</Name><Name>Ignacio Juez</Name><Name>Jesus Rodriguez-Pascual</Name><Name>Jesus Rodriguez-pascual</Name><Name>Manuel Hidalgo, MD</Name><Name>Manuel Hidalgo, MD, PhD</Name><Name>Pia Morelli</Name><Name>Ulpiano Guardia</Name><Name>Ulpiano Lopez de la Guardia</Name></ContactNames></Trial><Trial Id="198405"><Indications><Indication>Bacterial infection</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-23T00:00:00Z</DateChangeLast><DateEnd>2011-03-31T00:00:00Z</DateEnd><DateStart>2010-02-28T00:00:00Z</DateStart><Identifiers><Identifier>NCT01330706</Identifier><Identifier>UCM 2011</Identifier><Identifier>ribebeva</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>polihexanide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to examine the antiseptic efficacy of intraoperative irrigation methods during nail avulsion surgery.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response - Change in bacterial count</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ribebeva: Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery</TitleDisplay><PrimaryCompletionDate type="Actual">2011-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ricado Becerro de Bengoa Vallejo, PhD</Name></ContactNames></Trial><Trial Id="359670"><Indications><Indication>Diabetic foot ulcer</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-25T00:00:00Z</DateChangeLast><DateEnd>2019-12-01T00:00:00Z</DateEnd><DateStart>2019-03-25T00:00:00Z</DateStart><Identifiers><Identifier>NCT03725917</Identifier><Identifier>V2.0_16.07.18</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Physiotherapy protocol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>143</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the effects of a physiotherapy protocol (manual therapy and exercise) in the prevention of diabetic foot ulcers in patients with diabetic neuropathy. A group of participants will receive a physiotherapy protocol added to their usual medical treatment and the other group will not receive physiotherapy treatment.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain</EndpointIndex><EndpointIndex>Diabetic complication - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Patients With Diabetic Neuropathy Who Receive Physiotherapy Treatment Will Have a Decrease in Diabetic Foot Ulcers</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Diabetic Complications</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Foot pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Guido F Gómez Chiguano</Name><Name>Guido F Gómez Chiguano, Physiotherapist</Name><Name>Guido Gomez Chiguano</Name><Name>José L Lázaro Martínez</Name><Name>Mateo López Moral</Name></ContactNames></Trial><Trial Id="332498"><Indications><Indication>Obesity</Indication><Indication>Weight gain</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-03-20T00:00:00Z</DateChangeLast><DateEnd>2050-12-31T00:00:00Z</DateEnd><DateStart>2013-10-10T00:00:00Z</DateStart><Identifiers><Identifier>NCT03465657</Identifier><Identifier>PR6/13-18866</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to stablish a direct relationship between salt intake and the health parameters previously mentioned in a representative sample of Spanish schoolchildren between 7 to 11 years old. The investigators are applying a 3-day dietary records to collect dietary data, and collecting 24-h urine samples in order to analyze biochemical indicators of sodium intake and other nutrients. Anthropometric data are also being recorded and body composition is also analyzed using bioimpedance</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term></TermsDesign><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of Body Weight</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of body composition</EndpointIndex><EndpointIndex>Obesity - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>Obesity - Assessment of Dietary Intake - Assessment of salt intake</EndpointIndex><EndpointIndex>Obesity - Assessment of Urinary Metabolomic Profile - Urinary calcium and sodium excretion</EndpointIndex><EndpointIndex>Obesity - Assessment of fat - Assessment of abdominal fat/obesity</EndpointIndex><EndpointIndex>Obesity - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Obesity - Protocol Specified Other Endpoints - Bio-Body impedance methods</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Sodium Sources and Sodium Intake in a Representative Sample of Spanish Children</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Fractional excretion of sodium </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>446 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rosa M Ortega Anta, Full Prof.</Name></ContactNames></Trial><Trial Id="154894"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Topoisomerase I inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody murine</Technology><Technology>Natural product</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-29T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2013-04-30T00:00:00Z</DateStart><Identifiers><Identifier>BEAMING</Identifier><Identifier>BEAMING</Identifier><Identifier>NCT01943786</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-flurouracil , cetuximab , folinic acid , irinotecan</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this prospective, non-interventional study is to investigate the K-RAS status switch in K-RAS native patients with metastatic colorectal tumors treated with FOLFIRI (folinic acid, 5-flurouracil and irinotecan ) + cetuximab as first-line treatment.</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Tumor Related Parameters - Assessment of shrinkage of tumor</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Pharmacogenomic Evaluation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BEAMING: RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With First Line FOLFIRI-Cetuximab</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with KRAS Wild-type Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer - Subjects with rectal adenocarcinoma</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with specific disease - Subjects with colon adenocarcinoma</PatientSegment><PatientSegment>Colorectal tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>GTPase KRas</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antonio Cubillo, Doctor</Name></ContactNames></Trial><Trial Id="128937"><Indications><Indication>Female infertility</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Estradiol agonist</Action><Action>Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Female contraceptive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drug combination</Technology><Technology>Intramuscular formulation</Technology><Technology>Oral formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-03T00:00:00Z</DateChangeLast><DateEnd>2013-02-28T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>IVIMAD-GV-OCPE-2011</Identifier><Identifier>NCT01501448</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>estradiol valerate alone</Intervention><Intervention>levonorgestrel + estrogen, Bayer Schering alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>118</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was to compare oral contraceptive pill (OCP) versus oral estrogens to plan the initiation of invitro fertilization (IVF) cycles.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of embryo implantation rate</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) - Women with in vitro fertilisation(IVF)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="247023"><Indications><Indication>Pregnancy disorder</Indication></Indications><CompaniesSponsor><Company>Universidad Politecnica de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-12-13T00:00:00Z</DateChangeLast><DateEnd>2017-06-30T00:00:00Z</DateEnd><DateStart>2011-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02602106</Identifier><Identifier>UFLO_UPM_12</Identifier><Identifier>aquapreg</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Aquatic activities exercise alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the effect of moderate regular aquatic exercise during pregnancy on maternal and fetus outcomes.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>aquapreg: Regular Aquatic Activities and Pregnancy Outcomes</TitleDisplay><BiomarkerNames><BiomarkerName>Birth weight </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>72 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mariano Bacchi</Name><Name>Ruben Barakat Carballo, PhD</Name><Name>Rubén Barakat, PhD</Name><Name>Rubén O Barakat Carballo, PhD</Name></ContactNames></Trial><Trial Id="104147"><CompaniesSponsor><Company>Universidad Politecnica de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2015-11-30T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01753622</Identifier><Identifier>Overweight-obese pregnant</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Exercise therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to assess whether a specific exercise program during pregnancy has a positive effect on maternal mood and other pregnancy outcomes.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Depression - Anthropometric Assessments</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Center For Epidemiologic Studies-Depression Scale (CES-D)</EndpointIndex><EndpointIndex>Depression - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Physical Exercise Program in Obese and Overweight Pregnant Women</TitleDisplay><BiomarkerNames><BiomarkerName>Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Maria Perales, PhD student</Name><Name>María Perales, PhD student</Name><Name>Ruben Barakat, PhD</Name><Name>Rubén Barakat, PhD</Name></ContactNames></Trial><Trial Id="342671"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-04-30T00:00:00Z</DateEnd><DateStart>2017-03-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03547752</Identifier><Identifier>OA PLUS MI IN NECK PAIN</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>observed action and motor imaginery therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This randomized, double-blind. clinical trial in patients with DCCI would be conducted at a primary health care center in the Community of &lt;b&gt;Madrid&lt;/b&gt;. A random distribution of study subjects would be made into two groups: Group 1 (experimental: ineffective movement group): observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it. Group 2 (active-comparator: effective movement group): </Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Neck Disability Index</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Inmediate Effect of the Visualization of Action</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cervical motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Raúl Ferrer-Peña</Name></ContactNames></Trial><Trial Id="266924"><Indications><Indication>Injury</Indication></Indications><CompaniesSponsor><Company>Universidad Politecnica de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-08-31T00:00:00Z</DateEnd><DateStart>2016-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02842008</Identifier><Identifier>UPMADRID</Identifier></Identifiers><InterventionsControlDisplay><Intervention>postural hygiene protocol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>home exercise program alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the effects of therapeutic exercise program in wheelchair basketball players, in order to prevent shoulder injuries. The hypothesis of the study was that the exercise program would be effective to prevent shoulder injuries in this population.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects Of A Therapeutic Exercise Program For Injuries Prevention In Wheelchair Basketball (WB) Players</TitleDisplay><BiomarkerNames><BiomarkerName>Shoulder motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Javier Pérez Tejero, PhD</Name></ContactNames></Trial><Trial Id="374119"><Indications><Indication>Breast tumor</Indication><Indication>Pain</Indication></Indications><CompaniesCollaborator><Company>Instituto Oncológico Balselga</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-23T00:00:00Z</DateChangeLast><DateEnd>2019-12-15T00:00:00Z</DateEnd><DateStart>2018-04-15T00:00:00Z</DateStart><Identifiers><Identifier>NCT03873519</Identifier><Identifier>R-2017/UEM11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>chemotherapy alone</Intervention><Intervention>chromatic environment (cold color scheme) alone</Intervention><Intervention>chromatic environment (warm color scheme) alone</Intervention><Intervention>room orientation (North) alone</Intervention><Intervention>room orientation (South) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The primary objective is to examine the acute effect of color, room orientation (affecting amount of luminosity) on perceived health status and stress levels in oncologic patients during chemotherapy sessions at outpatient clinic. The secondary objectives will be to study the effect on vital signs (body temperature, heart rate, systolic blood pressure).</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Anxiety by Protocol Specified Scales</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Cardio-Pulmonary System</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Depression Severity by Specific Criteria</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Pain</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Breast tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Acute Effect of Chromatic Environment During Chemotherapy</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Almudena Corredera, RN</Name><Name>Margarita Perez</Name><Name>Margarita Pérez Ruiz, MD, PhD</Name><Name>Margarita Pérez Ruiz, MD,PhD</Name><Name>Paula Gomez Vela, BS</Name></ContactNames></Trial><Trial Id="373976"><Indications><Indication>Gingiva disease</Indication><Indication>Periodontitis</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-25T00:00:00Z</DateChangeLast><DateEnd>2018-01-15T00:00:00Z</DateEnd><DateStart>2012-09-19T00:00:00Z</DateStart><Identifiers><Identifier>12/207</Identifier><Identifier>NCT03880448</Identifier></Identifiers><InterventionsControlDisplay><Intervention>periodontal surgery alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>metronidazole alone</Intervention><Intervention>periodontal surgery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>severe chronic periodontitis (stages III and IV) and positive to Porphyromonas gingivalis who potentially need periodontal surgery would be recruited from those who attended the postgraduate program in periodontics at the Complutense University in &lt;b&gt;Madrid&lt;/b&gt; . Patients would be randomly assigned to the test group (periodontal surgery + metronidazole) or control group (periodontal surgery + placebo). Metronidazole or placebo (cornstarch) would be given at the rate of 500 mg/8 h/7 days. Study visits would</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other infectious disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other infectious disease - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Other infectious disease - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Other infectious disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Laboratory/Diagnostic Measures - Assessment of microbiological/serological parameters</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Safety and Tolerability - Assessment of bleeding</EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments - Assessment of probing pocket depth</EndpointIndex><EndpointIndex>Other mouth disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TitleDisplay>Metronidazole versus Placebo as Adjuncts to Periodontal Surgery for Patients Positive to Porphyromonas Gingivalis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other infectious disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other infectious disease - Subjects with specific disease - Subjects with bacterial infection</PatientSegment><PatientSegment>Other mouth disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Periodontitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-01-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>63 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mariano Sanz Alonso</Name><Name>Prof. Elena Figuero</Name></ContactNames></Trial><Trial Id="138947"><Indications><Indication>Renal failure</Indication></Indications><CompaniesCollaborator><Company>Instituto de Salud Carlos III</Company></CompaniesCollaborator><CompaniesSponsor><Company>Gerencia de Atención Primaria, Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-04-17T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>09/90845</Identifier><Identifier>NCT01872468</Identifier><Identifier>RENAP</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Structured intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>269</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>control of the glucose levels and glycosylated hemoglobin of the diabetic patients with chronic kidney failure. Design: This was a multicenter, randomized, controlled clinical trial by conglomerates with parallel groups in primary care health centres (&lt;b&gt;Madrid&lt;/b&gt; health service). Data collection: The variable of the main answer would be the creatinine clearance measured in ml/min. Demographic variables of morbidity and prognosis: clinical, analytical, anthropometrical, adherence to processing and consumption</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RENAP: Effectiveness of a Structured Intervention to Reduce the Progression of Chronic Kidney</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marta Sánchez-Celaya, Doctor</Name></ContactNames></Trial><Trial Id="214891"><Indications><Indication>Female infertility</Indication></Indications><CompaniesCollaborator><Company>Igenomix Spain</Company></CompaniesCollaborator><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-10-16T00:00:00Z</DateChangeLast><DateEnd>2015-04-30T00:00:00Z</DateEnd><DateStart>2014-12-31T00:00:00Z</DateStart><Identifiers><Identifier>1407-MAD-056-MC</Identifier><Identifier>ERA</Identifier><Identifier>NCT02280798</Identifier></Identifiers><PatientCountEnrollment>5</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the trial was to assess whether differences in endometrial gene expression exist after different protocols of endometrial preparation for embryo transfer.</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>ERA: Endometrial Gene Expression in Different Protocols of Endometrial Preparation for Embryo Transfer</TitleDisplay><BiomarkerNames><BiomarkerName>Estradiol </BiomarkerName><BiomarkerName> Glutathione peroxidase 3 </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Metallothionein-1G </BiomarkerName><BiomarkerName> Osteopontin </BiomarkerName><BiomarkerName> Progesterone </BiomarkerName><BiomarkerName> Sodium/potassium-transporting ATPase subunit gamma</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cerrillo M Maria, doctor</Name></ContactNames></Trial><Trial Id="200146"><Indications><Indication>Vitamin B12 deficiency</Indication></Indications><CompaniesCollaborator><Company>Instituto de Salud Carlos III</Company><Company>Ministry of Health, Spain</Company></CompaniesCollaborator><CompaniesSponsor><Company>Gerencia de Atención Primaria, Madrid</Company><Company>Spanish Clinical Research Network</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-11-28T00:00:00Z</DateEnd><DateStart>2014-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-024129-20</Identifier><Identifier>EC10-(115, 116, 117,119, 122)</Identifier><Identifier>EC10-122</Identifier><Identifier>NCT01476007</Identifier><Identifier>OB12</Identifier><Identifier>ProyectoOB12</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Optovite alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>284</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>effectiveness of orally administered vitamin B12 compared with intramuscular to reestablish the seric level of vitamin B12 at 8, 26 and 52 weeks in patients &gt;/= 65 years with B12 deficiency, attended in the primary care centers in the community of &lt;b&gt;Madrid&lt;/b&gt;. Secondary objectives of the trial were: To evaluate the safety of both treatment groups. To analyze the quality of life measured by Euroqol-5D. To describe the satisfaction and preferences with specific questions designed for this project, in both</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OB12: Oral/Intramuscular B12 to Treat Cobalamin Deficiency</TitleDisplay><PrimaryCompletionDate type="Actual">2017-11-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Esperanza Escortell-Mayor, MD Phd</Name><Name>Isabel DelCura-González, MD Phd</Name><Name>Jesús Martín-Fernández, MD Phd</Name><Name>Rosario Riesgo, MD</Name><Name>Sofía Garrido-Elustondo, MD</Name><Name>Teresa Sanz-Cuesta, MD</Name></ContactNames></Trial><Trial Id="377868"><Indications><Indication>Joint disease</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-27T00:00:00Z</DateChangeLast><DateEnd>2020-12-15T00:00:00Z</DateEnd><DateStart>2019-09-02T00:00:00Z</DateStart><Identifiers><Identifier>HE-FOAM</Identifier><Identifier>NCT03914287</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Foam Roller alone</Intervention><Intervention>self-myofascial release alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Aim of this randomized clinical trial is to evaluate the safety and effectiveness of a protocol by self-myofascial release with Foam Roller applied in patients with hemophilic ankle arthropathy.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Exercise Capacity/Tolerance - Assessment of muscle strength</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Hemophilia - Assessment of pain</EndpointIndex><EndpointIndex>Hemophilia - Clinical Assessments - Assessment of joints</EndpointIndex><EndpointIndex>Hemophilia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Hemophilia - Patient Reported Outcomes/Quality of Life Assessments - Hemophilia Joint Health Score (HJHS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Self-myofascial Release With Foam Roller in Patients With Hemophilic Ankle Arthropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Others - Healthy Subjects</PatientSegment><PatientSegment>Hemophilia - Subjects with Hemophilia A</PatientSegment><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Elbow motion </BiomarkerName><BiomarkerName> Knee motion </BiomarkerName><BiomarkerName> Lumbar spine motion </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> Painful joint count </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-06-26T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rubén Cuesta-Barriuso, PhD</Name></ContactNames></Trial><Trial Id="339015"><Indications><Indication>Tendon disease</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-01-15T00:00:00Z</DateEnd><DateStart>2017-01-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT03515148</Identifier><Identifier>Tendon02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>Eccentric exercise alone</Intervention><Intervention>Vibration program alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>61</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determinate de efectiveness of eccentric exercise combined with vibration or cryotherapy in achilles tendinopathy and its effects on the anterior rectus abdominis muscle. The investigators hypothesis was the combined eccentric exercise with vibration get better results than cryotherapy with eccentric exercise in rectus abdominis muscle parameters.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effectiveness of EE With Vibration Versus Cryotherapy in Rectus Abdomini Muscle Thickness and Inter-recti Distance</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease - Subjects with Achilles Tendinopathy</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle </BiomarkerName><BiomarkerName> Rectus abdominis muscle</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pedro J Martin</Name></ContactNames></Trial><Trial Id="287160"><Indications><Indication>Tendon disease</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2018-01-15T00:00:00Z</DateEnd><DateStart>2017-01-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT03029910</Identifier><Identifier>UEMADRID-TENDON01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cryotherapy alone</Intervention><Intervention>eccentric exercise alone</Intervention><Intervention>vibration therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>132</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the effectiveness of eccentric exercise combined with vibration or cryotherapy in Achilles tendon pathology. The investigators hypothesis was that the combined eccentric exercise was better than the results presented by the exclusive eccentric exercise. This intervention differs from the classic studies in that the investigators maintain the intensity throughout the treatment.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Eccentric Training and Cryotherapy Versus Eccentric Training and Whole Body Vibration in Achilles Tendinopathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease - Subjects with Achilles Tendinopathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Calcaneal tendon</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="84176"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Phosphoinositide 3-kinase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR complex 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Metastasis inhibitor</Action><Action>Neuroprotectant</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-04-10T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>CBKM120XES01T</Identifier><Identifier>NCT01513356</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>buparlisib alone</Intervention><Intervention>dactolisib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 0 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was the evaluation of PI3K/AKT/mTOR signaling pathway using BKM-120 or BEZ-235 in early breast cancer patients.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pharmacodynamic Study of BKM-120 and BEZ-235 in Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eukaryotic translation initiation factor 4E binding protein 1 </BiomarkerName><BiomarkerName> FKBP12-rapamycin complex-associated protein </BiomarkerName><BiomarkerName> Homeobox protein cut-like 1 </BiomarkerName><BiomarkerName> Insulin-like growth factor 1 receptor </BiomarkerName><BiomarkerName> P protein </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> RAC-alpha serine/threonine-protein kinase </BiomarkerName><BiomarkerName> Ribosomal protein S6 kinases</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="171086"><Indications><Indication>Rectal tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Thymidylate synthase inhibitor</Action><Action>Topoisomerase I inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Monoclonal antibody murine</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-05-23T00:00:00Z</DateChangeLast><DateEnd>2011-04-30T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>62 202-878</Identifier><Identifier>NCT01366118</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Proctitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Intensity modulated radiotherapy alone</Intervention><Intervention>Variable regimens including bevacizumab , capecitabine , capecitabine + oxaliplatin + bevacizumab + cetuximab + irinotecan + Intensity modulated radiotherapy , cetuximab , irinotecan , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study aimed to demonstrate in a prospective manner the feasibility of personalizing chemotherapy regimen base in therapeutic targets (TT) in combination with intensity modulated radiotherapy (IMRT) in patients with rectal cancer (RC). Secondary objectives included the number of complete pathologic response (ypCR) and safety. The hypothesis was that with the actual knowledge and technology, a prospective tailored chemotherapy selection in combination with intensity modulated radiotherapy was feasible</Teaser><TrialCategories><Category>Biological</Category><Category>Radiation therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Laboratory Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study of Therapeutic Targets Tailored Chemotherapy and Intensity Modulated Radiotherapy (IMRT) as Neoadjuvant Treatment in Rectal Carcinoma Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-Raf proto-oncogene serine/threonine-protein kinase </BiomarkerName><BiomarkerName> DNA excision repair protein ERCC-1 </BiomarkerName><BiomarkerName> DNA topoisomerase 1 </BiomarkerName><BiomarkerName> GTPase KRas </BiomarkerName><BiomarkerName> Phosphatidylinositol 3-kinase regulatory subunit beta </BiomarkerName><BiomarkerName> Thymidylate synthase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Antonio Cubillo, MD.PhD</Name></ContactNames></Trial><Trial Id="81300"><Indications><Indication>Pancreas tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Microtubule stabilizer</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Pharmaceutical carrier</Technology><Technology>Protein conjugated</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-03-25T00:00:00Z</DateChangeLast><DateEnd>2012-06-30T00:00:00Z</DateEnd><DateStart>2011-01-31T00:00:00Z</DateStart><Identifiers><Identifier>ABX271-PA09EU</Identifier><Identifier>NCT01442974</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gemcitabine plus paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary purpose of this pilot trial was to evaluate the effect of the neo-adjuvant treatment with Abraxane in combination with gemcitabine on tumor stroma in pancreatic cancer patients . The secondary end-point was to correlate tumor stroma changes with treatment activity.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - BP control rate</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Biomarkers - CA19-9 biomarker</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pancreas tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex><EndpointIndex>Pancreas tumor - Protocol Specified Other Endpoints - Assessment of Other Treatment Related Outcomes</EndpointIndex><EndpointIndex>Pancreas tumor - Protocol Specified Other Endpoints - Assessment of surgical resection rate</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Resectable Pancreatic Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Collagen type I </BiomarkerName><BiomarkerName> Glucose transporters and hexokinases </BiomarkerName><BiomarkerName> Hemoglobin subunit alpha 1 </BiomarkerName><BiomarkerName> Microvessel density </BiomarkerName><BiomarkerName> SPARC </BiomarkerName><BiomarkerName> Smooth muscle actin </BiomarkerName><BiomarkerName> Vascular endothelial growth factor A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Manuel Hidalgo, MD, PhD</Name></ContactNames></Trial><Trial Id="260559"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology></Technologies><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-12T00:00:00Z</DateChangeLast><DateEnd>2017-08-11T00:00:00Z</DateEnd><DateStart>2016-03-01T00:00:00Z</DateStart><Identifiers><Identifier>2014-004696-24</Identifier><Identifier>NCT02768272</Identifier><Identifier>PIEB-CT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>spinal-epidural technique alone</Intervention><Intervention>fentanyl plus levobupivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this randomized, double-blind clinical trial was to know the incidence of breaktrough pain (BP) in high-risk of BP parturients (nulliparous with early cervical dilation) comparing two epidural analgesic regimes: programed intermittent epidural boluses versus patient controlled epidural analgesia. The role of the epidural technique (epidural versus combined spinal-epidural) in the incidence of BP would be also evaluated.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Disease Relapse/Recurrence - Assessment of breakthrough pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of other outcomes associated with anesthetic use</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Pregnancy/Labor related outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>PIEB-CT: PIEB versus PCEA With Epidural or CSE Technique. A Randomized, Double-Blind Clinical Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gynecological disorder - Women giving birth/Obstetrics</PatientSegment><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Emilia Guasch, MD, PhD</Name></ContactNames></Trial><Trial Id="164880"><Indications><Indication>Factor VIII deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IIa agonist</Action><Action>Factor IX agonist</Action><Action>Factor VIIa agonist</Action><Action>Factor X agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Blood system agent</Action><Action>Coagulation stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Blood constituents</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-12-27T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2014-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02018393</Identifier><Identifier>PI-1405</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FEIBA NF alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This study aims to evaluate the immunomodulatory effect of FEIBA in patients with severe hemophilia A and inhibitors.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term><Term>Case Control</Term></TermsDesign><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Hemophilia A and Inhibitors</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia A - Subjects with hemophilia A and inhibitors</PatientSegment><PatientSegment>Hemophilia - Subjects with Severe Hemophilia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ihosvany Fernandez-Bello, Pharmacist</Name><Name>Victor Jimenez-Yuste, Medical doctor, PhD</Name></ContactNames></Trial><Trial Id="113346"><Indications><Indication>Non-insulin dependent diabetes</Indication><Indication>Sleep apnea</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>DM-SAHS</Identifier><Identifier>HULP-DM-SAHS-2012</Identifier><Identifier>NCT01801150</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>continuous positive airway pressure alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>61</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to assess if 6 months of treatment with Continuous positive airway pressure (CPAP) associated with conventional drug therapy, contribute to improved glycemic control in patients with type 2 diabetes and sleep apnea-hypopnea syndrome (SAHS).</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Beta Cell Function - Homeostasis model assessment (HOMA)- beta cell function Index (HOMA-B)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Glucose Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Obesity - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Obesity - Assessment of HbA1c levels</EndpointIndex><EndpointIndex>Obesity - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Obesity - Assessment of Inflammatory &amp; Oxidative Stress Markers - Cytokines/Adipokines</EndpointIndex><EndpointIndex>Obesity - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis - Homeostasis model assessment - HOMA</EndpointIndex><EndpointIndex>Obesity - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Co-morbidity - Assessment of metabolic disorders/diseases</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of Life (Unspecified)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>DM-SAHS: CPAP in Diabetes Type 2 Patients With Sleep Apnea</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring Insulin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Type 2 Diabetes Subjects Controlled by Diet/Exercise</PatientSegment><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/Obese Subjects with Diabetes</PatientSegment><PatientSegment>Sleep apnea - Subjects with comorbid conditions - Sleep Apnea in Obese Subjects</PatientSegment><PatientSegment>Sleep apnea - Subjects with comorbid conditions - Subjects with metabolic disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alberto Alonso-Fernández, MD</Name><Name>Elizabet Martínez-Cerón, MD</Name><Name>Francisco Garcia-Rio, MD</Name></ContactNames></Trial><Trial Id="216013"><Indications><Indication>Pulmonary hypertension</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-07-27T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2015-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02288442</Identifier><Identifier>UEMADRID</Identifier><Identifier>WHOLEi+12</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Whole muscle exercise training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this RCT was to study the effects of whole muscle training (inspiratory muscle training + aerobic training + muscle resistance training) on muscle power, VO2 peak and gas-exchange variables obtained during cardiopulmonary exercise testing, QoL, functional capacity (eg, 6-min walking distance), and maximal inspiratory pressure in patients with pulmonary artery hypertension.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Assessment of Exercise Capacity/Tolerance - Assessment of peak VO2</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Imaging/Radiological Assessments - Echocardiographic parameters</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>WHOLEi+12: Whole Muscle Exercise Training in Pulmonary Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Pulmonary artery hypertension - Subjects with WHO Functional Class II</PatientSegment><PatientSegment>Pulmonary artery hypertension - Subjects with WHO Functional Class III</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Maximal oxygen uptake </BiomarkerName><BiomarkerName> Muscle </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="269039"><Indications><Indication>Macular edema</Indication><Indication>Non-proliferative diabetic retinopathy</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2020-10-31T00:00:00Z</DateEnd><DateStart>2016-08-31T00:00:00Z</DateStart><Identifiers><Identifier>HULP PI-2476</Identifier><Identifier>NCT02874313</Identifier><Identifier>RetinAS</Identifier></Identifiers><InterventionsControlDisplay><Intervention>antidiabetic drug therapy alone</Intervention><Intervention>conventional anti-diabetic diet recommendations alone</Intervention><Intervention>insulin therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>antidiabetic drug therapy alone</Intervention><Intervention>continuous positive airway pressure therapy alone</Intervention><Intervention>conventional anti-diabetic diet recommendations alone</Intervention><Intervention>insulin therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of the study is to compare the percentage of patients with new microaneurysm or hard exudates after 12 months between the CPAP group and the control group. The secondary objectives are: To compare the central macula volume, ganglion cell layer thickness and central fovea thickness at baseline and 12, 24 and 52 weeks after randomization between the two study groups. To compare the percentage of patients who have an improvement loss of visual acuity (&gt;/= 15 letters in patients</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Best Corrected Visual Acuity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Blood Glucose Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Cardiovascular Events - Cardiac structure and function</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Central Macular Thickness (CMT)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Change in Visual Acuity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Diabetic Complications &amp; Events - Diabetic macular edema</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Diabetic Complications &amp; Events - Diabetic retinopathy</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Diabetic Complications &amp; Events - Retinal events/measures</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular cell adhesion molecule-1 (VCAM-1)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Intercellular adhesion molecule-1 (ICAM-1)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Insulin Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Intraocular Pressure</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Vascular Endothelial Function - Endothelial dysfunction</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Visual Function</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of ocular function</EndpointIndex><EndpointIndex>Diabetic complication - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Diabetic retinopathy - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic retinopathy - Assessment of Visual Function</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vascular Indices or Parameters - Assessment of endothelial function</EndpointIndex><EndpointIndex>Sleep apnea - Clinical Assessments</EndpointIndex><EndpointIndex>Sleep apnea - Clinical Assessments - Assessment of hematological function</EndpointIndex><EndpointIndex>Sleep apnea - Imaging/Radiological Assessments - Assessment of imaging modalities</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of Life (Unspecified)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>RetinAS: CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Macular Edema</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Retinopathy - Subjects with mild nonproliferative retinopathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring Insulin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic macular edema</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic retinopathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adiponectin </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Endothelins </BiomarkerName><BiomarkerName> Fovea centralis </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Homocysteine </BiomarkerName><BiomarkerName> Intercellular adhesion molecule-1 </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Intraocular pressure </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Macula retinae </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Retinal ganglion cell layer </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1 </BiomarkerName><BiomarkerName> Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Aldara García Sánchez, MD</Name><Name>Francisco Garcia-Rio, MD</Name><Name>Jesús Ramón García Martínez, MD</Name><Name>Mónica Asencio Durán, MD</Name></ContactNames></Trial><Trial Id="178102"><Indications><Indication>Tendon injury</Indication></Indications><CompaniesCollaborator><Company>Spanish society of orthopedics and traumatology</Company></CompaniesCollaborator><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-19T00:00:00Z</DateChangeLast><DateEnd>2011-06-30T00:00:00Z</DateEnd><DateStart>2007-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01612845</Identifier><Identifier>PI-523</Identifier><Identifier>PRP-Fibrin</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Platelet Rich Fibrin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>28</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this study was to prospectively evaluate the influence of local application of Platelet Rich Fibrin (PRF) on the functional outcome and integrity of the arthroscopically repaired tendons in patients with massive tears of the rotator cuff.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PRP-Fibrin: Effect of Platelet-rich Fibrin on Rotator Cuff Repair</TitleDisplay><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jose Martinez</Name><Name>Jose Sanchez</Name><Name>Raul Barco</Name><Name>Samuel Antuna</Name></ContactNames></Trial><Trial Id="176065"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-07-11T00:00:00Z</DateChangeLast><DateEnd>2018-06-30T00:00:00Z</DateEnd><DateStart>2009-12-31T00:00:00Z</DateStart><Identifiers><Identifier>HULP PI-825</Identifier><Identifier>NCT01037387</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional treatment alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Noninvasive mechanical ventilation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this parallel, randomized and controlled clinical trial is to evaluate the effect of noninvasive ventilation versus conventional treatment on c-reactive protein concentration and daily physical activity in hypercapnic patients with stable Chronic obstructive pulmonary disease (COPD). Secondary objectives are: To compare the plasmatic concentration of other inflammatory biomarkers between COPD patients with conventional treatment and with noninvasive ventilation. To determine</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of partial pressure of O2(PaO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Partial pressure of carbon dioxide (PaCO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - pH analysis</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Muscle force /strength</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of FEV1/FVC Ratio</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6) assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum fibrinogen assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inspiratory Capacity (IC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Lung Volumes</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Mortality/Morbidity</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function - Assessment of total lung capacity (TLC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function - Assessment of total lung capacity/residual volume</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Vital Capacity (VC) - Inspiratory vital capacity (IVC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Activities of Daily Living scale (ADL)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Baseline Dyspnea Index (BDI) score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>1-Pentadecanoyl-2-(octadecenoyl)-3-(octadecenoyl)-glycerol </BiomarkerName><BiomarkerName> 8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> FEV / FVC ratio </BiomarkerName><BiomarkerName> Fibrinogen </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Interleukin 1 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Maximal expiratory pressure </BiomarkerName><BiomarkerName> Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Partial pressure of carbon dioxide </BiomarkerName><BiomarkerName> Partial pressure of oxygen </BiomarkerName><BiomarkerName> Residual Volume/Total Lung Capacity </BiomarkerName><BiomarkerName> Six-minute walk distance </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>102 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Claudia Llontop</Name><Name>Francisco Garcia-Rio, PhD</Name><Name>Maria Antonia Gómez-Mendieta</Name><Name>María Antonia Gomez-Mendieta, MD</Name><Name>María Antonia Gómez-Mendieta, MD</Name></ContactNames></Trial><Trial Id="178528"><Indications><Indication>Sleep apnea</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-03-24T00:00:00Z</DateChangeLast><DateEnd>2012-10-31T00:00:00Z</DateEnd><DateStart>2007-06-30T00:00:00Z</DateStart><Identifiers><Identifier>HULP051937</Identifier><Identifier>NCT00487929</Identifier><Identifier>OSCAMSA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nasal CPAP alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to compare the levels of 8-isoprostane and other oxidative stress biomarkers in plasma and condensed exhaled air between patients with SAHS and cardiovascular complications, patients with SAHS without cardiovascular complications and control subjects. The study also evaluated the effect of 3 months of treatment with CPAP on the oxidative stress biomarkers.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>OSCAMSA: Oxidative Stress and Cardiovascular Morbidity in Sleep Apnea-Hypopnea Syndrome (SAHS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Sleep apnea - Subjects with Day-time Sleepiness Due to Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Mild Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Moderate Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Severe Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Endothelin-1 </BiomarkerName><BiomarkerName> Homocysteine </BiomarkerName><BiomarkerName> Hypoxia-inducible factor 1 alpha </BiomarkerName><BiomarkerName> Intercellular adhesion molecule-1 </BiomarkerName><BiomarkerName> Interleukin 1 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Nitrate </BiomarkerName><BiomarkerName> Nitrite </BiomarkerName><BiomarkerName> Nuclear factor kappa B subunit 1 </BiomarkerName><BiomarkerName> Transcription factor AP-1 </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>64 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Francisco García-Rio, PhD</Name></ContactNames></Trial><Trial Id="225227"><Indications><Indication>Hypertension</Indication><Indication>Sleep apnea</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2016-03-31T00:00:00Z</DateEnd><DateStart>2013-05-31T00:00:00Z</DateStart><Identifiers><Identifier>99/0252</Identifier><Identifier>NCT02398032</Identifier><Identifier>SAHS2-3</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nasal CPAP alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this controlled, crossover, longitudinal study was to assess the nocturnal changes in mechanosensitivity and chemosensitivity in hypertensive sleep apnea-hypopnea syndrome (SAHS) patients and in SAHS patients with isolated nocturnal hypertension and to value the continuous positive airway pressure (CPAP) effect on these parameters.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular cell adhesion molecule-1 (VCAM-1)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Endothelin 1-21</EndpointIndex><EndpointIndex>Hypertension - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Sleep apnea - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>SAHS2-3: CPAP in SAHS Patients With Hypertension</TitleDisplay><BiomarkerNames><BiomarkerName>Aldosterone </BiomarkerName><BiomarkerName> Angiotensins </BiomarkerName><BiomarkerName> Arterial oxygen saturation </BiomarkerName><BiomarkerName> Basal metabolic rate </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body surface area </BiomarkerName><BiomarkerName> Catecholamines </BiomarkerName><BiomarkerName> Endothelin-1 </BiomarkerName><BiomarkerName> Mouth occlusion pressure at 0.1 second after the onset of inspiratory effort </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Francisco Garcia-Rio, MD</Name></ContactNames></Trial><Trial Id="258144"><Indications><Indication>Lower back pain</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-10-19T00:00:00Z</DateChangeLast><DateEnd>2017-03-31T00:00:00Z</DateEnd><DateStart>2016-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CIPI/054/15</Identifier><Identifier>NCT02736201</Identifier><Identifier>T-Care</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Instrumental manual therapy alone</Intervention><Intervention>T-CaRe alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The objective of this  pilot, single-blind, randomized, controlled clinical study is to determine the effectiveness of the capacitive diathermy in the mechanosensitivity, morphological, functional and contractility changes in patients with lumbopelvic pain.</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Oswestry Disability Index (ODI)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Physical Examination - Assessment of anthropometric measures</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Respiratory disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>T-Care: Capacitive Diathermy in the Lumbopelvic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain - Subjects with low back pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Skinfold thickness </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Beatriz Martínez Pascual, PhD, MSc, PT</Name><Name>Cesar Calvo Lobo, PhD, MSc, PT</Name><Name>César Calvo Lobo, PhD, MSc, PT</Name><Name>David Rodríguez Sanz, PhD, MSc, PT</Name><Name>Ignacio Diez Vega, PhD, MSc, PT</Name><Name>Mónica de la Cueva Reguera, PhD, MSc, PT</Name><Name>Silvia Fernández Martínez, PhD, MSc, PT</Name></ContactNames></Trial><Trial Id="381838"><Indications><Indication>Muscle injury</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-28T00:00:00Z</DateChangeLast><DateEnd>2018-12-21T00:00:00Z</DateEnd><DateStart>2018-10-22T00:00:00Z</DateStart><Identifiers><Identifier>NCT03961022</Identifier><Identifier>Nat.Origins-ReWin(d)-2019</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ReWin(d) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This double-blind, randomized, placebo-controlled, parallel-group, pilot study assessed the recovery and performance of young athletes suffering from muscle damage, induced by physical exercise and compared the safety and efficacy of ReWin(d) supplemention.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Fatigue</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of microbiological/serological parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Pain - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of ReWin(d) Supplementation on the Recovery of DOMS Induced by Acute Exercice</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with Delayed Onset Muscle Soreness (muscle fever)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-12-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Margarita Perez Ruiz, MD(Res)</Name></ContactNames></Trial><Trial Id="237357"><Indications><Indication>Headache</Indication><Indication>Migraine</Indication><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-06-06T00:00:00Z</DateChangeLast><DateEnd>2019-10-31T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>CSEULS-PI-002/2013</Identifier><Identifier>NCT02514148</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>manual therapy alone</Intervention><Intervention>therapeutic exercise alone</Intervention><Intervention>therapeutic patient education alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>86</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to know wich combination of treatments are the most effective in patients with chronic migraine. The study design is a simple, blinded, randomized, controlled trial (outcomes assessor).</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by HIT-6 questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Neck Disability Index</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Chronic Pain Self-Efficacy Scale (CPSS</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with other types of headache</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment><PatientSegment>Pain - Subjects with specific disease - Subjects with chronic migraine</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cervical motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Beatriz Gómez Ramiro, MsC</Name><Name>Paula Kindelan, MSc</Name><Name>paula Kindelan, MsC</Name></ContactNames></Trial><Trial Id="126944"><Indications><Indication>Nail disease</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-11T00:00:00Z</DateChangeLast><DateEnd>2013-04-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01844141</Identifier><Identifier>RIC11022013</Identifier></Identifiers><InterventionsControlDisplay><Intervention>alcohol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>alcohol plus clorhexidine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to compare the efficacy of the lavage with 70% alcohol plus 0.5% chlorhexidine versus 70% alcohol during the phenolization procedure in the surgical treatment of ingrown toenails in patients undergoing for chemical matricectomy.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effectiveness of Lavage With Alcohol-Chlorhexidine for Chemical Matricectomy</TitleDisplay><PrimaryCompletionDate type="Anticipated">2013-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ricardo Becerro de Bengoa, Phd</Name><Name>Ricardo Berceo, PhD</Name></ContactNames></Trial><Trial Id="222729"><Indications><Indication>Varicosis ulcer</Indication></Indications><CompaniesCollaborator><Company>Fondo de Investigacion Sanitaria</Company><Company>Instituto de Salud Carlos III</Company></CompaniesCollaborator><CompaniesSponsor><Company>Gerencia de Atención Primaria, Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2018-01-31T00:00:00Z</DateEnd><DateStart>2014-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02364921</Identifier><Identifier>PI13/01975</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Crepe bandage alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>K2 Urgo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>93</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the effectiveness of a multilayer compression bandage (two layers), compared with the crepe bandage, on healing of venous leg ulcers, in patients attended in nursing primary care health centers, at 12 weeks follow-up. This study also compared the effectiveness of the multilayer and the crepe bandage, on healing of venous leg ulcers measured by the Resvech 2.0 scale and evaluates improvement in quality of life, measured by the Charing Cross Venous Ulcer</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effectiveness of Double-layer Compression Therapy in the Healing of Chronic Venous Ulcers in Primary Health Care</TitleDisplay><PrimaryCompletionDate type="Actual">2018-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Maria del Carmen Folguera, Nurse</Name></ContactNames></Trial><Trial Id="382550"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-06-02T00:00:00Z</DateChangeLast><DateEnd>2019-07-15T00:00:00Z</DateEnd><DateStart>2019-06-05T00:00:00Z</DateStart><Identifiers><Identifier>NCT03959449</Identifier><Identifier>UAMMADRID8</Identifier></Identifiers><InterventionsControlDisplay><Intervention>motor imagery alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Exercise alone</Intervention><Intervention>action observation and motor imagery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This study evaluates the influence of motor imagery and the observation of actions on pain perception.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of Pressure Pain Thresholds (PPT)</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Dermatological disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Respiratory disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Tampa Scale of Kinesiophobia (TSK)</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Action Observation and Motor Imagery Induced Hypoalgesia in Asymptomatic Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Skin conductance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Luis Suso Marti</Name><Name>Roy La Touche</Name><Name>Roy La Touche Arbizu</Name></ContactNames></Trial><Trial Id="376566"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-14T00:00:00Z</DateChangeLast><DateEnd>2019-07-31T00:00:00Z</DateEnd><DateStart>2019-04-15T00:00:00Z</DateStart><Identifiers><Identifier>7</Identifier><Identifier>NCT03905577</Identifier><Identifier>uamadrid7</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>action observation training alone</Intervention><Intervention>motor imagery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This study will evaluate the influence of motor imagery or action observation training on pain perception in patients with chronic neck pain. Perception of pain will be measured by the pain pressure threshold. It is necessary to clarify the controversial aspects of motor imagery, which lead the investigators to perform this study.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Cognitive, Global and Functional Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Tampa Scale of Kinesiophobia (TSK)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Motor Imagery and Action Observation Training on Pain Perception in Patients With Chronic Neck Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cervical motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Luis Suso-Martí, MSc</Name><Name>Roy La Touche</Name><Name>Roy La Touche Arbizu</Name><Name>Roy La Touche, PhD</Name></ContactNames></Trial><Trial Id="361616"><Indications><Indication>Insomnia</Indication><Indication>Restless legs syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Orexin 1 receptor antagonist</Action><Action>Orexin 2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypnotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Instituto de Investigaciones del Sueno</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-30T00:00:00Z</DateChangeLast><DateEnd>2020-03-31T00:00:00Z</DateEnd><DateStart>2019-02-28T00:00:00Z</DateStart><Identifiers><Identifier>IISP-57325</Identifier><Identifier>NCT03755310</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>suvorexant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>43</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The study hypothesis will be treatment of restless legs syndrome(RLS) symptoms with the hypocretin antagonist suvorexant will lead to an improvement of sleep as well as to an improvement of both dysesthesias and motor symptoms (PLMs).The investigators will consider that suvorexant provide a stable therapeutic efficacy for the long treatment, avoiding the risk of augmentation of symptoms commonly seen under dopamine agonists.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Insomnia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Insomnia - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of total sleep time (TST)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of wake time after sleep onset (WASO)</EndpointIndex><EndpointIndex>Insomnia - Assessment of motor function</EndpointIndex><EndpointIndex>Insomnia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Functional Disability/Physical Function - Assessment of motor symptoms</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Laboratory/Diagnostic Measures - Assessment by protocol specified suggested immobilization tests [SIT]</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of RLS Symptoms with Protocol Specified Scales - Assessment by International Restless Legs Study Group RLS rating scale</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of RLS Symptoms with Protocol Specified Scales - Assessment by Periodic Limb Movement (PLM) during Wakefulness Index (PLMWI)</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep</EndpointIndex><EndpointIndex>Restless legs syndrome - Assessment of Sleep - Assessment of wake time after sleep onset (WASO)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with Insomnia Secondary to Other Sleep Disorders - Secondary to restless legs syndrome</PatientSegment><PatientSegment>Insomnia - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Insomnia - Treatment Naive Subjects</PatientSegment><PatientSegment>Restless legs syndrome - Subjects with Idiopathic Restless Legs Syndrome</PatientSegment><PatientSegment>Restless legs syndrome - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Restless legs syndrome - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Diego García-Berreguero</Name><Name>Diego García-Borreguero, MD. PhD.</Name><Name>Rocío Prieto Pérez</Name></ContactNames></Trial><Trial Id="67092"><Indications><Indication>Diabetic foot ulcer</Indication><Indication>Osteomyelitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta lactamase inhibitor</Action><Action>DHFR inhibitor</Action><Action>DNA gyrase inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Fungicide</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-11-21T00:00:00Z</DateChangeLast><DateEnd>2011-11-30T00:00:00Z</DateEnd><DateStart>2010-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01137903</Identifier><Identifier>OM-2010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including amoxicillin + potassium clavulanate (bacterial infections, oral/tablet), GL PharmTech , ciprofloxacin hydrochloride , trimethoprim + sulphamethoxazole</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>88</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The hypothesis was that surgical treatment of osteomyelitis in diabetic foot was more effective that medical treatment through anti-biotherapy and leads wound healing in ulcers complicated with bone infection. This was a randomized clinical trial which include two groups of patients (n = 88), one group received medical treatment through anti-biotherapy during 90 days and the other received conservative surgical treatment and antibiotics during 7 days after surgery. It was to study differences</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Diabetic Complications &amp; Events - Diabetic foot examination/assessments</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Morbidity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Diabetic Complications &amp; Events - Diabetic foot examination/assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Morbidity</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Foot Diseases</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Foot Diseases - Subjects with diabetic foot ulcers</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Diabetic Complications - Subjects with diabetic foot</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2011-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Almudena Cecilia Matilla, DP</Name><Name>Almudena Matilla</Name><Name>Esther Alicia García Morales, PhD</Name><Name>Esther Morales</Name><Name>Francisco Javier Aragon Sanchez</Name><Name>Franciso Javier Aragón Sánchez, MD, PhD</Name><Name>Gabriel Rivera San Martín, DP</Name><Name>Jose Luis Lazaro Martinez</Name><Name>José Luis Lázaro Martínez, PhD</Name><Name>Juan Vicente Beneit Montesinos, MD,PhD</Name><Name>Juan Montesinos</Name><Name>María del Carmen García Carrión, MD, PhD</Name><Name>Máximo Antonio González Jurado, RN, DP, PhD</Name><Name>Silvia Allas Aguado, DP</Name><Name>Yolanda García Álvarez, RN, DP</Name></ContactNames></Trial><Trial Id="75776"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Topoisomerase II inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>DNA intercalator</Action><Action>Microtubule stabilizer</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liposome formulation injectable</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Natural product</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Hospital Universitario Madrid Sanchinarro</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-12-19T00:00:00Z</DateChangeLast><DateEnd>2013-11-30T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>AVANTHER</Identifier><Identifier>AVANTHER</Identifier><Identifier>NCT01321775</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including bevacizumab , cyclophosphamide , doxorubicin (liposome formulation), Cephalon , paclitaxel , trastuzumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>44</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to determine the efficacy of the combined therapy with bevacizumab , trastuzumab and paclitaxel as neo-adjuvant therapy in patients with breast cancer human epidermal growth factor receptor-2-positive (HER2+) followed by surgery and adjuvant therapy with cyclophosphamide, trastuzumab and Myocet (liposomal doxorubicin).</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>AVANTHER: Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With HER2+ Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2013-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Diego Perez</Name><Name>Laura Garcia</Name><Name>Noelia Martinez</Name></ContactNames></Trial><Trial Id="264482"><Indications><Indication>Albuminuria</Indication><Indication>Diabetic nephropathy</Indication><Indication>Obstructive sleep apnea</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-09-21T00:00:00Z</DateChangeLast><DateEnd>2019-09-30T00:00:00Z</DateEnd><DateStart>2016-06-30T00:00:00Z</DateStart><Identifiers><Identifier>DIANA</Identifier><Identifier>HULP</Identifier><Identifier>NCT02816762</Identifier></Identifiers><InterventionsControlDisplay><Intervention>dietary intervention alone</Intervention><Intervention>pharmacological treatment alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>continuous positive airway pressure (CPAP) alone</Intervention><Intervention>dietary intervention alone</Intervention><Intervention>pharmacological treatment alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this study is to assess the effect of 12 months of CPAP treatment added to conventional drug treatment on the albuminuria in patients with diabetic nephropathy and obstructive sleep apnea (OSA). Secondary objectives: To evaluate the effect of CPAP treatment on the estimated glomerular filtration rate of patients with diabetic nephropathy and OSA. To determine the additional longterm CPAP effect on glycemic control, insulin resistance, lipid profile, health-related quality of</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - 8-isoprostane (8-iso-prostaglandin (PG)f2a)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular cell adhesion molecule-1 (VCAM-1)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Intercellular adhesion molecule-1 (ICAM-1)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Insulin Sensitivity - Homeostasis model assessment (HOMA)- insulin sensitivity index (HOMA-I, HOMA-IR)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Renal Function</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Vascular Endothelial Function</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints - Appetite assessment</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vascular Indices or Parameters - Assessment of endothelial function</EndpointIndex><EndpointIndex>Sleep apnea - Clinical Assessments - Assessment of hematological function</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EuroQoL Questionnaire-5 Dimension (EQ-5D)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EuroQoL Questionnaire-6 Dimension (EQ-6D)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Sleep apnea - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DIANA: CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Nephropathy</PatientSegment><PatientSegment>Diabetic complication - Subjects with comorbid conditions</PatientSegment><PatientSegment>Sleep apnea - Subjects with Obstructive Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with comorbid conditions - Sleep Apnea in Obese Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Adiponectin </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Endothelins </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin resistance </BiomarkerName><BiomarkerName> Homocysteine </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Intercellular adhesion molecule-1 </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Pro-neuropeptide Y </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Urinary albumin to creatinine ratio </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Alberto Alonso-Fernández</Name><Name>Alberto Alonso-Fernández, MD</Name><Name>Elisabet Martínez-Cerón, MD</Name><Name>Ester Zamarrón, MD</Name><Name>Francisco Garcia-Rio, MD</Name><Name>Mayte Ramirez, MD</Name><Name>Nicolas González Mangado</Name><Name>Nicolás González-Mangado, MD</Name><Name>Olga Costero, MD</Name><Name>Olga Mediano, MD</Name><Name>Paula Rodríguez Rodríguez, MD</Name><Name>Pilar Resano Barrio, MD</Name><Name>Sheila Cabello Pelegrín, MD</Name><Name>Trinidad Diaz Cambriles, MD</Name><Name>Trinidad Diaz-Cambriles, MD</Name><Name>Vanesa Lores, MD</Name></ContactNames></Trial><Trial Id="176033"><Indications><Indication>Sleep apnea</Indication><Indication>Ventricular arrhythmia</Indication></Indications><CompaniesCollaborator><Company>Hospital Virgen de la Macarena</Company><Company>Hospital Virgen de la Salud</Company></CompaniesCollaborator><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-03-25T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2008-10-31T00:00:00Z</DateStart><Identifiers><Identifier>HULP PI-719</Identifier><Identifier>NCT00765713</Identifier><Identifier>SAHS-ICD</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>continuous positive airway pressure alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>224</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The hypotheis of this study was that the continuous positive airway pressure (CPAP) treatment diminishes the effect of ventricular arrhythmias in subjects with ischemic heart disease or dilated myocardiopathy, systolic ventricular dysfunction and sleep apnea-hypopnea syndrome (SAHS) The primary objectives of this study were: To analyze the incidence of ventricular arrhythmias (premature ventricular beat, non-sustained ventricular tachycardia and sustained ventricular tachycardia) and appropriate</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Incidence of Other Arrhythmic Events - Assessment of tachycardia</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of inflammatory cytokines</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of interleukins</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Disease Progression - Assessment by apnea-hypopnea index [AHI]</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>SAHS-ICD: Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart arrhythmia - Subjects with cardiac intervention</PatientSegment><PatientSegment>Sleep apnea - Subjects with comorbid conditions - Subjects with other cardiovascular disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Nepsilon-Hcy-Lys</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Francisco Garcia-Rio</Name></ContactNames></Trial><Trial Id="173831"><Indications><Indication>Osteonecrosis</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>France</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2014-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2012-002010-39</Identifier><Identifier>NCT02065167</Identifier><Identifier>ORTHO -2</Identifier><Identifier>ORTHO-2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cultured autologous mesenchymal cells alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>26</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of the study is to assess the safety and feasibility of an in situ single injection of a high dose of autologous bone marrow-derived, in vitro expanded mesenchymal stem cells, and its contribution to the resolution of the early stages of avascular osteonecrosis of the femoral head.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Markers of Bone/Cartilage/Collagen Turnover</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Systemic Function - Assessment of changes in bone cytomorphology</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Therapy Related Outcomes - Assessment by imaging techniques</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ORTHO-2: Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip</TitleDisplay><PatientSegmentTerms><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Bone Marrow Transplantation(BMT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Mesenchymal Stem Cell Transplantation(MSCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Enrique Gomez-Barrena, Prof</Name></ContactNames></Trial><Trial Id="317586"><Indications><Indication>Bone injury</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Germany</Country><Country>Italy</Country><Country>France</Country></Countries><DateChangeLast>2019-03-02T00:00:00Z</DateChangeLast><DateEnd>2021-12-30T00:00:00Z</DateEnd><DateStart>2017-09-05T00:00:00Z</DateStart><Identifiers><Identifier>2015-000431-32</Identifier><Identifier>EUCTR2015-000431-32-ES</Identifier><Identifier>NCT03325504</Identifier><Identifier>ORTHOUNION</Identifier><Identifier>ORTHOUNION</Identifier></Identifiers><InterventionsControlDisplay><Intervention>autologous lliac crest graft alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>autologous cultured mesenchymal cell therapy alone</Intervention><Intervention>biomaterial therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>ORTHOUNION is a multicenter, open, comparative, randomized, clinical trial with three parallel-arms that aims to compare the efficacy of three treatments to enhance bone healing in patients with long bone non-union and this study focuses on the opportunity to test the hypothesis of superiority of MSC, the investigational ATMP, versus the currently accepted standard therapy, iliac crest bone autograft to biologically augment surgical treatment of long-bone non-unions. Main objective of the trial is</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Other Measures of Pain Quality</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Clinical Assessments - Fracture healing/callus formation assessment</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Neurological Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ORTHOUNION: A Comparative Study of Two-Doses of BM Autologous H-MSC+Biomaterial versus Iliac Crest AutoGraft for Bone Healing in Non-Union</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease - Subjects with Bone Injury</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Bone Marrow Transplantation(BMT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Mesenchymal Stem Cell Transplantation(MSCT)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>19</NumberOfSites><ContactNames><Name>Atesch Ateschrang, Prof. Dr.</Name><Name>Basilio de la Torre, MD</Name><Name>Charles-Henri Flouzat -Lachaniette, Prof. Dr.</Name><Name>Cristina Avendano-Sola, MD</Name><Name>Didier Mainard, Prof. Dr.</Name><Name>Enrique Gomez-Barrena, Prof</Name><Name>Enrique Gomez-Barrena, Prof. Dr.</Name><Name>Fabio Cattani, Prof. Dr.</Name><Name>Fernando Marco, Prof. Dr.</Name><Name>François Gouin, Prof. Dr.</Name><Name>Ingo Marzi, Prof. Dr.</Name><Name>Javier Vaquero, Prof. Dr.</Name><Name>Jose Cordero, Prof. Dr.</Name><Name>Jörg Bayer, Prof. Dr.</Name><Name>Luigi Zagra, MD</Name><Name>Markus Huber-Lang, Prof. Dr.</Name><Name>Nicola Baldini, Prof. Dr.</Name><Name>Nicolas Reina, Prof. Dr.</Name><Name>Pablo de la Cuadra, MD</Name><Name>Pedro Caba, MD</Name><Name>Philippe Rosset, Prof. Dr</Name><Name>Rodolfo Capanna, Prof. Dr.</Name><Name>Ugo Pazzaglia, Prof. Dr.</Name></ContactNames></Trial><Trial Id="252125"><Indications><Indication>Lung disease</Indication><Indication>Surgical resection</Indication></Indications><CompaniesCollaborator><Company>Baxter International Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Universitario Quironsalud Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2019-04-30T00:00:00Z</DateEnd><DateStart>2016-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02668978</Identifier><Identifier>SEALLS</Identifier><Identifier>SEALLS</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Lung resuturing/restapling alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Hemopatch sealing hemostat alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>144</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The primary objective is to assess the efficacy and safety of Hemopatch sealing hemostat in reducing the incidence and duration of air leaks after lung resection compared to standard techniques. This study hypothesis is that 'the routine application of Hemopatch sealing hemostat on the visceral pleura in lung resection areas, during lung resection procedures, is more efficient to reduce the incidence and duration of prolonged air leaks as compared to standard surgical measures.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Procedure and Procedure Related Events</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SEALLS: Sealing Evaluation of Air Leaks After Lung Surgery Trial Using Hemopatch</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects Undergoing Surgery</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Francisco Javier Moradiellos, MD</Name><Name>Javier Moradiellos, MD</Name></ContactNames></Trial><Trial Id="254943"><Indications><Indication>Knee injury</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-23T00:00:00Z</DateChangeLast><DateEnd>2016-09-30T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>EUROPEAN UNIVERSITY</Identifier><Identifier>NCT02699411</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Dry needling alone</Intervention><Intervention>Stability and propioception exercise alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to check dry needling effectiveness of patients on break anterior cruciate ligament.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment by Global Assessment Scales - Visual analogue scales (VAS) for local and general pain/overall disease activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on WOMAC scale</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Dry Needling Effectiveness of Patients on Break Anterior Cruciate Ligament (ACL)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with History of/Undergoing Specified Procedures</PatientSegment><PatientSegment>Other musculoskeletal disease - Subjects with specific disease - Subjects with anterior cruciate ligament injury</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Knee motion </BiomarkerName><BiomarkerName> Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Beatriz Ruiz, Mrs</Name><Name>César Calvo, Mr</Name><Name>Jorge Velázquez</Name><Name>Jorge Velázquez, Mr</Name><Name>Jorge Velázquez, Sr</Name><Name>Jorge Velázquez, sr</Name></ContactNames></Trial><Trial Id="242805"><Indications><Indication>Cystic fibrosis</Indication></Indications><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-08-24T00:00:00Z</DateChangeLast><DateEnd>2016-07-31T00:00:00Z</DateEnd><DateStart>2015-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02552043</Identifier><Identifier>UAMADRID</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Nintendo Wii exercise program alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this randomized and longitudinal study is to evaluate the efficacy of a long-term domiciliary exercise program using the Wii video game platform as a training modality in Cystic Fibrosis (CF) patients. Investigators hypothesize that an exercise program performed by active videogames (AVG) will produce an improvement in exercise tolerance and muscular strength to be maintained over time in young CF patients.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exercise Capacity/Tolerance - Assessment of muscle strength</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Cystic fibrosis questionnaire (CFQ)</EndpointIndex><EndpointIndex>Cystic fibrosis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle strength </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="377571"><Indications><Indication>Acute stress disorder</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-24T00:00:00Z</DateChangeLast><DateEnd>2020-12-15T00:00:00Z</DateEnd><DateStart>2017-05-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03920241</Identifier><Identifier>PSI-559959-R</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>compassion cultivation training alone</Intervention><Intervention>mindfulness-based stress reduction alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>650</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The study is aimed at comparing the differential effects of two widely used standardized meditation programs: mindfulness-based stress reduction (MBSR) and compassion cultivation training (CCT) in general population samples. There are two main corresponding hypotheses. First, meditation practice in general (both mindfulness and compassion) changes the attentional processing of emotional information, reflected by a significant reduction of the attentional blink deficit after the programs as compared</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Brain Structure and Function</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment of attention/concentration</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment of cognitive symptoms</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Life Orientation Test (LOT)</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Satisfaction with Life Scale (SWLS)</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Self-Compassion Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Cognition and Emotion in Meditation: A Comparison Between Mindfulness and Compassion Standardized Programs</TitleDisplay><PatientSegmentTerms><PatientSegment>Anxiety disorder - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carmelo Vazquez, PhD</Name><Name>Gustavo Diex, MSc</Name><Name>Nazareth Castellanos, PhD</Name><Name>Pablo Roca, MSc</Name></ContactNames></Trial><Trial Id="307260"><Indications><Indication>Lower back pain</Indication></Indications><CompaniesCollaborator><Company>Universidad De La Salle</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Autonoma de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-06-30T00:00:00Z</DateEnd><DateStart>2017-01-30T00:00:00Z</DateStart><Identifiers><Identifier>2</Identifier><Identifier>NCT03232879</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Action Observation alone</Intervention><Intervention>Motor Imagery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to compare the activation of the Sympathetic Nervous System in a program that combined Motor Imagery with Action Observation, in contrast to an isolated Motor Imagery program  on the one hand in asymptomaticsubjects and in the other hand in patients with chronic low back pain. The secondary objective of the present study was to explore whether there is any relationship between the sympathetic-excitatory response and the ability to generate motor imagery, the mental</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Combining Motor Imagery With Action Observation Does Not Lead to a Greater Autonomic Response Than Motor Imagery Alone During Simple and Functional Movements: a Randomized, Controlled Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain - Subjects with low back pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Skin conductance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-04-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="292518"><Indications><Indication>Obstructive sleep apnea</Indication></Indications><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-12T00:00:00Z</DateChangeLast><DateEnd>2020-11-01T00:00:00Z</DateEnd><DateStart>2017-04-03T00:00:00Z</DateStart><Identifiers><Identifier>HULP-2613</Identifier><Identifier>NCT03086850</Identifier><Identifier>PASOS</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional treatment alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>conventional treatment alone</Intervention><Intervention>daily physical activity based intervention alone</Intervention><Intervention>pedometer (Geonaute, France) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>144</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of the trial is to assess the effect of the daily physical activity promotion with a pedometer during 12 months on the apnea-hypopnea index (AHI) in patients with mild to moderate obstructive sleep apnea (OSA).</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Sleep apnea - Anthropometric Assessments</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Co-morbidity - Asssessment of cardiovascular disorders/ diseases</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Disease Progression - Assessment by apnea-hypopnea index [AHI]</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Sleep - Assessment of day-time sleepiness</EndpointIndex><EndpointIndex>Sleep apnea - Clinical Assessments - Assessment of hematological function</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Sleep apnea - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PASOS: Long-term Effect of the Physical Activity Promotion on the Clinical Characteristics and Vascular Risk in Patients With Mild to Moderate Obstructive Sleep Apnea</TitleDisplay><PatientSegmentTerms><PatientSegment>Sleep apnea - Subjects with Mild Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Moderate Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Obstructive Sleep Apnea</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin sensitivity </BiomarkerName><BiomarkerName> Homocysteine </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Lean body mass </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide </BiomarkerName><BiomarkerName> Oxyhemoglobins </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-04-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Begoña Sánchez-Sánchez, MD</Name><Name>Francisco Garcia-Rio, MD</Name><Name>Raquel Casitas, MD</Name></ContactNames></Trial><Trial Id="190340"><Indications><Indication>Mastitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-18T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2008-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00716183</Identifier><Identifier>PROMAST08</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Lactobacillus fermentum LC40 alone</Intervention><Intervention>Lactobacillus reuteri CR20 alone</Intervention><Intervention>Lactobacillus salivarius HN6 alone</Intervention><Intervention>amoxicillin alone</Intervention><Intervention>cloxacillin alone</Intervention><Intervention>amoxicillin plus clavulanic acid</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase II/III study was evaluation of three Lactobacilli strains isolated from human milk for the treatment of infectious mastitis during the lactation period.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis</TitleDisplay><PrimaryCompletionDate type="Actual">2008-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="278701"><Indications><Indication>Spondylarthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TNF antagonist</Action><Action>TNF binding agent</Action><Action>Type II TNF receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Follow on biological product</Technology><Technology>Liquid formulation</Technology><Technology>Protein fusion</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Sun Yat-Sen University</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2016-11-30T00:00:00Z</DateChangeLast><DateStart>2014-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02960035</Identifier><Identifier>[2015]2-158</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>etanercept follow-on biologic, Shanghai Citic Pacific Guojian Pharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this randomized, double-blind, multicentral clinical trial was to investigate the efficacy of recombinant human tumor necrosis factor-alpha receptor Ⅱ IgG Fc fusion protein injection ( Yisaipu ) in the treatment of peripheral enthesitis in active axial spondyloarthritis (SpA) patients. Mardird sonographic enthesis index (MASEI) was one of the most wide used scoring systems for peripheral enthesitis and the only one based on OMERACT definition of enthesopathy by EULAR. The primary purpose</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Active Ankylosing Spondylitis</PatientSegment><PatientSegment>Ankylosing spondylitis - Severe Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial><Trial Id="362269"><Indications><Indication>Metastatic breast cancer</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-05T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2018-10-01T00:00:00Z</DateStart><Identifiers><Identifier>ESICA</Identifier><Identifier>NCT03760653</Identifier><Identifier>UEM0002</Identifier></Identifiers><InterventionsControlDisplay><Intervention>sedentary lifestyle alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>physical exercise alone</Intervention><Intervention>probiotic alone</Intervention><Intervention>sedentary lifestyle alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to determine the effects of physical exercise together with the supplementation of a probiotic on gut microbiota balance, the gut immune system and quality of life (intended as functional and muscular capacity, physical qualities and emotional state) in breast cancer survivors.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Biological</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Anthropometric Assessments</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Anxiety by Protocol Specified Scales - Assessment by Spielberger State-Trait Anxiety Inventory (STAI)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Cardio-Pulmonary System</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Depression Severity by Specific Criteria</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-BR23</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Food Frequency Questionnaire (FFQ)</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by International Physical Activity Questionnaire (IPAQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>ESICA: Synergic Effects of Physical Activity and Probiotic on Gut Immune System and Quality of Life of Breast Cancer Survivors</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage I Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Immunoglobulin A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando Herrero</Name><Name>Luis Miguel Lopez Mojares</Name><Name>Mar Larrosa</Name><Name>Margarita Perez</Name></ContactNames></Trial><Trial Id="385137"><Indications><Indication>Aging</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2019-08-30T00:00:00Z</DateEnd><DateStart>2019-07-01T00:00:00Z</DateStart><Identifiers><Identifier>CIPI/</Identifier><Identifier>NCT03986840</Identifier></Identifiers><InterventionsControlDisplay><Intervention>usual care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>exercise training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This will be a experimental, randomized, controlled, intervention, study in frail. Subjects will be recruited at the Albertia Care Center, &lt;b&gt;Madrid&lt;/b&gt;. The exercise training group will developed a concurrent training 3 days per week during 6 weeks. The control group will follow an usual care also for 6 weeks. All the subjects will be assessed two times. The main variables will be as follows: Ultrasound imaging measurements for the lower limb: core muscles, vastus medialis, rectus femoris, vastus intermedius</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Multicomponent Exercise Training in Frail Elderly</TitleDisplay><BiomarkerNames><BiomarkerName>Heart rate </BiomarkerName><BiomarkerName> Muscle </BiomarkerName><BiomarkerName> Rectus femoris muscle </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Vastus intermedius muscle </BiomarkerName><BiomarkerName> Vastus medialis muscle</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-07-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carlos Romero Morales</Name><Name>Carlos Romero Morales, PhD</Name><Name>Sergio López, MsC</Name></ContactNames></Trial><Trial Id="185768"><Indications><Indication>Acute leukemia</Indication></Indications><CompaniesCollaborator><Company>Merck KGaA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Apices Soluciones, S.L.</Company><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-11-22T00:00:00Z</DateChangeLast><DateEnd>2016-09-30T00:00:00Z</DateEnd><DateStart>2014-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-005146-38</Identifier><Identifier>LANK-2</Identifier><Identifier>LYDIA</Identifier><Identifier>NCT02074657</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>activated natural killer cells alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>13</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in children, adolescents and young adults with relapsed or refractary acute leukemia. The objectives of this study were: To assess the safety of activated and expanded NK cell (NKAE) immunotherapy after salvage chemotherapy in patients with relapsed or refractary acute leukemia. To analyze incidence of episodes of febrile neutropenia</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Leukemia - Assessment of Immune Response - Assessment of immune reconstitution</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Leukemia - Assessment of Safety and Tolerability - Assessment of risk or incidence of infections</EndpointIndex><EndpointIndex>Leukemia - Assessment of hospitalization - Assessment of duration/frequency of hospitalization</EndpointIndex><EndpointIndex>Sepsis - Assessment of Immune Response</EndpointIndex><EndpointIndex>Sepsis - Assessment of Morbidity - Incidence of infections</EndpointIndex><EndpointIndex>Sepsis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Sepsis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Sepsis - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>LYDIA: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment><PatientSegment>Leukemia - Subjects with Relapsed/Recurrent Leukemia - Subjects with relapsed/recurrent leukemia after stem cell therapy</PatientSegment><PatientSegment>Sepsis - Subjects at risk of developing disease</PatientSegment><PatientSegment>Sepsis - Subjects with Bacteremia/Septicemia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Dendritic cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Antonio Pérez-Martínez, MD, PhD</Name><Name>CLINICAL RESEARCH DEPARTMENT</Name></ContactNames></Trial><Trial Id="380835"><Indications><Indication>Brain disease</Indication><Indication>Cerebral palsy</Indication><Indication>Down syndrome</Indication><Indication>Neurological disease</Indication><Indication>Respiratory disease</Indication></Indications><CompaniesCollaborator><Company>Sociedad Española de Neumología y Cirugía Torácica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-18T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2013-09-30T00:00:00Z</DateStart><Identifiers><Identifier>COMPLUTENSE UNIVERSITY</Identifier><Identifier>NCT03946137</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Chest therapy alone</Intervention><Intervention>postural hygiene alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>of 0.8, in a bilateral contrast, 27 participants would be required to detect a difference &gt;/= 3.5 units. A standard deviation of 5 was assumed. The participants would be recruited from four centres of early care and foundations of the Community of &lt;b&gt;Madrid&lt;/b&gt;. From their respective centres, all the parents of children with chronic neurological syndromes, who could enter the study according to the inclusion and exclusion criteria previously described, participated in the project. The informed consent of</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of hospitalization - Assessment of frequency/length of hospitalization</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments - Pediatric Quality of Life Inventory (PedsQL Inventory)</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Chest Therapy and Postural Education in Children With Cerebral Palsy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Others - Children and adolescents</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Encephalopathy</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Cerebral Palsy</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Down syndrome</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Inmaculada M Moreno, Doctora</Name><Name>Moreno Bermejo</Name></ContactNames></Trial><Trial Id="379971"><Indications><Indication>Eating disorder</Indication></Indications><CompaniesSponsor><Company>Universidad Ceu San Pablo De Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-30T00:00:00Z</DateChangeLast><DateEnd>2018-04-01T00:00:00Z</DateEnd><DateStart>2017-09-01T00:00:00Z</DateStart><Identifiers><Identifier>CEU-0013</Identifier><Identifier>NCT03911674</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Oral stimulation protocol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study hypothesis was that oral stimulation in preterm infants has beneficial effects on the feeding performance, the length of hospitalization and anthropometric variables, including weight at discharge, height at discharge and head circumference at discharge.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Effects of Oral Stimulation in Preterm Infants</TitleDisplay><BiomarkerNames><BiomarkerName>Body height </BiomarkerName><BiomarkerName> Head circumference </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-04-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>CEU San Pablo University</Name></ContactNames></Trial><Trial Id="256606"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-03-06T00:00:00Z</DateChangeLast><DateEnd>2019-04-30T00:00:00Z</DateEnd><DateStart>2018-04-30T00:00:00Z</DateStart><Identifiers><Identifier>1512-MAD-067-JG</Identifier><Identifier>NCT02718105</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>KIR HLAC determination alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the maternal KIR haplotype an impact in pregnancy, miscarriage and live birth rates per embryo transfer in donor oocytes-ART by paternal and oocyte donor HLA-C.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Infertility - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Others - Healthy Subjects</PatientSegment><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Killer cell immunoglobulin-like receptor 2DL2 </BiomarkerName><BiomarkerName> Killer cell immunoglobulin-like receptor 2DL3 </BiomarkerName><BiomarkerName> Killer cell immunoglobulin-like receptor 2DS2 </BiomarkerName><BiomarkerName> Killer cell immunoglobulin-like receptor 2DS4 </BiomarkerName><BiomarkerName> Killer cell immunoglobulin-like receptor 3DL1 </BiomarkerName><BiomarkerName> Killer cell immunoglobulin-like receptor 3DS1 </BiomarkerName><BiomarkerName> Major histocompatibility complex, class I, C </BiomarkerName><BiomarkerName> killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Diana Alesandru, PhD</Name><Name>Juan Antonio Garcia Velasco, PhD</Name></ContactNames></Trial><Trial Id="373702"><Indications><Indication>Labor complication</Indication></Indications><CompaniesCollaborator><Company>Clínica IVI Madrid</Company></CompaniesCollaborator><CompaniesSponsor><Company>IVI Sevilla</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-11T00:00:00Z</DateChangeLast><DateEnd>2022-04-30T00:00:00Z</DateEnd><DateStart>2019-04-15T00:00:00Z</DateStart><Identifiers><Identifier>1801-SEV-009-MF</Identifier><Identifier>NCT03877939</Identifier><Identifier>TESTKM</Identifier></Identifiers><PatientCountEnrollment>433</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this study is to detect the kisspeptins and miRNAs in patients with non-viable pregnancy. The utility of a diagnostic test using kisspeptin 54 and miR-324-3p biomarkers and other related ones in a population with other types of non-viable pregnancies should still be analyzed.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Laboratory/Diagnostic Measures - Assessment of pathological parameters</EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of immunological markers</EndpointIndex><EndpointIndex>Other gynecological disorder - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>TESTKM: Detection of Kisspeptins and miRNAs in Patients With Non-viable Pregnancy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gynecological disorder - Others - Pregnant subjects</PatientSegment><PatientSegment>Other gynecological disorder - Women giving birth/Obstetrics - Subjects with Spontaneous abortion (Miscarriage)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Choriogonadotropin subunit beta </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Insulin resistance substrates </BiomarkerName><BiomarkerName> Killer cell immunoglobulin-like receptor 2DL2 </BiomarkerName><BiomarkerName> Major histocompatibility complex, class I, C </BiomarkerName><BiomarkerName> Metastasis-suppressor KiSS-1 </BiomarkerName><BiomarkerName> Progesterone </BiomarkerName><BiomarkerName> microRNA 15b </BiomarkerName><BiomarkerName> microRNA 324-3p </BiomarkerName><BiomarkerName> microRNA 424-5p</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Diana Alecsandru</Name><Name>Esther Santamaria-Lopez</Name><Name>Manuel Fernandez-Sanchez</Name></ContactNames></Trial><Trial Id="96530"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><CompaniesCollaborator><Company>Gerencia de Atención Primaria, Madrid</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Carlos III</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-10T00:00:00Z</DateChangeLast><DateEnd>2011-11-30T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>070865</Identifier><Identifier>NCT01482481</Identifier><Identifier>PI070865</Identifier></Identifiers><PatientCountEnrollment>23488</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The computerized clinical record system (CCR) form for primary care of the &lt;b&gt;Madrid&lt;/b&gt; Health Service was used as the data source. NCPSM was identified by clinical records of North American Nursing Diagnosis Association (NANDA) and Nursing Interventions Classification (NIC) nursing taxonomies, and were defined as nursing care based on the following three criteria: Criterion 1: a patient's CCR must register valuation data based on Marjory Gordon 'functional pattern' in at least the following areas: health</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effectiveness of Nursing Care Plans Based in Nursing Diagnoses in Metabolic Control of Type 2 Diabetes Mellitus</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>JUAN CARDENAS</Name></ContactNames></Trial><Trial Id="241268"><Indications><Indication>Lipid metabolism disorder</Indication><Indication>Obstructive sleep apnea</Indication></Indications><CompaniesCollaborator><Company>Hospital Universitario Principe de Asturias</Company></CompaniesCollaborator><CompaniesSponsor><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-06-28T00:00:00Z</DateChangeLast><DateEnd>2018-05-31T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02557412</Identifier><Identifier>PINML01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Continuous positive airway pressure alone</Intervention><Intervention>Hygiene and dietary recommendation alone</Intervention><Intervention>Intensive lifestyle intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this randomized, parallel-group, non-blind, controlled clinical trial is to assess if 6 months of treatment with CPAP, associated with conventional treatment, improves the lipid profile of patients with dyslipidemia and mild-moderate apnea-hypopnea syndrome (OSA). Secondary objectives: To determine the additional effect of CPAP on insulin resistance and dyslipidemia in patients with mild-moderate OSA. To assess the impact of CPAP treatment in reducing cardiovascular risk in</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of High Density Lipoprotein (HDL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor (TNF)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles - Assessment of Triglycerides</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Glycemic Control Analysis - Assessment of HbA1c</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by International Physical Activity Questionnaire (IPAQ)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Protocol Specified Other Endpoints - Physical activity</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of adverse events</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Sleep apnea - Clinical Assessments</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidemia and Sleep Apnea</TitleDisplay><PatientSegmentTerms><PatientSegment>Lipid metabolism disorder - Subjects with Increased LDL-cholesterol Levels</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Increased Total Cholesterol Levels</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Increased Triglyceride Levels</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Reduced HDL-cholesterol Levels</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD)</PatientSegment><PatientSegment>Sleep apnea - Subjects with Mild Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Moderate Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Obstructive Sleep Apnea</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Appetite regulating hormone </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Endothelins </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Intercellular adhesion molecule-1 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Orexin-A </BiomarkerName><BiomarkerName> Pro-neuropeptide Y </BiomarkerName><BiomarkerName> Thyroid-stimulating hormone </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Vascular cell adhesion protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Barros, MD</Name><Name>Francisco Garcia-Rio, MD</Name></ContactNames></Trial><Trial Id="179494"><Indications><Indication>Osteitis</Indication></Indications><CompaniesSponsor><Company>University of Granada</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-18T00:00:00Z</DateChangeLast><DateStart>2009-01-31T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>articaine + epinephrine (Laboratorios Normon SA, Madrid, Spain) alone</Intervention><Intervention>chlorhexidine digluconate 0.2% (Laboratorios KIN SA, Barcelona, Spain) alone</Intervention><Intervention>chlorhexidine digluconate 1% (GlaxoSmithline Consumer Healthcare, Ireland) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>88</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>the surgical treatment, the surgeons registered several variables at the base level (baseline), and taught the patients to measure them over a week. Patients received local anesthesia (articaine 40 mg/ml- epinephrine 0.01%; Laboratorios Normon SA, &lt;b&gt;Madrid&lt;/b&gt;, Spain) and underwent surgery. Patients were randomized to to receive either 0.2% chlorhexidine digluconate gel (Laboratorios KIN SA, Barcelona, Spain) (n = 46) or 1% chlorhexidine digluconate gel ( GlaxoSmithline Consumer Healthcare, Dublin, Ireland</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A randomized, double-blind, parallel-group clinical trial to evaluate the effectiveness of 1% versus 0.2% chlorhexidine gels in reducing alveolar osteitis in patients who underwent mandibular third molar surgery</TitleDisplay><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>0</NumberOfSites></Trial><Trial Id="86474"><Indications><Indication>Cardiovascular disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 3 inhibitor</Action><Action>Potassium channel stimulator</Action><Action>Troponin C modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Calcium metabolism modulator</Action><Action>Inotropic agent</Action><Action>Sensitizer</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>La Paz University Hospital (Madrid)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-21T00:00:00Z</DateChangeLast><DateEnd>2010-11-30T00:00:00Z</DateEnd><DateStart>2009-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EUCTR2009-010404-28-ES</Identifier><Identifier>MilevoNeo</Identifier><Identifier>NCT01576094</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>levosimendan alone</Intervention><Intervention>milrinone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this pilot, phase I and feasibility study was to systematically test the efficacy and safety of milrinone (MR) and levosimendan (LEVO) in newborns undergoing cardiovascular surgery with cardiopulmonary bypass (CPB).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Two Inodilators Postsurgery in Neonates</TitleDisplay><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-7 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Adelina Pellicer, PhD</Name><Name>Antonio Buño, PhD</Name><Name>Carlos Labrandero, MD</Name><Name>Fernando Cabañas, PhD</Name><Name>Jesús Pérez-Rodríguez, PhD</Name><Name>Joan Riera, MBE</Name><Name>José Quero, PhD</Name><Name>Luis Castro, MD</Name><Name>María Carmen Bravo, PhD</Name><Name>Paloma López, MD</Name><Name>Rosario Madero, MD</Name></ContactNames></Trial><Trial Id="113704"><Indications><Indication>Perianal fistula</Indication></Indications><CompaniesSponsor><Company>Instituto de Investigación Sanitaria de la Fundacion Jimenez Diaz</Company><Company>La Paz University Hospital (Madrid)</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2017-10-31T00:00:00Z</DateEnd><DateStart>2013-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2012-001178-28</Identifier><Identifier>FISPAC</Identifier><Identifier>FISPAC-2011</Identifier><Identifier>NCT01803347</Identifier></Identifiers><InterventionsControlDisplay><Intervention>fibrin glue alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>surgery alone</Intervention><Intervention>adipose derived mesenchimals stem cells plus fibrin glue</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study evaluated safety and efficacy of mesenchymal stem cells derived from expanded adipose tissue (ASC) and surgery for the treatment of perianal fistula. The primary study objective was to compare the efficacy of autologous stem cells (ASC) plus fibrin glue versus fibrin glue for the closure of complex perianal fistulas not associated to inflammatory bowel disease. Fistula closure was defined as the absence of suppuration in the external orifice of the fistula and complete re-epithelialization</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>FISPAC: Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells</TitleDisplay><PatientSegmentTerms><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Adipose Derived Stem Cell Therapy</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Mesenchymal Stem Cell Transplantation(MSCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>56 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Damián García-Olmo, Prof.</Name></ContactNames></Trial><Trial Id="358082"><Indications><Indication>Obesity</Indication></Indications><CompaniesCollaborator><Company>Centro Medico Teknon</Company><Company>Hospital Universitario Madrid Sanchinarro</Company></CompaniesCollaborator><CompaniesSponsor><Company>USGI Medical Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-13T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2018-09-18T00:00:00Z</DateStart><Identifiers><Identifier>50518 TPR</Identifier><Identifier>NCT03721731</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Transport endoscopic access device alone</Intervention><Intervention>g-Cath EZ with Snowshoe suture anchor delivery catheter alone</Intervention><Intervention>g-Lix endoscopic grasper alone</Intervention><Intervention>g-Prox EZ endoscopic grasper alone</Intervention><Intervention>moderate-intensity diet and exercise programme alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Current patients of Roman Turro, MD at Centro Medico Teknon in Barcelona, Spain and Gontrand Lopez-Nava, MD at &lt;b&gt;Madrid&lt;/b&gt; Sanchinarro University Hospital in &lt;b&gt;Madrid&lt;/b&gt;, Spain will be recruited and observed. Patients with obesity will be treated with a plication device which will involve plicating the stomach. Efficacy of the treatment will be evaluated based on changes in weight loss over 12 months, and adverse events will be recorded throughout the duration of the study.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of weight loss</EndpointIndex><EndpointIndex>Obesity - Assessment of Gastric Function Tests - Gastric emptying</EndpointIndex><EndpointIndex>Obesity - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Obesity - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Post-Market Surveillance Study of Using the g-Cath EZ for Treating Obesity</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/Obese Subjects with Diabetes</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/Obese Subjects with Dyslipidemia</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/Obese Subjects with Hypertension</PatientSegment><PatientSegment>Obesity - Subjects with comorbid conditions - Overweight/obese prediabetics subjects</PatientSegment><PatientSegment>Obesity - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Barham Abu Dayyeh, MD</Name><Name>Chris Earley</Name><Name>Gontrand Lopez-Nava, MD</Name><Name>Roman Turro, MD</Name></ContactNames></Trial><Trial Id="354166"><Indications><Indication>Chronic fatigue syndrome</Indication></Indications><CompaniesCollaborator><Company>La Paz University Hospital (Madrid)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Escuela Universitaria de Fisioterapia de la ONCE</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-01T00:00:00Z</DateChangeLast><DateEnd>2019-09-30T00:00:00Z</DateEnd><DateStart>2019-02-27T00:00:00Z</DateStart><Identifiers><Identifier>1</Identifier><Identifier>NCT03675087</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>peak cardiopulmonary exercise testing alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>22</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Syndrome of the Community of &lt;b&gt;Madrid&lt;/b&gt;, to the Escuela Universitaria de Fisioterapia de la ONCE and to the Department of Functional Tests of the Pneumology Service of the Hospital Universitario La Paz, &lt;b&gt;Madrid&lt;/b&gt; (Spain) from October 1st, 2018 to July 1st, 2019 and that fulfill the inclusion criteria and do not present any exclusion criteria will be enrolled. This study has been approved in August 2018 by the Ethics and Research Committee of the La Paz University Hospital in &lt;b&gt;Madrid&lt;/b&gt; (HULP Code: PI-3320). The</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term></TermsDesign><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Assessment of Exercise Response in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Chronic Fatigue Syndrome</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> FEV / FVC ratio </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Maximal oxygen uptake </BiomarkerName><BiomarkerName> Oxygen pulse </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> Respiratory exchange ratio </BiomarkerName><BiomarkerName> Six-minute walk distance </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ana B Varas-de-la-Fuente, Chair</Name><Name>Irene Rodríguez-Andonaegui, Lecturer</Name><Name>Susana García-Juez</Name><Name>Susana García-Juez, Lecturer</Name></ContactNames></Trial><Trial Id="347252"><ActionsPrimaryInterventionsPrimary><Action>Dehydropeptidase-1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Protectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>La Paz University Hospital (Madrid)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Spherium Biomed</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-27T00:00:00Z</DateChangeLast><DateEnd>2018-08-09T00:00:00Z</DateEnd><DateStart>2018-06-19T00:00:00Z</DateStart><Identifiers><Identifier>2017-004795-63</Identifier><Identifier>NCT03595189</Identifier><Identifier>SP15016-09</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cilastatin sodium (iv infusion), Spherium Biomed alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>23</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase I, randomized, single-blind, parallel-group, placebo-controlled, multi-cohort, first-in-human dose-escalation study of a single intravenous 3-h administration of cilastatin as stand-alone in healthy male and female subjects [ 2062944 ], [ 2062950 ]. The study objectives were: The evaluation of safety and tolerability of single intravenous doses of cilastatin in healthy subjects administered as a 3-h infusion. The evaluation of the pharmacokinetic characteristics of cilastatin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> QT interval</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-08-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jesus Frias</Name><Name>Montserrat Cano</Name></ContactNames></Trial><Trial Id="229299"><ActionsPrimaryInterventionsPrimary><Action>Chorionic gonadotropin ligand</Action><Action>Estradiol agonist</Action><Action>Follicle stimulating hormone receptor agonist</Action><Action>GNRH receptor antagonist</Action><Action>Luteinizing hormone receptor agonist</Action><Action>Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Female contraceptive</Action><Action>Ovulation stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drug combination</Technology><Technology>Glycoprotein</Technology><Technology>Intramuscular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><DateChangeLast>2015-06-16T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2009-04-30T00:00:00Z</DateStart><Identifiers><Identifier>MAD-GV-04-2009-01</Identifier><Identifier>NCT02437032</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Fostipur , HMG-Lepor , cetrorelix , choriogonadotropin alfa , follitropin alfa , levonorgestrel + estrogen, Bayer Schering</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The investigators study aimed to determine if there is any relationship between different gonadotropin preparations and oocyte-secreted factor secretion, the endocrine pattern in follicular fluid, and the apoptotic rate in cumulus cells during controlled ovarian stimulation.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Ovulation</EndpointIndex><EndpointIndex>Infertility - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Infertility - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Infertility - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Infertility - Protocol Specified Other Endpoints - Other laboratory assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Gonadotropin Type in Ovarian Stimulation</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Apoptotic Index </BiomarkerName><BiomarkerName> Bone morphogenetic protein 15 </BiomarkerName><BiomarkerName> Estradiol </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Growth/differentiation factor 9 </BiomarkerName><BiomarkerName> Progesterone </BiomarkerName><BiomarkerName> Testosterone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Antonio Requena, PhD, MD</Name></ContactNames></Trial><Trial Id="220284"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><DateChangeLast>2016-04-06T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>1406-MAD-035-JG</Identifier><Identifier>NCT02341365</Identifier></Identifiers><PatientCountEnrollment>269</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this retrospective trial was to investigate the correlation between total and bioavailable serum 25-OH vitamin D, ovarian reserve and ovarian response to controlled stimulation in egg donors.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of embryo implantation rate</EndpointIndex><EndpointIndex>Infertility - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Ovarian Function - Assessment of ovarian follicle size/number</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Vitamin D Influence on Oocyte Donation</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment><PatientSegment>Infertility - Subjects with Other Infertility Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antral follicles </BiomarkerName><BiomarkerName> Muellerian-inhibiting factor </BiomarkerName><BiomarkerName> Oocytes </BiomarkerName><BiomarkerName> Vitamin D</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Juan Antonio García Velasco, Professor</Name></ContactNames></Trial><Trial Id="216801"><Indications><Indication>Female infertility</Indication></Indications><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><DateChangeLast>2016-04-07T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>MAD-CI-01-2012-01</Identifier><Identifier>NCT02210013</Identifier></Identifiers><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a prospective study of 400 infertile Caucasian and Indian women who would undergo a controlled ovarian stimulation for in vitro fertilization (IVF). The investigators would collect data about ovarian reserve markers and also the results after ovarian stimulation in both ethnic groups.The aim of this study was to identify differences in ovarian response after IVF stimulation between both groups.</Teaser><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Infertility - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Ovarian Function - Assessment of ovarian follicle size/number</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Differences in Ovarian Aging Between Caucasian and Indian Women</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) - Women with in vitro fertilisation(IVF)</PatientSegment><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment><PatientSegment>Infertility - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antral follicles </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Muellerian-inhibiting factor </BiomarkerName><BiomarkerName> Oocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Antonio Pellicer, M.D.</Name><Name>Carlos Iglesias, M.D.</Name><Name>Juan Antonio Garcia-Velasco, M.D.</Name><Name>Leyre Herrero, Ph. D.</Name><Name>Manish Banker, M.D.</Name><Name>Nalini Mahajan, M.D.</Name></ContactNames></Trial><Trial Id="264358"><Indications><Indication>Female infertility</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Chorionic gonadotropin ligand</Action><Action>GNRH receptor agonist</Action><Action>Luteinizing hormone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Ovulation stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Glycoprotein</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Clínica IVI Madrid</Company></CompaniesSponsor><DateChangeLast>2017-05-04T00:00:00Z</DateChangeLast><DateEnd>2015-11-30T00:00:00Z</DateEnd><DateStart>2014-11-30T00:00:00Z</DateStart><Identifiers><Identifier>1408-MAD-058-JG</Identifier><Identifier>NCT02813239</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>choriogonadotropin alfa alone</Intervention><Intervention>in vitro fertilization alone</Intervention><Intervention>choriogonadotropin alfa plus triptorelin pamoate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>81</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Investigators performed an observational study analyzing the difference in the percentage of mature oocytes retrieved in patients with more than 50% immature oocytes in a previous IVF cycle triggered with human chorionic gonadotropin (rhCG) ( Ovitrelle , Merck Serono ) compared to the rate of mature oocytes retrieved in subsequent cycles, triggered with both gonadotropin-releasing hormone agonist (GnRHa) ( Decapeptyl , Ipsen Pharma ) and (hCG). The main outcome measure was the number and percentage</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Dual Triggering in Patients With a High Immature Oocyte Rate</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Others - Healthy Subjects</PatientSegment><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) - Women with intracytoplasmic sperm injection(ICSI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antral follicles </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Muellerian-inhibiting factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Juan Antonio Garcia Velasco, MD</Name></ContactNames></Trial><Trial Id="129967"><Indications><Indication>Pancreas tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Grupo Hospital de Madrid</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-09-18T00:00:00Z</DateChangeLast><DateStart>2007-02-22T00:00:00Z</DateStart><Identifiers><Identifier>CIOCC 012007</Identifier><Identifier>EudraCT 2007-006260-29</Identifier><Identifier>FIS (EC07/98011)</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mycophenolate mofetil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 0 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Neutrophils &gt; or = 1500 cells/microl Platelets &gt; or = 100,000 cellsmicrol Histological or cytological diagnostic pancreatic cancer or pancreatic mass highly suspicious for pancreatic cancer Candidate resection surgery at the Hospital of North Sanchinarro &lt;b&gt;Madrid&lt;/b&gt; Age &gt; or = 18 years Parámetros within normal hematological Funcion kidney and liver within normal Informed consent</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of angiogenesis</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of apoptosis</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Pancreas tumor - Protocol Specified Other Endpoints - Assessment of Other Treatment Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase 0 Pharmacodynamic Study Mycophenolate Mofetil (MMF, Cellcept) In Patients With Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Resectable Pancreatic Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>1</NumberOfSites></Trial><Trial Id="245765"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Universidad Europea De Madrid</Company></CompaniesSponsor><Countries><Country>Venezuela</Country></Countries><DateChangeLast>2016-06-17T00:00:00Z</DateChangeLast><DateEnd>2015-10-31T00:00:00Z</DateEnd><DateStart>2015-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CE0072015-3</Identifier><Identifier>NCT02596815</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Goniometer alone</Intervention><Intervention>median nerve neural mobilization alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>51</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of these study was to compare the effectivity of the median nerve neural mobilization technique to the complete absence of treatment in a group of patients who suffer cervicobrachial pain.</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by DASH scale</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Hypoalgesic Effect of Median Nerve Neural Mobilization Compared to a Controlled Group</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cervical motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Francisco H Unda, PT, MSc</Name></ContactNames></Trial><Trial Id="236097"><Indications><Indication>Dermatological disease</Indication><Indication>Infectious disease</Indication></Indications><CompaniesSponsor><Company>Universidad Complutense de Madrid</Company></CompaniesSponsor><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2016-01-31T00:00:00Z</DateEnd><DateStart>2015-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ECP</Identifier><Identifier>NCT02500758</Identifier><Identifier>RBLM</Identifier></Identifiers><InterventionsControlDisplay><Intervention>chlorhexidine digluconate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>parachlorometaxylenol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The investigators looked to evaluate the difference in reducing bacterial load, using 4% chlorhexidine digluconate and 3% parachlorometaxylenol after a preoperative surgical scrubbing.</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ECP: Effectiveness of Preoperative Surgical Scrubbing Using Clorhexidine Digluconate and Parachlorometaxylenol</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial skin infection - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Ricardo Becerro de Bengoa Vallejo, DPM</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>